COMMUNICATION

Metal-Free Oxidative Cross Coupling of Indoles with Electron-Rich (Hetero)arenes.

Paola Caramenti, [§ a] Raj Kumar Nandi, [§ a] and Jerome Waser[*a]

Abstract: Herein, we report a new method for the synthesis of biheteroaryls, based on the Umpolung of indoles with benziodoxol(on)e hypervalent iodine reagents (IndoleBX). The oxidative coupling of IndoleBX with an equimolar amount of electron-rich benzenes, indoles, pyrroles and thiophenes proceeded under mild transition-metal free conditions. Functionalized non-symmetrical bi-indolyl heterocycles were accessed efficiently. Introduction of a new type of C2-substituted indole benziodoxole reagents further allowed extending the scope of the reaction to NH unprotected and C3-alkylated indoles. The obtained bi-heterocycles are important building blocks in synthetic and medicinal chemistry, and could be easily transformed into more complex heterocyclic systems.

Bi- and oligo- (hetero)aryl indoles are important building blocks in synthetic and medicinal chemistry. [1] They are usually accessed via multi-step ring-forming processes. [2] Since 2007, more efficient approaches based on metal-catalyzed direct C-H coupling of two (hetero)arenes have been intensively studied, especially for the coupling of indoles with electron-neutral or -poor (hetero)-arenes. [3-5] However, the direct coupling of indoles with electron-rich heterocycles was successful only in the case of homo-coupling to form symmetrical bi-indolyl compounds. [6] This is an important limitation, as non symmetrical derivatives can be found in natural products like Asteropusazole A (1), [7] synthetic bioactive molecules like anti-estrogen 2, [8] hole transport materials like indole trimer 3, [9] and transition metal ligands like indole phosphine 4. [10]




Figure 1. Selected reported compounds containing bi-heteroaryls.

To access non-symmetrical electron-rich bi-heteroaryls, cyclization methods^[11] or cross coupling reactions requiring pre-

 Paola Caramenti, Dr. Raj Kumar Nandi and Prof Dr. Jerome Waser Laboratory of Catalysis and Organic Synthesis Ecole Polytechnique Fédérale de Lausanne EPFL SB ISIC LCSO, BCH 4306, 1015 Lausanne (CH) Fax: (+)41 21 693 97 00
 E-mail: jerome.waser@epfl.ch

Supporting information for this article is given via a link at the end of the document.

functionalization of both partners^[12] remain most often used.^[13] The Umpolung of the reactivity of the indole ring to enable selective cross-coupling with electron-rich heterocycles is an attractive alternative approach (Scheme 1).[14] The protonation of 3-bromo indole followed by Friedel-Crafts reaction and elimination has been reported, but required the use of strong acids (Scheme 1A).[15] This led to multiple arylation and oligomerization, and therefore to a limited scope. Oxidative methods based on activation with hypochlorite^[16] or sulfonium reagents^[17] have been successful only for 3-substituted indoles. Kita and co-workers have been highly successful in the Umpolung of electron-rich benzene rings, [18] pyrroles[19] and thiophenes[20] through the use of hypervalent iodine reagents activated by Lewis acids without the need for any transition metal catalyst (Scheme 1B).[21] However, only very few examples of the Umpolung of indoles were reported.[22] In particular, the synthesis of hetero bi-indolyl compounds has never been reported. Therefore, there is currently no general method for the Umpolung of indoles allowing for reaction with electron-rich heterocycles under mild conditions.

A) State of the Art: coupling conditions to access electron-rich bi-heteroaryls

B) Kita's and Dohi's seminal work: hypervalent iodine mediated oxidative coupling

Het
$$N_{\mathbf{u}^{\delta-}}$$
 X_2 Lewis acid $X = NR^1$, S pyrroles, thiophenes established X_2 Lewis acid X_3 X_4 X_5 X_4 X_5 X_5

C) This work: First general coupling with indoles



Scheme 1. Umpolung of indoles for accessing non-symmetrical bi-heteroaryls.

The availability of stable isolable indole-based iodonium salts would allow oxidative coupling under more controlled conditions. However, these compounds are often not easily accessible, unstable or substituted with de-activating electron-withdrawing substituents.^[23] Our group and Yoshikai and coworkers have introduced more stable indole- and pyrrole

benziodoxol(on)es (BX).^[24]. Herein, we report the first use of these reagents for the oxidative coupling of indoles with electronrich heteroarenes under mild, transition metal free conditions, resulting in the first general coupling method for accessing hetero bi-indolyl compounds (Scheme 1C).

As benchmark reagent for the optimization process we chose 1,3,5-trimethoxy benzene (1) as nucleophile. Using Kita's conditions (hexafluoroisopropanol (HFIP) as solvent and trimethylsilylbromide as Lewis acid),^[19c] but with indoleBX **2a**, we obtained product **7a** in 41% yield (Table 1, entry 1). Bis-arylated byproduct **8** was also observed in 17% yield. Interestingly, only C2 functionalized indole **7a** was obtained starting from C3-substituted indoleBX **2a**, whereas C3-substituted products were formed when using transition metal catalysis.^[24a-c]

Table 1. Optimization of the (hetero)arylation on electrophilic heterocycles.

$$\begin{array}{c} \text{Me} \\ \text{OMe} \\ \text{1.0 equiv} \\ \text{1.0 equiv} \\ \text{Requiv} \\ \text{Ar} \\ \text{Ar$$

1 2a 1.5 equiv 2a, 2.0 equiv TMSBr, HFIP 0.1 M 41%/17% 2 2a 1.0 equiv TMSBr, HFIP 0.1 M 44%/12% 3 2a 1.0 equiv TMSCI, HFIP 0.1 M 68%/-% 4 2a 0.5 equiv TMSCI, HFIP 0.1 M 10%/-% 5 2a 1.5 equiv 2a, 2.0 equiv HCI, HFIP 0.1 M - 6 2a no HFIP or no TMSCI 7 2a 1.0 equiv TMSCI, 10 equiv HFIP, DCM 0.1 M 76%/-% 8 3a 1.0 equiv TMSCI, 10 equiv HFIP, DCM 0.1 M 22%/ 9 4a 1.0 equiv TMSCI, 10 equiv HFIP, DCM 0.1 M traces 10 5 1.5 equiv 4-F-PIDA, 2.0 equiv TMSCI, HFIP 0.1 M 16% [c] 11 6 1.5 equiv 6, 2.0 equiv TMSBr, HFIP 0.1 M -	Entry Reagent		Reaction Conditions ^[a]	Yield ^[b] 7a/8
3 2a 1.0 equiv TMSCI, HFIP 0.1 M 68%/-% 4 2a 0.5 equiv TMSCI, HFIP 0.1 M 10%/-% 5 2a 1.5 equiv 2a, 2.0 equiv HCI, HFIP 0.1 M - 6 2a no HFIP or no TMSCI 7 2a 1.0 equiv TMSCI, 10 equiv HFIP, DCM 0.1 M 76%/-% 8 3a 1.0 equiv TMSCI, 10 equiv HFIP, DCM 0.1 M 22%/ 9 4a 1.0 equiv TMSCI, 10 equiv HFIP, DCM 0.1 M traces 10 5 1.5 equiv 4-F-PIDA, 2.0 equiv TMSCI, HFIP 0.1 M 16% ^[c]	1	2a	1.5 equiv 2a , 2.0 equiv TMSBr, HFIP 0.1 M	41%/17%
4 2a 0.5 equiv TMSCI, HFIP 0.1 M 10%/-% 5 2a 1.5 equiv 2a, 2.0 equiv HCI, HFIP 0.1 M - 6 2a no HFIP or no TMSCI 7 2a 1.0 equiv TMSCI, 10 equiv HFIP, DCM 0.1 M 76%/-% 8 3a 1.0 equiv TMSCI, 10 equiv HFIP, DCM 0.1 M 22%/ 9 4a 1.0 equiv TMSCI, 10 equiv HFIP, DCM 0.1 M traces 10 5 1.5 equiv 4-F-PIDA, 2.0 equiv TMSCI, HFIP 0.1 M 16% ^[c]	2	2a	1.0 equiv TMSBr, HFIP 0.1 M	44%/12%
5	3	2a	1.0 equiv TMSCI, HFIP 0.1 M	68%/-%
6 2a no HFIP or no TMSCI 7 2a 1.0 equiv TMSCI, 10 equiv HFIP, DCM 0.1 M 76%/-% 8 3a 1.0 equiv TMSCI, 10 equiv HFIP, DCM 0.1 M 22%/ 9 4a 1.0 equiv TMSCI, 10 equiv HFIP, DCM 0.1 M traces 10 5 1.5 equiv 4-F-PIDA, 2.0 equiv TMSCI, HFIP 0.1 M 16% ^[c]	4	2a	0.5 equiv TMSCI, HFIP 0.1 M	10%/-%
7 2a 1.0 equiv TMSCI, 10 equiv HFIP, DCM 0.1 M 76%/-% 8 3a 1.0 equiv TMSCI, 10 equiv HFIP, DCM 0.1 M 22%/ 9 4a 1.0 equiv TMSCI, 10 equiv HFIP, DCM 0.1 M traces 10 5 1.5 equiv 4-F-PIDA, 2.0 equiv TMSCI, HFIP 0.1 M 16%/el	5	2a	1.5 equiv 2a , 2.0 equiv HCl, HFIP 0.1 M	
8 3a 1.0 equiv TMSCI, 10 equiv HFIP, DCM 0.1 M 22%/ 9 4a 1.0 equiv TMSCI, 10 equiv HFIP, DCM 0.1 M traces 10 5 1.5 equiv 4-F-PIDA, 2.0 equiv TMSCI, HFIP 0.1 M 16% ^[c]	6	2a	no HFIP or no TMSCI	7
9 4a 1.0 equiv TMSCI, 10 equiv HFIP, DCM 0.1 M traces 10 5 1.5 equiv 4-F-PIDA, 2.0 equiv TMSCI, HFIP 0.1 M 16% ^[c]	7	2a	1.0 equiv TMSCI, 10 equiv HFIP, DCM 0.1 M	76%/-%
10 5 1.5 equiv 4-F-PIDA, 2.0 equiv TMSCI, HFIP 0.1 M 16% ^[c]	8	3a	1.0 equiv TMSCI, 10 equiv HFIP, DCM 0.1 M	22%/
	9	4a	1.0 equiv TMSCI, 10 equiv HFIP, DCM 0.1 M	traces
11 6 1.5 equiv 6 , 2.0 equiv. TMSBr, HFIP 0.1 M	10	5	1.5 equiv 4-F-PIDA, 2.0 equiv TMSCI, HFIP 0.1 M	16% ^[c]
	11	6	1.5 equiv 6, 2.0 equiv. TMSBr, HFIP 0.1 M	-

[a] Reaction performed at 0.10 mmol scale at r.t. using 1.0 equiv indole reagent 2-6 unless stated otherwise. [b] Isolated yield after purification by column chromatography. [c] Yield of 7a given. Oligomers, bis-indoles and indole-indolines were also detected.

Importantly, using equimolar amounts of TMSBr and reagent **2a** did not change the outcome of the reaction (Table 1, entry 2). Switching from TMSBr to the milder TMSCI improved the yield of the mono-arylated product **7a**, and suppressed the formation of **8** (Table 1, entry 3). A sub-stoichiometric amount of TMSCI led to a lower yield (Table 1, entry 4). Replacing TMSCI with HCI didn't work and both Lewis acid and HFIP were necessary for the reaction to proceed (Table 1, entries 5-6). The latter is probably needed to stabilize cationic aromatic and iodine(III) species. When running the reaction in dichloromethane (DCM), 10 equivalents of HFIP were enough to give indole **7a** in 76% yield (Table 1, entry 7). Only very low yields were obtained with benziodoxole reagents **3a** and **4a** (Table 1,

entries 8-9). Using 4-fluorophenyl iodobenzene diacetate (4-F-PIDA) as oxidant together with *N*-methylindole (**5**) as reported by Kita and co-workers, [19c] afforded **7a** in only 16% yield (Table 1, entry 10). Oligomers, bis-indoles and indole-indolines resulting from homocoupling were also detected in the reaction mixture. A control experiment with C3-iodoindole **6** confirmed the necessity of iodine(III) as activator (Table 1, entry 11).

The reaction of different benziodoxolone reagents with trimethoxybenzene as nucleophile was then examined (Scheme 2A). Products **7b** and **7c** bearing an iodine and a boronic esters substituent were obtained in 69 and 54% yield respectively. The method is therefore orthogonal to transition-metal catalyzed cross-couplings, allowing access to useful functionalities. Reagents with a NH-free indole were not successful. Starting from C2-methylated indoleBX, C3-arylated indole **7d** was accessed in 40% yield. Arylated pyrroles **7e-f** were obtained in yield comparable to those reported by Kita and Dohi.[19c]

Scheme 2. Scope of the Lewis acid promoted (hetero)arylation of indoles and pyrroles. Reaction conditions; 0.30 mmol nucleophile, 0.30 mmol indole/pyrroleBX **2**, 0.30 mmol TMSCI, 3.0 mmol HFIP, DCM 0.2 M, r.t. [a] As a 9:1 mixture of mono-/bi- arylation products. [b] As a 12:1 mixture of C3:C7 heteroarylation products. [c] As a 1:1 mixture of C2:C3 heteroarylation products.

With indoles as nucleophiles, we were delighted to obtain 3',2 mixed bi-indoles in moderate to good yields, with only minor formation of de-aromatization, oligomerization and homocoupling side products (Scheme 2B). In addition to homocoupling product 8a, mixed bi-indolyls 8b-f bearing electron-donating groups, halogens or boronic esters were obtained in 64-72% yield. When C6-OBn-methylindole was used, benzyl deprotected

product **8g** was formed. *N*-Unprotected indoles afforded products **8h-j** in 61-78% yield. When C3-substituted indoles were used as nucleophiles, 2',3 connected bi-indolyl **8k-l** were obtained in 45-57% yield. Using substituted IndoleBX's allowed to introduce functionalities on the other indole ring (products **8m-o**). For example, bi-indolyls **8e** and **8m** differ only by the position of the iodine atom. This could not have been achieved selectively with any previously reported method. Finally, preliminary results with pyrroles and thiophenes were also obtained (products **9a-b** and **10a-b** respectively, Scheme 1C).

The synthesis of IndoleBXs developed in our group^[24a] did not allow access to indoles bearing easily removable nitrogen protecting groups or C3 substituents. We therefore developed a new synthetic approach for IndoleBXs bearing the iodine atom on the C2 position. After intensive screening of indole precursors and conditions,^[26] we accessed the desired reagents 13 by reacting indole trifluoroborate salts 11^[27] with fluoro benziodoxol(on)e 12 (Scheme 3).^[28] Benziodoxolone reagents 13a-b were obtained in low yield. IndoleDBX (dimethylbenziodoxole) 13c-d were isolated in 86% and 53% yield respectively (the procedure was scalable up to two grams for the former). Substituents in C5, C6 and C3, including ethers, halogens and protected amines, were well tolerated, affording benziodoxoles 13e-i in 63-97% yield.^[29]

Best results in the heteroarylation of trimethoxybenzene (1) were obtained with *N*-Boc protected IndoleDBX reagents using TMSBr (Scheme 4). Under these conditions, the Boc group was removed, giving NH free indoles **14a-d** in 50-94% yield. [30] It was now possible to obtain C2-arylated-C3-alkylated indoles **14e** and **14f** in 82% and 75% yield respectively. The use of indoles as nucleophiles required milder TMSCI as Lewis acid and gave access to NH unprotected heterodimers **15a-c** in 34-56% yield. Thiophene-indole heteroaryl **16** was obtained in 28% yield.

Scheme 3. Synthesis of C2-substituted IndoleBX reagents.

At this stage, it is difficult to propose a reaction mechanism rationalizing the observed regioselectivity. Either a nucleophilic (vicarious) aromatic substitution pathway or a single electron transfer (SET) from a charge-transfer complex could be

considered.^[18-21] In both cases, Lewis acid activation of the hypervalent iodine reagent would initiate the reaction.^[31] The obtained products could be easily modified (Scheme 5). Cyclization of **8j** with acetal **17** gave indole-carbazole **18** in 81% yield (Scheme 5A).^[32] Palladium catalysed oxidative cyclization of **8d** led to the formation of carbazole **20** (Scheme 5B).^[33] Indolecarbazoles are important sub-structures in optoelectronic materials.^[9,34] Finally, a Ciamician-Dennstedt rearrangement converted indole **14a** into quinoline **21** (Scheme 5C).^[35]

Scheme 4. Scope of the oxidative heteroarylation using C2-IndoleDBX reagents **13**. Reaction conditions; 0.22 mmol nucleophile, 0.20 mmol indoleDBX, 0.40 mmol TMSBr, 2.0 mmol HFIP, DCM 0.2 M, r.t. [a] TMSCI was used instead of TMSBr.

In conclusion, we have reported a straightforward approach for the selective synthesis of mixed bi-(hetero)arenes. Electrophilic hypervalent iodine reagents (IndoleBX) were combined with equimolar amounts of functionalized indole, pyrrole and thiophene nucleophiles in a metal-free protocol. Selectively functionalized bi-indolyl heterocycles were obtained with high efficiency. New C2-IndoleDBXs reagents were synthesized, increasing significantly the scope of accessible bi-heterocycles. Further investigations are ongoing on the use of benziodoxol(on)e reagents in the Umpolung of electron-rich heterocycles.

Scheme 5. Product derivatizations.

Acknowledgements

This work is supported by the Swiss National Science Foundation (No. 200021_159920), the European Research Council (ERC Starting Grant 334840) and the COST action CA15106 (C-H Activation in Organic Synthesis, CHAOS). We thank Dr R. Scopelliti and Dr F. F. Tirani from ISIC at EPFL for X-ray analysis, and Dr. Fides Benfatti and Marylene Stempien from Syngenta for the DSC analysis.

Authors Contribution


§P. Caramenti and §Dr. R.K. Nandi contributed equally to this work.

Keywords: Indoles • Hypervalent lodine • Umpolung • C-H Functionalization • Heterocycles

- [1] P. J. Steel, "Aromatic biheterocycles: Syntheses, structures, and properties" in *Advances in Heterocyclic Chemistry*, Vol. 67 (Ed.: A. R. Katritzky), 1997, pp. 1-117.
- [2] J. A. Joule, K. Mills, "Heterocyclic Chemistry, 5th Edition", Heterocyclic Chemistry, 5th Edition, Wiley-Blackwell, 2010.
- [3] Y. Yang, J. Lan, J. You, Chem. Rev. 2017, 117, 8787.
- [4] Selected examples for coupling of indoles with electron-neutral arenes: a) D. R. Stuart, K. Fagnou, *Science* 2007, 316, 1172; b) D. R. Stuart, E. Villemure, K. Fagnou, *J. Am. Chem. Soc.* 2007, 129, 12072.
- [5] Selected examples for coupling of indoles with electron-poor arenes and heterocycles: a) X. Gong, G. Y. Song, H. Zhang, X. W. Li, Org. Lett. 2011, 13, 1766; b) M. Nishino, K. Hirano, T. Satoh, M. Miura, Angew. Chem., Int. Ed. 2012, 51, 6993; c) N. Kuhl, M. N. Hopkinson, F. Glorius, Angew. Chem., Int. Ed. 2012, 51, 8230; d) Z. Wang, F. J. Song, Y. S. Zhao, Y. M. Huang, L. Yang, D. B. Zhao, J. B. Lan, J. S. You, Chem. Eur. J. 2012, 18, 16616; e) X. R. Qin, H. Liu, D. K. Qin, Q. Wu, J. S. You, D. B. Zhao, Q. Guo, X. L. Huang, J. B. Lan, Chem. Sci. 2013, 4, 1964; f) B. Liu, Y. M. Huang, J. B. Lan, F. J. Song, J. S. You, Chem. Sci. 2013, 4, 2163; g) X. C. Cambeiro, N. Ahlsten, I. Larrosa, J. Am. Chem. Soc. 2015, 137, 15636.
- [6] Selected examples: a) J. Bergman, N. Eklund, Tetrahedron 1980, 36, 1439;
 b) Y. Li, W.-H. Wang, S.-D. Yang, B.-J. Li, C. Feng, Z.-J. Shi, Chem. Commun.
 2010, 46, 4553; c) Z. Liang, J. Zhao, Y. Zhang, J. Org. Chem. 2010, 75, 170;
 d) G. Dupeyre, P. Lemoine, N. Ainseba, S. Michel, X. Cachet, Org. Biomol. Chem. 2011, 9, 7780; e) Y.-X. Li, K.-G. Ji, H.-X. Wang, S. Ali, Y.-M. Liang, J. Org. Chem. 2011, 76, 744; f) J. Le, Y. D. Gao, Y. S. Ding, C. Jiang, Tetrahedron Lett. 2016, 57, 1728; g) P. Huang, X. Peng, D. Hu, H. Liao, S. Tang, L. Liu, Org. Biomol. Chem. 2017, 15, 9622; h) L. Bering, F. M. Paulussen, A. P. Antonchick, Org. Lett. 2018, DOI: 10.1021/acs.orglett.8b00521.
- [7] a) F. Russell, D. Harmody, P. J. McCarthy, S. A. Pomponi, A. E. Wright, J. Nat. Prod. 2013, 76, 1989; b) X. Zheng, L. Lv, S. Lu, W. Wang, Z. Li, Org. Lett. 2014, 16, 5156.
- [8] A. Kaczor Agnieszka, K. Pihlaja, J. Sinkkonen, K. Wiinamäki, C. Kronbach, K. Unverferth, T. Wróbel, T. Stachal, D. Matosiuk, *Heterocycl. Commun.* 20, 2014, 103.
- [9] K. Rakstys, A. Abate, M. I. Dar, P. Gao, V. Jankauskas, G. Jacopin, E. Kamarauskas, S. Kazim, S. Ahmad, M. Grätzel, M. K. Nazeeruddin, J. Am. Chem. Soc. 2015, 137, 16172.
- [10] W. C. Fu, C. M. So, W. K. Chow, O. Y. Yuen, F. Y. Kwong, Org. Lett. 2015, 17, 4612.
- [11] Selected recent examples: a) J. E. Perea-Buceta, T. Wirtanen, O. V. Laukkanen, M. K. Makela, M. Nieger, M. Melchionna, N. Huittinen, J. A. Lopez-Sanchez, J. Helaja, Angew. Chem., Int. Ed. 2013, 52, 11835; b) E. Kumaran, W. Y. Fan, W. K. Leong, Org. Lett. 2014, 16, 1342; c) B. Yao, Q. Wang, J. Zhu, Chem. Eur. J. 2015, 21, 7413; d) N. H. Ansari, C. A. Dacko, N. G. Akhmedov, B. C. G. Söderberg, J. Org. Chem. 2016, 81, 9337.
- [12] Selected example: Y. Zou, G. Yue, J. Xu, J. Zhou, Eur. J. Org. Chem. 2014, 2014, 5901.

- [13] D. S. Black, N. Kumar, "Biindolyls" in Advances in Heterocyclic Chemistry, Vol 101, Vol. 101 (Ed.: A. R. Katritzky), 2010, pp. 97-123.
- [14] M. Bandini, Org. Biomol. Chem. 2013, 11, 5206.
- [15] a) V. Bocchi, G. Palla, J. Chem. Soc., Chem. Commun. 1983, 1074; b) V. Bocchi, G. Palla, Tetrahedron 1984, 40, 3251; c) V. Bocchi, G. Palla, Tetrahedron 1986, 42, 5019.
- [16] a) J. M. Schkeryantz, J. C. G. Woo, P. Siliphaivanh, K. M. Depew, S. J. Danishefsky, J. Am. Chem. Soc. 1999, 121, 11964; b) M. Sun, X.-Y. Hao, S. Liu, X.-J. Hao, Tetrahedron Lett. 2013, 54, 692.
- [17] M. Tayu, K. Nomura, K. Kawachi, K. Higuchi, N. Saito, T. Kawasaki, *Chem. Eur. J.* 2017, 23, 10925.
- [18] a) Y. Kita, H. Tohma, K. Hatanaka, T. Takada, S. Fujita, S. Mitoh, H. Sakurai, S. Oka, J. Am. Chem. Soc. 1994, 116, 3684; b) Y. Kita, M. Gyoten, M. Ohtsubo, H. Tohma, T. Takada, Chem. Commun. 1996, 1481; c) T. Dohi, M. Ito, K. Morimoto, M. Iwata, Y. Kita, Angew. Chem. Int. Ed. 2008, 47, 1301; d) K. Morimoto, K. Sakamoto, T. Ohshika, T. Dohi, Y. Kita, Angew. Chem., Int. Ed. 2016, 55, 3652.
- [19] a) T. Dohi, K. Morimoto, A. Maruyama, Y. Kita, *Org. Lett.* **2006**, *8*, 2007; b) K. Morimoto, Y. Ohnishi, A. Nakamura, K. Sakamoto, T. Dohi, Y. Kita, *Asian J. Org. Chem.* **2014**, *3*, 382; c) K. Morimoto, Y. Ohnishi, D. Koseki, A. Nakamura, T. Dohi, Y. Kita, *Org. Biomol. Chem.* **2016**, *14*, 8947.
- [20] a) Y. Kita, K. Morimoto, M. Ito, C. Ogawa, A. Goto, T. Dohi, *J. Am. Chem. Soc.* **2009**, *131*, 1668; b) K. Morimoto, N. Yamaoka, C. Ogawa, T. Nakae, H. Fujioka, T. Dohi, Y. Kita, *Org. Lett.* **2010**, *12*, 3804;
- [21] For reviews, see: a) T. Dohi, M. Ito, N. Yamaoka, K. Morimoto, H. Fujioka, Y. Kita, *Tetrahedron* 2009, 65, 10797; b) Y. Kita, T. Dohi, *Chem. Rec.* 2015, 15, 886; c) K. Morimoto, T. Dohi, Y. Kita, *Synlett* 2017, 28, 1680.
- [22] Kita reported the Umpolung of N-benzyl and N-phenyl indoles and their C2-coupling with trimethoxybenzene in 50% yield, see Ref. 20c. Gu and Wang reported the Umpolung of N-acetyl indoles, which reacted in C3 position with anisoles, see: Y. Gu, D. Wang, Tetrahedron Lett. 2010, 51, 2004.
- [23] a) B. Y. Karele, L. E. Treigute, S. V. Kalnin, I. P. Grinberga, O. Y. Neiland, Chem. Heterocycl. Compd. 1974, 10, 189; b) V. A. Budylin, M. S. Ermolenko, F. A. Chugtai, P. A. Sharbatyan, A. N. Kost, Chem. Heterocycl. Compd. 1981, 17, 1095; c) R. M. Moriarty, Y. Y. Ku, M. Sultana, A. Tuncay, Tetrahedron Lett. 1987, 28, 3071; d) O. Neilands, Chem. Heterocycl. Compd. 2003, 39, 1555; e) D. Lubriks, I. Sokolovs, E. Suna, J. Am. Chem. Soc. 2012, 134, 15436; f) I. Sokolovs, D. Lubriks, E. Suna, J. Am. Chem. Soc. 2014, 136, 6920; g) K. Ishida, H. Togo, K. Moriyama, Chem. Asian J. 2016, 11, 3583.
- [24] a) P. Caramenti, S. Nicolai, J. Waser, Chem. Eur. J. 2017, 23, 14702; b) P. Caramenti, J. Waser, Helv. Chim. Acta 2017, 100, e170022; c) E. Grenet, J. Waser, Org. Lett. 2018, 20, 1473; d) B. Wu, J. Wu, N. Yoshikai, Chem. Asian J. 2017, 12, 3123.
- [25] I. Colomer, C. Batchelor-McAuley, B. Odell, T. J. Donohoe, R. G. Compton, J. Am. Chem. Soc. 2016, 138, 8855.
- [26] See Supporting Information for details of the optimization studies.
- [27] Available in two steps from the corresponding indoles, see Supporting Information.
- [28] M. Yoshida, K. Osafune, S. Hara, Synthesis, 2007, 10, 1542. Reagent 12a is unstable and needs to be generated in situ, reagent 12b is stable and commercially available.
- [29] The structure of 13h was confirmed by X-ray analysis (CCDC number 1824408).
- [30] The structure of **14a** was confirmed by X-ray analysis (CCDC number 1824407).
- [31] See Supporting Information for a detailed mechanistic working model.
- [32] T. Janosik, J. Bergman, Tetrahedron 1999, 55, 2371.
- [33] Z. Shi, S. Ding, Y. Cui, N. Jiao, Angew. Chem. Int. Ed. 2009, 48, 7895.
- [34] T. Kai, T. Yamamoto, M. Komori, M. Matsumoto, "Organic Electroluminescent Device", Kitakyushu-shi, US patent 2012/0235133A1.
- [35] a) G. L. Ciamician, M. Dennstedt, *Ber.* 1981, 14, 1153; b) K. C. Joshi, R. Jain, S. Arora, *J. Indian Chem. Soc.* 1993, 70, 567.

COMMUNICATION



Smooth Umpolung: The use of stable Indole-BenziodoXol(on)e (IndoleBX) hypervalent iodine reagents allows oxidative coupling of electron-rich (hetero)arenes under mild metal-free conditions to access hetero-bi-heterocycles in high yields. High functional group tolerance set the stage for easy and regioselective post-functionalization to access more complex heterocyclic systems.

P. Caramenti, R. K. Nandi, J. Waser*

Page No. – Page No. XXX.



Supporting Information

Table of contents

1. Materials and Methods.	2
2. Preparation of IndoleBXs.	3
2.1 Preparation of Hypervalent Iodine Precursors	3
2.2 Preparation of N-carbamoylated and -tosylated indoles	
salts.	
2.3 Optimization of the synthesis of C2-IndoleBX	17
2.4 Preparation of PyrroleBX and IndoleBX Reagents	18
3. Metal Free (Hetero)-Arylation of Indoles	30
3.1 Synthesis of Methylated Indoles.	30
3.2 Optimization of the Metal Free (Hetero)-Arylation of In	_
	33
3.3 Control experiments	39
3.4 Scope of the Metal Free (Hetero)-Arylation of Indoles.	41
3.4.1: Scope of trimethoxyphenylated-N-protected-Indol	es and -Pyrroles42
3.4.2: Scope of mixed 3'-2 biindoles.	46
3.4.3: Scope of pyrrole- and thiophene-2-methylindoles.	53
3.4.4: Scope of trimethoxy(methyl)phenylated-NH-indole	es 56
3.4.5: Scope of mixed 3'-2-NH-biindoles	60
4. Working model for the reaction mechanism.	62
5. Further Modifications of the (Hetero)-Arylated Indoles.	69
6. Crystal Structures.	72
7. Determination of the regio-distribution.	73
6. DSC studies.	78
7. Bibliography	79
8. Spectra of new compounds	81

1. Materials and Methods.

All reactions were carried out in oven dried glassware under an atmosphere of nitrogen, unless stated otherwise. For quantitative flash chromatography, technical grade solvents were used. For flash chromatography for analysis, HPLC grade solvents from Sigma-Aldrich were used. THF, Et₂O, CH₃CN, toluene, hexane and CH₂Cl₂ were dried by passage over activated alumina under nitrogen atmosphere (H₂O content < 10 ppm, Karl-Fischer titration). The solvents were degassed through Freeze-Pump-Thaw method when mentioned. All chemicals were purchased from Acros, Aldrich, Fluka, VWR, Aplichem, or Merck and used as such unless otherwise stated. Chromatographic purification was performed as flash chromatography using Macherey-Nagel silica 40-63, 60 Å, with the solvents indicated as eluent under 0.1-0.5 bar pressure. TLC was performed on Merck silica gel 60 F₂₅₄ TLC glass plates or aluminium plates and visualized with UV light, permanganate stain, CAN stain, or Anisaldehyde stain. Melting points were measured on a Büchi B-540 melting point apparatus using open glass capillaries, the data is uncorrected. ¹H-NMR spectra were recorded on a Brucker DPX-400 400 MHz spectrometer in CDCl₃, DMSO-d₆CD₃OD, C₆D₆ and CD₂Cl₂, all signals are reported in ppm with the internal chloroform signal at 7.26 ppm, the internal DMSO signal at 2.50 ppm the internal methanol signal at 3.30 ppm, the internal dichloromethane signal at 5.30 ppm as standard. The data is being reported as (s = singlet, d = doublet, t = triplet, q = quadruplet, q = quintet, m = multipletor unresolved, br = broad signal, app = apparent, coupling constant(s) in Hz, integration, interpretation). ¹³C-NMR spectra were recorded with ¹H-decoupling on a Brucker DPX-400 100 MHz spectrometer in CDCl₃, DMSO-d₆, CD₃OD or CD₂Cl₂, all signals are reported in ppm with the internal chloroform signal at 77.0 ppm, the internal DMSO signal at 39.5 ppm, the internal methanol signal at 49.0 ppm and the internal dichloromethane signal at 54.0 ppm as standard. Infrared spectra were recorded on a JASCO FT-IR B4100 spectrophotometer with an ATR PRO410-S and a ZnSe prisma and are reported as cm^{-1} (w = weak, m = medium, s = strong, br = broad). High resolution mass spectrometric measurements were performed by the mass spectrometry service of ISIC at the EPFL on a MICROMASS (ESI) Q-TOF Ultima API.

2. Preparation of IndoleBXs.

The synthesis of the precursors for HeterocyclicBX reagents **2a-2f'**, **3a**, **4a**, **13a-13i** and their starting materials had been already described before. ^[1,2] The procedures here reported are taken from the cited publications to facilitate reproduction of the results by having all the data in the same file. Compound **12b** is commercially available.




Figure 2.1: Heterocyclic hypervalent iodine reagents precursor.

2.1 Preparation of Hypervalent Iodine Precursors.

1-Chloro-1,2-benziodoxol 3(1*H***)-one (12d)**:

Following a slightly modified procedure, [3] commercially available 2- iodobenzoic acid **22** (4.00 g, 16.1 mmol, 1 equiv.) was dissolved in anhydrous MeCN (30 mL). The resulting stirred suspension was heated to 75 °C in an oil bath. The dropping funnel was charged with a solution of trichloroisocyanuric acid **23** (1.41 g, 6.07 mmol, 1.02 Cl⁺ equiv.) in 10 mL of anhydrous MeCN by syringe. The solution of trichloroisocyanuric acid **23** was dropped into the vigorously stirred reaction mixture within 5 min. After addition was complete, the reaction mixture was refluxed for an additional 5 min. The reaction mixture was vacuum-filtered over a preheated,

sintered-glass funnel with a tightly packed pad of Celite (1 cm thick), and the filter cake was rinsed with additional hot MeCN (20-50 mL). The combined filtrates were evaporated to near-dryness, and the resulting yellow solid was filtered over a sintered-glass funnel and washed with a small amount of cold MeCN. The mother liquor from filtration was partially concentrated on vacuum, giving a second crop of solids. The combined crops were dried under high vacuum to obtain 1-Chloro-1,2-benziodoxol 3(1H)-one **12d** (3.16 g, 11.2 mmol, 69% yield) as light yellow solid. ¹H NMR (400 MHz, *Acetone-d6*) δ 8.34 – 8.24 (m, 1H), 8.16 (ddd, J = 7.8, 6.5, 1.8 Hz, 2H), 7.96 – 7.85 (m, 1H). The NMR values correspond to the reported ones. ^[3]

1-Chloro-1,3-dihydro-3,3-dimethyl-1,2-benziodoxole (12e)

Following a reported procedure,^[3] commercially available methyl 2-iodobenzoate **24** (12.0 mL, 76.0 mmol) was dissolved under N₂ atmosphere in dry diethyl ether (400 mL) and then the solution was cooled to 0 °C with an ice bath. Methylmagnesium bromide (56.0 mL, 0.168 mol, 2.20 equiv.) was added dropwise and the reaction was stirred for 30 min at 0 °C. The reaction mixture was then allowed to warm to room temperature and it was further stirred for 2 h. The reaction was quenched with NH₄Cl in an iced bath. The organic layer was separated and extracted with Et₂O (3 x 100 mL), washed with water (2 x 200 mL), brine (1 x 100 mL) then dried over MgSO₄. The solvent was removed *in vacuo*.

With no further purification the crude mixture was dissolved in CCl₄ (7 mL) and *tert*-butyl hypochlorite (100 mL, 92.0 mmol, 1.20 equiv.) and the reaction mixture was stirred at room temperature. After one hour a yellow precipitate was collected by filtration and washed with hexane (60 mL) to afford compound **12e** (7.70 g, 26.0 mmol, 34% yield) as a yellow solid. ¹**H NMR** (400 MHz, CDCl₃) δ 8.03 (dd, 1 H, J = 8.1, 1.1 Hz, CHAr), 7.55 (m, 2 H, CHAr), 7.17 (dd, 1 H, J = 7.3, 1.7 Hz, CHAr), 1.55 (s, 6 H, (CH₃)₂). ¹³**C NMR** (101 MHz, CDCl₃) δ 149.5, 131.0, 130.5, 128.4, 126.1, 114.7, 85.2, 29.2. **IR** v 3729 (w), 3626 (w), 2972 (w), 2924 (w), 2362 (w), 2055 (w), 2018 (w), 1742 (w), 1564 (w), 1464 (w), 1439 (w), 1379 (w), 1378 (w), 1366 (w), 1277 (w), 1276 (w), 1256 (w), 1181 (w), 1154 (m), 1112 (w), 1048 (w), 1003 (w), 982 (w), 943 (m), 866 (m), 808 (w), 790 (w), 789 (w), 762 (s), 745 (w), 724 (w), 718 (w). The characterization data is in accordance with reported literature values. ^[4]

1-Chloro-1,3-dihydro-3,3-bis(trifluoromethyl)-1,2-benziodoxole (12f)

Following a reported procedure, TMEDA (distilled over KOH) (1.26 mL, 8.20 mmol, 0.200 equiv) was added to a solution of *n*BuLi (2.5 M in hexanes, 36.6 mL, 91.6 mmol, 2.20 equiv). After 15 min, the cloudy solution was cooled to 0 °C and 25 (7.00 mL, 42.0 mmol, 1 equiv) in THF (6 mL) was added dropwise. The reaction was stirred 30 min at 0 °C and then at RT overnight. I₂ (11.2 g, 44.0 mmol, 1.06 equiv) was then added portionwise at 0 °C and the mixture stirred at 0 °C for 30 min and 4 h at RT. The reaction was quenched with saturated NH₄Cl. Et₂O (100 mL) was added and the layers were separated. The aqueous layer was then extracted twice with Et₂O (3 x 50 mL). The organic layers were combined, washed twice with saturated NaS₂O₃ (2 x 50 mL), dried over MgSO₄, filtered and concentrated under reduced pressure to afford 15.6 g of crude 26 as an brown oil which was used without further purification. The crude oil was dissolved in MeCN (40 mL) in the dark under air. Trichloroisocyanuric acid 23 (3.42 g, 14.3 mmol, 0.340 equiv.) was then added portionwise at r.t. After 30 min, the resulting suspension was filtered to afford **12f** (7.30 g, 18.1 mmol, 43%) as a yellow solid. The mother liquors were carefully reduced to one third and filtered to afford more xx (8.85 g, 21.9 mmol, 52.1% yield) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 8.09 (d, 1 H, J = 8.4 Hz, ArH), 7.85 (m, 1 H, ArH), 7.73 (m, 2 H, ArH). ¹³C NMR (101 MHz, CDCl₃) δ 133.8, 132.1, 131.6, 129.7, 128.5, 122.8 (q, 289 Hz), 113.4, 84.8. The melting point and the ¹H NMR correspond to the reported values. ^[5]

Synthesis of 1-Acetoxy-1,2-benziodoxol-3-(1H)-one (12g)

Following a reported procedure,^[1] NaIO₄ (7.24 g, 33.8 mmol, 1.05 equiv) and 2-iodobenzoic acid **22** (8.00 g, 32.2 mmol, 1.00 equiv) were suspended in 30% (v/v) aq. AcOH (48 mL). The mixture was vigorously stirred and refluxed for 4 h. The reaction mixture was then diluted with cold water (180 mL) and allowed to cool to room temperature, protecting it from light. After 1 h, the crude product was collected by filtration, washed on the filter with ice water (3 x 20 mL) and acetone (3 x 20 mL), and air-dried in the dark to give the pure hydroxylated intermediate **12c**.

Following a reported procedure,^[3] hydroxylated intermediate **12c** (39.1 mmol, 1.00 equiv.) was suspended in acetic anhydride (35 mL) and heated to reflux for 5 minutes, up to dissolution of the starting material. The resulting clear, slightly yellow solution was slowly let to cool down to room temperature and then cooled to 0 °C for 30 minutes. The white suspension was filtered and the filtrate was again cooled to 0 °C for 30 minutes. The suspension was once again filtered and the combined two batches of solid product were washed with hexane (2 x 20 mL) and dried *in vacuo* to afford product **12g**. 1-Acetoxy-1,2-benziodoxol-3-(1*H*)-one **12g** (10.8 g, 35.3 mmol, 90%) as a white solid. ¹**H NMR** (CDCl₃, 400 MHz) δ 8.24 (dd, J = 7.6, 1.6 Hz, 1H, Ar*H*), 8.00 (dd, J = 8.3, 1.0 Hz, 1H, Ar*H*), 7.92 (ddd, J = 8.4, 7.2, 1.6 Hz, 1H, Ar*H*), 7.71 (td, J = 7.3, 1.1 Hz, 1H, Ar*H*), 2.25 (s, 3 H, COC*H*₃). ¹³**C NMR** (CDCl₃, 100 MHz) δ 176.5, 168.2, 136.2, 133.3, 131.4, 129.4, 129.1, 118.4, 20.4. NMR values are in accordance with the data reported in literature. ^[6]

1-Acetoxy-1,3-dihydro-3,3-dimethyl-1,2-benziodoxole (12h)

Following a reported procedure, ^[3] 1-chloro-1,3-dihydro-3,3-dimethyl-1,2-benziodoxole **12d** (2.60 g, 8.77 mmol) was dissolved in dry acetonitrile (25 mL) under N₂ atmosphere. The reaction flask was covered with aluminum foils and protected from light. Silver acetate (1.46 g, 8.77 mmol, 1.00 equiv.) was then added in one portion. The reaction mixture was stirred in the dark at room temperature for 16 h. Filtration over a Celite plug and evaporation of the solvent yielded compound **12h** (2.6 g, 8.8 mmol, 93%) as a brownish solid. ¹H **NMR** (400 MHz, CDCl₃) δ 7.79 (dd, 1 H, J = 8.0, 1.3 Hz, CHAr), 7.47 (m, 2H, CHAr), 7.18 (dd, 1 H, J = 7.2, 1.7 Hz, CHAr), 2.11 (s, 3 H, COCH₃), 1.52 (s, 6 H, (CH₃)₂). ¹³C **NMR** (101 MHz, CDCl₃)

δ 177.4, 149.4, 130.4, 130.0, 129.9, 126.2, 115.7, 84.6, 29.2, 21.5. **IR** v 3099 (w), 3057 (w), 2975 (w), 2930 (w), 2930 (w), 2865 (w), 1740 (w), 1640 (s), 1588 (w), 1566 (w), 1462 (w), 1438 (m), 1363 (s), 1294 (s), 1259 (m), 1158 (m), 1114 (w), 1047 (w), 1033 (w), 1009 (w), 949 (m), 926 (w), 866 (w), 761 (s), 723 (w). The characterization data is in accordance with reported literature values.^[3]

1-Acetoxy-1,3-dihydro-3,3-bis(trifluoromethyl)-1,2-benziodoxole (12i)

1-Chloro-1,3,-dihydro-3,3-bis(trifluoromethyl)-1,2-benziodoxole **12f** (8.85 g, 21.9 mmol) and AgOAc (3.65 g, 21.9 mmol, 1.00 equiv.) were suspended in MeCN (109 mL, 0.2 M). After being stirred overnight in the dark, AgCl precipitated and was filtered off. The residue was washed with MeCN. The solvent was removed in vacuo to give **12i** (9.37 g, 21.9 mmol, 100%) as a white solid. ¹**H NMR** (300 MHz, CDCl₃) δ 7.93 (d, J = 8.4 Hz, 1H, ArH), 7.61–7.79 (m, 3H, ArH), 2.18 (s, 3H, CH_3). The NMR values correspond to the reported ones. ^[6]

2.2 <u>Preparation of N-carbamoylated and -tosylated indoles and their trifluoroborate</u> salts.

In this section, only the synthesis of non-commercially available indole compounds is reported. The synthesis of the precursors for HeterocyclicBX reagents **13a-13i** had been already described by our group before. The procedures reported here are taken from the cited publications to facilitate reproduction of the results by having all the data in the same file.^[7,8]

General Procedure GP1 for the N-Carbamoylation of Indoles.

$$R^{1}$$
 R^{2}
 R^{1}
 R^{2}
 R^{2

Following a reported procedure,^[9] to a solution of commercially available *1H*-indoles (10.0 mmol, 1.00 equiv.) and *N*,*N*-dimethylaminopyridine (122 mg, 1.00 mmol, 0.100 equiv) in 0.5 M CH₂Cl₂, di-*tert*-butyl dicarbonate (2.40 g, 11.0 mmol, 1.10 equiv.) was added under vigorous stirring at 0 °C. The reaction was then allowed to stir at room temperature overnight. Brine (50 mL) and CH₂Cl₂ (30 mL) were added to the reaction mixture and the organic layer extracted. The aqueous layer was further extracted with CH₂Cl₂ (2 x 50 mL). The combined organic layers were dried over MgSO₄ concentrated in vacuum and the crude was directly submitted to shortpath flash chromatography (Pentane: EtOAc: 95:5) to afford the desired *N*-Boc indole derivatives **27a-27e**.

Figure 2.2 N-carbamoylated indoles.

Tert-butyl 1*H*-indole-1-carboxylate (27a)

Following the general procedure **GP1** (*synthesis of tert-butyl 1H-indole-1-carboxylate was scaled up to 20.0 mmol without reoptimization of the protocol.*), starting from commercially available 1*H*-indole (2.34 g, 20.0 mmol, 1.00 equiv.), after 16 hours *tert*-butyl 1*H*-indole-1-carboxylate **27a** was obtained as colorless oil (3. 90 g, 17.9 mmol, 90% yield). **R**_f: 0.8 (Pentane: EtOAc 9:1) ¹**H NMR** (400 MHz, CDCl₃) δ 8.36 (d, J = 8.5 Hz, 1H, Ar*H*), 7.74 (d, J = 3.8 Hz, 1H, Ar*H*), 7.69 (dt, J = 7.7, 1.0 Hz, 1H, Ar*H*), 7.47 (ddd, J = 8.4, 7.1, 1.3 Hz, 1H, Ar*H*), 7.37 (td, J = 7.5, 1.1 Hz, 1H, Ar*H*), 6.68 (d, J = 3.8 Hz,

1H, Ar*H*), 1.79 (s, 9H, C(CH_3)₃). ¹³C **NMR** (101 MHz, CDCl₃) δ 149.5, 135.0, 130.3, 125.6, 123.9, 122.4, 120.7, 114.9, 107.1, 83.2, 27.9. The NMR values correspond to the reported ones.^[9]

Tert-butyl 5-methoxy-1*H*-indole-1-carboxylate (27b)

Following general procedure **GP1**, starting from commercially available 5-methoxy-1*H*-indole (1.47 g, 10.0 mmol), after 14 hours *tert*-butyl 5-methoxy-1*H*-indole-1-carboxylate **27b** (1.92 g, 7.80 mmol, 78% yield) was obtained as a colorless solid. **R**_f: 0.8 (Pentane: EtOAc 95:5). ¹**H NMR** (400 MHz, CDCl₃) δ 8.06 (d, J = 9.1 Hz, 1H, Ar*H*), 7.59 (d, J = 3.6 Hz, 1H, Ar*H*), 7.04 (d, J = 2.6 Hz, 1H, Ar*H*), 6.96 (dd, J = 9.0, 2.6 Hz, 1H, Ar*H*), 6.51 (d, J = 3.7 Hz, 1H, Ar*H*), 3.86 (s, 3H, O*CH*₃), 1.68 (s, 9H, C(*CH*₃)₃). ¹³**C NMR** (101 MHz, CDCl₃) δ 155.7, 149.6, 131.3, 129.8, 126.4, 115.7, 112.9, 107.1, 103.4, 83.4, 55.5, 28.1. The NMR values correspond to the reported ones. ^[10]

Tert-butyl 6-methoxy-1*H*-indole-1-carboxylate (27c)

Following general procedure **GP1**, starting from commercially available 6-methoxy-1*H*-indole (1.47 g, 10.0 mmol), after 12 hours *tert*-butyl 6-methoxy-1*H*-indole-1-carboxylate **27c** (2.23 g, 9.02 mmol, 90% yield) was obtained as a colorless solid. **R**_f: 0.8 (Pentane: EtOAc 9:1). **H NMR** (400 MHz, CDCl₃) δ 7.75 (s, 1H, Ar*H*), 7.47 (d, J = 3.7 Hz, 1H, Ar*H*), 7.42 (d, J = 8.6 Hz, 1H, Ar*H*), 6.87 (dd, J = 8.5, 2.4 Hz, 1H, Ar*H*), 6.49 (dd, J = 3.7, 0.8 Hz, 1H, Ar*H*), 3.88 (s, 3H, O*CH*₃), 1.67 (s, 9H, C(*CH*₃)₃). **13C NMR** (101 MHz, CDCl₃) δ 157.6, 149.8, 136.1, 124.5, 124.2, 121.2, 112.1, 107.1, 99.2, 83.4, 55.6, 28.8. NMR values correspond to the reported ones. [11]

Tert-butyl 6-bromo-1*H*-indole-1-carboxylate (27d)

Following general procedure **GP1**, starting from commercially available 6-bromo-1H-indole (2.00 g, 10.2 mmol), after 16 hours *tert*-butyl 6-bromo-1*H*-indole-1-carboxylate **27d** (2.94 g, 9.93 mmol, 97% yield) was obtained as a white solid. **R**_f: 0.7 (Pentane: EtOAc 9:1) ¹**H NMR** (400 MHz, CDCl₃) δ 8.37 (s, 1H, Ar*H*), 7.56 (d, J = 3.7 Hz, 1H, Ar*H*), 7.41 (d, J = 8.3 Hz, 1H, Ar*H*), 7.34 (dd, J = 8.3, 1.8 Hz, 1H, Ar*H*), 6.56 – 6.50 (m, 1H, Ar*H*), 1.68 (s, 9H, C(*CH*₃)₃). ¹³**C NMR** (101 MHz, CDCl₃) δ 149.3, 135.8, 129.2, 126.2, 125.8, 121.9, 118.3, 117.8, 106.9, 84.1, 28.1. NMR values correspond to the reported ones. ^[12]

Tert-butyl 3-methyl-1*H*-indole-1-carboxylate (27e)

Following general procedure **GP1**, starting from commercially available 3methyl-1*H*-indole (1.31 g, 9.99 mmol), after 16 hours tert-butyl 6-bromo-1*H*indole-1-carboxylate 27e (2.00 g, 8.65 mmol, 87% yield) was obtained as a colorless liquid. R_f: 0.9 (Pentane: EtOAc 95:5). ¹H NMR (400 MHz, CDCl₃) δ 8.16 (br-s, 1H, ArH), 7.53 (d, J = 7.6 Hz, 1H, , ArH), 7.39 (s, 1H, ArH), 7.35 (ddd, J = 8.3, 7.2, 1.4 Hz, 1H, ArH), 7.31 – 7.24 (m, 1H, ArH), 2.31 (s, 3H, CH_3), 1.70 (s, 9H, $C(CH_3)_3$). ¹³C **NMR** (101 MHz, CDCl₃) δ 149.5, 135.3, 131.2, 123.9, 122.5, 122.1, 118.6, 116.0, 114.9, 82.7, 27.9, 9.3. NMR values correspond to the reported ones. [13]

Synthesis of 1-Tosyl-1*H*-indole (30)

Following a reported procedure^[14] to a solution of the commercially available NH-indole 28 (3.52 g, 30.0 mmol, 1.00 equiv.) in anhydrous DCM (0.10 M, 300 mL) was added nBu₄NHSO₄ (1.02 g, 3.00 mmol, 0.100 equiv.) followed by addition of freshly powdered NaOH (4.81 g, 120 mmol, 4.00 equiv.). The resultant solution was allowed to stir at room temperature for 10 minutes before addition of 4-methylbenzene-1-sulfonyl chloride 29 (11.4 g, 60.0 mmol, 2.00 equiv.) and then allowed to stir at room temperature. After 3 hours, the reaction was quenched with H₂O (equal amount to reaction solvent volume), the organic layer was collected, and the aqueous layer was extracted three times with CH₂Cl₂ (equal to reaction volume). The combined organic layers were dried over MgSO₄, filtered and the solvent was removed under reduced pressure. The crude product was then purified via flash column chromatography and 1-tosyl-1*H*-indole **30** (6.20 g, 22.8 mmol, 76% yield) was obtained as a colorless solid. **R**f: 0.6 (Pentane: EtOAc 8:2). ¹**H NMR** (400 MHz, CDCl₃) δ 8.01 (dd, J = 8.3, 0.9 Hz, 1H, ArH), 7.83 - 7.75(m, 2H, ArH), 7.58 (d, J = 3.6 Hz, 1H, ArH), 7.53 (dt, J = 7.8, 1.0 Hz, 1H, ArH), 7.32 (ddd, J= 8.4, 7.2, 1.3 Hz, 1H, ArH), 7.24 (dd, J = 7.8, 1.0 Hz, 1H, ArH), 7.22 - 7.16 (m, 2H, ArH),6.66 (dd, J = 3.7, 0.8 Hz, 1H, ArH), 2.32 (s, 3H, CH₃). ¹³C NMR (101 MHz, CDCl₃) δ 144.8, 135.2, 134.7, 130.6, 129.8, 126.7, 126.2, 124.4, 123.2, 121.3, 113.4, 108.9, 21.4. The NMR values correspond to the reported ones.[14]

Synthesis of 2-(2-(1*H*-Indol-3-yl)ethyl)isoindoline-1,3-dione (33)

$$NH_2$$
 NH_2 NH_2

Following the reported procedure, ^[15] a mixture of commercially available tryptamine **31** (1.00 g, 6.24 mmol) and phthalic anhydride **32** (1.02 g, 6.80 mmol) in toluene (25 mL) was refluxed overnight (the reaction was completed as judged by TLC (Pentane: EtOAc 3:2)). The reaction mixture was cooled to room temperature and the solution was concentrated under vacuum. The crude product was purified by column chromatography on silica gel to get 2-(2-(1H-indol-3-yl)ethyl)isoindoline-1,3-dione **33** (1.60 g, 5.50 mmol, 88% yield) as a yellow solid. **R**_f: 0.6 (Pentane: EtOAc 2:3). ¹**H NMR** (400 MHz, CDCl₃) δ 8.09 (br-s, 1H, NH), 7.83 (dd, J = 5.4, 3.1 Hz, 2H, ArH), 7.77 – 7.66 (m, 3H, ArH), 7.35 (d, J = 8.1 Hz, 1H, ArH), 7.22 – 7.03 (m, 3H, ArH), 4.07 – 3.96 (m, 2H, NCH₂), 3.16 (dd, J = 8.9, 6.7 Hz, 2H, C-CH₂). ¹³**C NMR** (101 MHz, CDCl₃) δ 168.3, 136.2, 133.8, 132.1, 127.3, 123.1, 122.1, 122.0, 119.5, 118.8, 112.3, 111.1, 38.5, 24.4. The NMR values correspond to the reported ones. ^[16]

General Procedure GP2 for the Borylation of N-Boc-Indoles.

With a slight modification of the reported procedure, [17] 2,2,6,6-tetramethylpiperidine (1.30 equiv.) in anhydrous THF (0.40 M) was cooled to -78 °C under an atmosphere of argon and treated dropwise with *n*-BuLi in Hexane (1.50 equiv.). The mixture was stirred at -78 °C for 10 min, then a solution of the corresponding 1-(*tert*-butoxycarbonyl)-1*H*-indole **27a-27e** (1.00 equiv.) in THF (1.00 M) was added dropwise. The mixture was stirred at -78 °C for 45 min. B(O*i*-Pr)₃ (3.00 equiv.) was added dropwise, and the reaction mixture was stirred for 30 min at -78 °C before being warmed to r.t. The reaction mixture was quenched with H₂O (30 mL), slowly acidified with 10% HCl at 0 °C (pH: 6), and extracted with EtOAc (3 times). The combined organic layers were washed with brine, dried over MgSO₄, and the solvent was removed under vacuum. In the next step, without further purification, the crude product was

dissolved in MeOH (0.20 M) and cooled at 0° C. Then a 4.5 M aqueous solution of KHF₂ (3.00 equiv.) was slowly added and the reaction mixture was stirred for 4 hours until the clear solution turned to a thick suspension. The solid was then filtered and washed with a minimum of cold MeOH (2 mL). The solid was dried on a high-vacuum line to afford the corresponding trifluoro borate salts **11a-11e**.

Figure 2.3 Indole-C2-trifluoroborate potassium salts.

Potassium trifluoro(1-tert-butoxycarbonyl-1H-indol-2-yl)borate (11a)

BF₃K N Boc Following general procedure **GP2**, starting from synthesized 1-(*tert*-butoxycarbonyl)-1*H*-indole **27a** (4.50 g, 20.7 mmol., 1.00 equiv.) with commercially available 2,2,6,6-tetramethylpiperidine (4.60 mL, 27.0 mmol. 1.30 equiv.), 2.5 M *n*-BuLi in hexane (12.4 mL, 31.1 mmol, 1.50

equiv.), triisopropyl borate (14.3 mL, 62.1 mmol, 3.00 equiv.) and 4.5 M aqueous solution of KHF₂ (13.8 mL, 62.0 mmol, 3.00 equiv.) Potassium trifluoro(1-*tert*-butoxycarbonyl-1*H*-indol-2-yl)borate (5.20 g, 16.1 mmol, 78% yield) **11a** was obtained as colorless solid. ¹**H NMR** (400 MHz, DMSO- d_6) δ 8.02 (dq, J = 8.3, 0.9 Hz, 1H, ArH), 7.47 – 7.31 (m, 1H, ArH), 7.22 – 7.03 (m, 2H, ArH), 6.46 (s, 1H, ArH), 1.59 (s, 9H, C(CH_3)₃). ¹³**C NMR** (101 MHz, DMSO- d_6) δ 151.3, 137.4, 130.7, 121.7, 121.3, 119.3, 114.6, 111.7, 81.5, 27.7. The NMR values correspond to the reported ones. ^[17] NB: the Carbon-Boron bond is not observed as reported in literature. ^[18]

Potassium trifluoro(1-(tert-butoxycarbonyl)-5-methoxy-1H-indol-2-yl)borate (11b)

Following general procedure **GP2**, starting from synthesized *tert*-butyl 5-methoxy-1*H*-indole-1-carboxylate **27b** (1.50 g, 6.00 mmol, 1.00 equiv.), with commercially available 2,2,6,6-tetramethylpiperidine (1.33 mL, 7.89 mmol. 1.30 equiv.), 1.6 M *n*-BuLi in hexane (5.70 mL, 9.10 mmol, 1.50 equiv.) triisopropyl borate (4.20 mL, 18.2 mmol, 3.00 equiv.) and 4.5 M aqueous solution of KHF₂ (4.02 mL, 18.1 mmol, 3.00 equiv.) Potassium trifluoro(1-(*tert*-

butoxycarbonyl)-5-methoxy-IH-indol-2-yl)borate **11b** (1.18 g, 3.34 mmol, 55% yield). ¹**H NMR** (400 MHz, CD₃CN) δ 7.56 (d, J = 9.0 Hz, 1H, ArH), 6.64 (d, J = 2.6 Hz, 1H, ArH), 6.44 (dd, J = 9.0, 2.6 Hz, 1H, ArH), 6.30 – 6.16 (m, 1H, ArH), 3.47 (s, 3H, OCH₃), 1.33

(s, 9H, $C(CH_3)_3$). ¹³C NMR (101 MHz, CD_3CN) δ 156.1, 152.2, 133.2, 132.9, 116.7, 113.7, 111.4, 103.1, 83.2, 55.8, 28.2. The NMR values correspond to the reported ones. ^[11] NB: the Carbon-Boron bond is not observed as reported in literature. ^[18]

Potassium trifluoro(1-(tert-butoxycarbonyl)-6-methoxy-1H-indol-2-yl)borate (11c)

Following general procedure **GP2**, starting from synthesized *tert*-butyl 6-methoxy-1*H*-indole-1-carboxylate **27c** (650 mg, 2.63 mmol, 1.00 equiv.), with commercially available 2,2,6,6-tetramethylpiperidine (582
$$\mu$$
L, 3.42 mmol. 1.30 equiv.), 2.5 M *n*-BuLi in hexane (1.58 mL, 3.94 mmol, 1.50 equiv.), triisopropyl borate (1.82 mL, 7.89 mmol, 3.00 equiv.) and 4.5 M aqueous solution of KHF2 (1.75 mL, 7.89 mmol, 3.00 equiv.). Potassium trifluoro(1-(*tert*-butoxycarbonyl)-6-methoxy-1*H*-indol-2-yl)borate **11c** (813 mg, 2.30 mmol, 88% yield) was obtained as colorless solid. **M.p.** 185 °C, decomposition). ¹**H NMR** (400 MHz, Acetone- d_6) δ 7.65 (d, $J = 2.3$ Hz, 1H, Ar*H*), 7.25 (d, $J = 8.4$ Hz, 1H, Ar*H*), 6.72 (dd, $J = 8.4$, 2.3 Hz, 1H, Ar*H*), 6.54 (s, 1H, Ar*H*), 3.79 (s, 3H, OC H_3), 1.68 (s, 9H, C(CH_3)₃). ¹³C **NMR** (101 MHz, Acetone- d_6) δ 157.2, 152.4, 139.4, 126.4, 120.4, 113.5, 111.0, 101.2, 82.8, 55.6, 28.4. **IR** v 2976 (w), 1730 (m), 1699 (m), 1619 (w), 1484 (m), 1440 (w), 1368 (s), 1222 (m), 1200 (s), 1147 (s), 1092 (s), 1004 (s), 920 (s), 843 (s), 778 (m). **HR-ESI-MS**: calcd for C₁₄H₁₆BF₃NO₃+314.1175 [M - K]+; found 314.1187. *NB*: the Carbon-Boron bond is not observed as reported in literature. ^[18]

Potassium trifluoro(1-(tert-butoxycarbonyl)-6-bromo-1H-indol-2-yl)borate (11d)

Following general procedure **GP2**, starting from synthesized *tert*-butyl 6-bromo-1*H*-indole-1-carboxylate **27d** (1.50 g, 5.06 mmol, 1.00 equiv.), with commercially available 2,2,6,6-tetramethylpiperidine (1.12 mL, 6.58 mmol. 1.30 equiv.), 2.5 M *n*-BuLi in hexane (3.04 mL, 7.60 mmol, 1.50 equiv.) triisopropyl borate (3.51 mL, 15.2 mmol, 3.00 equiv.) and 4.5 M aqueous solution of KHF₂ (3.38 mL, 15.2 mmol, 3.00 equiv.). Potassium trifluoro(1-(*tert*-butoxycarbonyl)-6-bromo-*1H*-indol-2-yl)borate **11d** (0.830 g, 2.06 mmol, 41% yield) was obtained as colorless solid. **M.p**:

200 °C, decomposition. ¹**H NMR** (400 MHz, Acetone- d_6) δ 8.26 (d, J = 1.9 Hz, 1H, ArH), 7.36 (d, J = 8.2 Hz, 1H, ArH), 7.23 (dd, J = 8.2, 1.8 Hz, 1H, ArH), 6.63 (d, J = 0.8 Hz, 1H, ArH), 1.69 (s, 9H, C(CH_3)₃). ¹³C NMR (101 MHz, Acetone- d_6) δ 152.0, 139.4, 131.4, 125.1, 121.6, 119.0, 115.7, 113.2, 83.5, 28.2 **IR** v 1737 (w), 1709 (w), 1448 (w), 1357 (m), 1325 (s), 1247 (w), 1211 (w), 1126 (s), 987 (s), 837 (w). **HR-ESI-MS**: calcd for C₁₃H₁₃B⁷⁹BrF₃NO₂⁺ 362.0175 [M - K]⁺; found 362.0180. *NB*: the Carbon-Boron bond is not observed as reported in literature. ^[18]

Potassium trifluoro(1-(tert-butoxycarbonyl)-3-methyl-1H-indol-2-yl)borate (11e)

Following general procedure **GP2**, starting from synthesized *tert*-butyl 6-Me methoxy-1*H*-indole-1-carboxylate **27e** (2.00 g, 8.65 mmol, 1.00 equiv.), with commercially available 2,2,6,6-tetramethylpiperidine (1.91 mL, 11.2 Boc mmol. 1.30 equiv.), 2.5 M n-BuLi in hexane (5.20 mL, 12.9 mmol, 1.50 11e equiv.), triisopropyl borate (6.00 mL, 25.9 mmol, 3.00 equiv.) and 4.5 M aqueous solution of KHF₂ (5.80 mL, 25.9 mmol, 3.00 equiv.). Potassium trifluoro(1-(tert-butoxycarbonyl)-3methyl-1H-indol-2-yl)borate 11e (2.50 g, 7.40 mmol, 86% yield) was obtained as colorless solid, (Mp: 205 °C). ¹H NMR (400 MHz, Acetone- d_6) δ 7.96 – 7.86 (m, 1H, ArH), 7.48 – 7.34 (m, 1H, ArH), 7.19 - 6.99 (m, 2H, ArH), 2.34 (s, 3H, CH_3), 1.66 (s, 9H, $C(CH_3)_3$). ¹³C NMR (101 MHz, Acetone- d_6) δ 152.4, 137.8, 133.8, 122.9, 121.8, 121.1, 118.3, 115.5, 82.6, 28.3, 10.3.**IR** v 2977 (w), 1726 (s), 1454 (w), 1374 (m), 1327 (s), 1238 (m), 1135 (s), 956 (s), 874 (m), 740 (s). **HR-ESI-MS**: calcd for $C_{14}H_{16}BF_3NO_2^+ 298.1226 [M - K]^+$; found 298.1230. *NB*: the Carbon-Boron bond is not observed as reported in literature. [18]

Synthesis of potassium trifluoro(1-(tosyl)-1H-indol-2-yl)borate (11f)

Following a reported procedure,^[19] 1.6 M *n*BuLi in hexane (9.38 mL, 15.0 mmol, 1.5 equiv.) was added dropwise to a solution of *N*-tosyl-1*H*-indole **30** (2.71 g, 10.0 mmol, 1.00 equiv) 50 mL of tetrahydrofuran at -78 °C. The reaction mixture was heated to room temperature and stirred for an additional 20 minutes. After cooling to -78 °C., triisopropyl borate (3.92 mL 17.0 mmol, 1.70 equiv) was added. After 10 minutes of addition, the reaction was allowed to warm

to room temperature and stirred overnight. The reaction mixture was quenched with H₂O (30 mL), slowly acidified with 10% HCl at 0 °C (pH:6), and extracted with EtOAc (3 x 50 mL). The combined organic layers were dried over magnesium sulfate and evaporated under reduced pressure to give 3.15 g of a green oil. The crude product was used without further purification in the next reaction. The crude product was dissolved in MeOH (100 mL) and cooled to 0 °C. A 4.5 M solution of KHF₂ in H₂O (6.6 mL, 30 mmol, 3 equiv.) was slowly added and the resulting pink thick suspension was stirred at r.t. for 4 hours. The solid was filtered and dried under reduced pressure and washed with a minimum of cold MeOH (3 mL). The solid was dried on a high-vacuum line to afford the corresponding trifluoro borate salt potassium trifluoro(1-(tosyl)-1H-indol-2-yl)borate **11f** (1.65 g, 4.40 mmol, 44% yield) as colorless solid. **M.p.** 235 °C. ¹**H NMR** (400 MHz, Acetone- d_6) δ 8.07 (dd, J = 8.8, 3.1 Hz, 3H, ArH), 7.39 – 7.25 (m, 1H, ArH), 7.14 (d, J = 8.1 Hz, 2H, ArH), 7.11 – 6.99 (m, 2H, ArH), 6.45 (d, J = 0.8 Hz, 1H, ArH), 2.22 (s, 3H, CH_3). ¹³C NMR (101 MHz, Acetone- d_6) δ 144.2, 138.9, 138.4, 132.7, 129.8, 128.3, 122.9, 122.8, 120.6, 116.8, 115.2, 21.3. **IR** v 2040 (w), 1834 (w), 1417 (s), 1217 (s), 853 (w). **HR-ESI-MS**: calcd for: Calcd for $C_{15}H_{12}BF_3NO_2S^+$ 338.0634[M - K]⁺; Found 338.0626. NB: the Carbon-Boron bond is not observed las reported in literature. [18]

Synthesis and characterization of tryptamine trifluoroborates (11g)

Following a reported procedure, [20] a flame dried 20-mL pressure flask was charged with (1,5-cyclooctadiene)(methoxy)iridium(I) dimer (17.0 mg, 30.0 µmol, 1.50 mol%), 4,4'-di-tert-butyl-2,2'-dipyridyl (14.0 mg, 50.0 µmol, 3.00 mol%), bis(pinacolato)diboron (868 mg, 3.42 mmol, 2.00 equiv.), *N*,*N*-phthaloyltryptamine **33** (500 mg, 1.72 mmol), and a stirring bar and sealed with a septum under an atmosphere of argon. Anhydrous dichloromethane (11 mL) was added via syringe to give a colorless suspension. The septum was replaced with the pressure flask's Teflon seal and the entire mixture was heated in an oil bath set to 65 °C. After completion of reaction (checked by TLC; Pentane: EtOAc 7:3), the reaction mixture is filtered through a small silica path and evaporate to dryness. The crude reaction mixture was used for the next step. The crude product was dissolved in 10 mL MeOH, and cooled at 0 °C, then a 4.5 M solution of

KHF₂ (1.20 mL, 5.20 mmol) was slowly added, and the reaction mixture was stirred for 4 hours until the clear solution turned thick. The solid was filtered and dried under reduced pressure and washed with a minimum of cold MeOH. The solid was dried on a high-vacuum line to afford as potassium trifluoro(2-(2-(1H-indol-3-yl)ethyl)isoindoline-1,3-dione) borate **11g** (523 mg, 1.32 mmol, 77%) as yellow solid. **M.p.** 210 °C, decomposition. ¹**H NMR** (400 MHz, DMSO- d_6) δ 9.90 (s, 1H, NH), 7.90 – 7.74 (m, 4H, ArH), 7.46 (d, J = 7.6 Hz, 1H, ArH), 7.23 (d, J = 7.7 Hz, 1H, ArH), 6.81 (dt, J = 20.5, 7.1 Hz, 2H, ArH), 3.74 (q, J = 9.0, 8.3 Hz, 2H, NCH₂), 3.04 (t, J = 7.8 Hz, 2H, NCH₂-CH₂-). ¹³C **NMR** (101 MHz, DMSO- d_6) δ 167.9, 136.5, 134.1, 131.8, 129.1, 122.8, 118.3, 116.8, 116.7, 111.0, 110.6, 39.1, 24.6. **IR** v 3431 (w), 1705 (m), 1616 (m), 1399 (w), 1325 (m), 1137 (s), 959 (s), 742 (s). **HR-ESI-MS:** calcd for C₁₈H₁₃BF₃K₀N₂O₂+ 357.1022 [M - K]+; found 357.1028. *NB: the Carbon-Boron bond is not observed as reported in literature.* ^[18]

2.3 Optimization of the synthesis of C2-IndoleBX.

Entry	X	R	Hypervalent reagent (Y,Z)	Promoter (mol%)	Solvents	Yielda
1	BF ₃ K	Boc	12c	Zn(OTf) ₂	DCM	_b
2	BF ₃ K	Boc	12f	Zn(OTf) ₂	DCM	_b
3	BF ₃ K	Boc	12c	ZnF ₂	DCM	-
4	BF ₃ K	Boc	12f	ZnF ₂	DCM	-
5	BF ₃ K	Boc	12c	TfOH	DCM	_b
6	BF ₃ K	Boc	12f	TfOH	DCM	_b
7	SiMe ₃	Н	12c	TMSOTf	MeCN	-
8	BF ₃ K	Boc	12a ^c	NaBF ₄	MeCN	27% ^{d,e}
9	BF ₃ K	Boc	12e	NaBF ₄	MeCN	86% ^{d,e}
10	SiMe ₃	Me	12e	NaBF ₄	MeCN,	_e,f
11	BF ₃ K	Boc	12e	AgBF ₄	MeCN,	_b,f
12	BF ₃ K	Boc	12d	AgBF ₄	MeCN	_b,f

a) Substrate (0.25 mmol), hypervalent iodine reagent **12a-12d**, **12g-12h** (0.25 mmol), Promoter (20 mol%.) and solvent (0.05 M) at 25 °C. all reactions are carried out overnight (except entry 8: carried out for 30 h; entry 9: best yield was observed only in 2 hours) b) Degradation of reagent, no expected product was observed. c) This reagent was prepared *in situ* d) Isolated yield after flash chromatography is given. e) Entries 8-10, reactions were quenched with 5% aqueous NaBF₄ solution. f) Entries 10-12, the reaction initially run at room temperature, no consumption of starting material was observed after 6 h then reactions were allowed to refluxing temperature for additional 12 h

2.4 Preparation of PyrroleBX and IndoleBX Reagents.

General Procedure GP3 for the Synthesis of C3-Heterocyclic-BX Reagents 2a-2f.

Note: prior to the reaction, the glassware requires to be carefully cleaned with aqua regia to remove all metal traces; the commercially available heterocyclic starting material were purified through a short plug of silica prior to being used.

GP3: for 1.00 mmol: in an open air flask, the corresponding heterocycle (1.00 mmol, 1.00 equiv.), freshly prepared acetoxy-benziodoxolone **12f** (1.10 mmol, 1.10 equiv.) and Zinc(II) trifluoromethanesulfonate (72.7 mg, 0.200 mmol, 20 mol%.) were dissolved in DCM (20 mL, 0.05 M). The reaction was stirred while being monitored by TLC (Pentane:EtOAc 9:1 for the starting materials, DCM:MeOH 9:1 for the products). Upon consumption of the starting material, the crude product was directly submitted to short-path flash chromatography (DCM:MeOH 10:1) to afford the desired Heterocyclic-BX compounds **2a-2f**.

$1-(3-1-Methyl-1H-indole)-1H-1\lambda_3$ -benzo[b]iodo-3(2H)-one (2a)

2a

Me The synthesis of 1-(3-1-methyl-1H-indole)-1H-1 λ_3 -benzo[b]iodo-3(2H)-one 2a was scaled up to 10 mmol without reoptimization of the protocol.

Following procedure **GP3**: starting from commercially available 1-methyl-1-H-indole **5** (1.35 g, 10.0 mmol), after 16 hours 1-(3-1-methyl-

1*H*-indole)-1*H*-1 λ_3 -benzo[*b*]iodo-3(2*H*)-one **2a** (3.28 g, 8.70 mmol, 87% yield) was obtained as a brown foam. **Rf**: 0.4 (DCM:MeOH 9:1). ¹**H NMR** (400 MHz, CDCl₃) δ 8.40 (dd, *J* = 7.5, 1.7 Hz, 1H, Ar*H*), 7.82 (s, 1H, N*CH*Cl), 7.55 – 7.48 (m, 2H, Ar*H*), 7.39 – 7.35 (m, 2H, Ar*H*), 7.34 – 7.23 (m, 2H, Ar*H* + CDCl₃), 6.84 (d, *J* = 8.3 Hz, 1H, Ar*H*), 4.02 (s, 3H, N*CH*₃). ¹³**C NMR** (101 MHz, CDCl₃) δ 166.8, 138.6, 137.6, 133.4, 133.3, 132.5, 130.5, 129.3, 125.2, 124.3, 122.6, 119.9, 116.1, 110.7, 78.9, 33.9. **IR** v 3107 (w), 3059 (w), 2948 (w), 1599 (s), 1552 (m),


1506 (m), 1454 (w), 1392 (m), 1277 (s), 1245 (s), 1225 (s), 1166 (s), 1131 (m), 1031 (s), 1004 (w), 842 (w). **HR-ESI-MS** calcd for $C_{16}H_{13}INO_2^+[M+H]^+377.9986$, found 377.9990.

$1-(3-5-Iodo-1-methyl-1H-indole)-1H-1\lambda_3$ -benzo[b]iodo-3(2H)-one (2b)

Following procedure **GP3**: starting from 5-iodo-1-methyl-1*H*-indole **34d** (257 mg, 1.00 mmol), after 16 hours 1-(3-5-iodo-1-methyl-1*H*-indole)-1*H*-1 λ_3 -benzo[*b*]iodo-3(2*H*)-one **2b** (380 mg, 0.755 mmol, 76% yield) was obtained as a yellow amorphous solid. *NB*: the reagent is unstable in acidic deuterated solvents and it decompose in short time,

we recommend the immediate use after the synthesis. The proton NMR presents about 21% of the open protonated form. Rf: 0.3 (DCM:MeOH 9:1). 1 H NMR (400 MHz, CDCl₃) δ 8.24 (m, 1H, Ar*H*), 7.83 (s, 1H, NCHCl), 7.58 – 7.47 (m, 2H, Ar*H*), 7.26 (m, 1H, Ar*H* + CDCl₃), 7.21 - 7.18 (m, 2H, Ar*H*), 6.67 (d, J = 8.1 Hz, 1H, Ar*H*), 3.87 (s, 3H, CH_3 N). 13 C NMR (101 MHz, CDCl₃) δ 168.6, 140.5, 136.8, 133.7, 132.6, 132.3, 131.4, 130.3, 128.1, 126.0, 122.3, 119.1, 115.7, 112.9, 86.1, 34.0. IR v 3092 (w), 3061 (w), 1600 (s), 1584 (m), 1557 (m), 1503 (m), 1436 (w), 1422 (w), 1371 (m), 1265 (s), 1245 (s), 1225 (m), 1163 (m), 1113 (w), 1031 (s), 1004 (w), 836 (w). HR-ESI-MS calcd for $C_{16}H_{12}I_2NO_2^+$ [M+H] $^+$ 503.8952; found 503.8952.

1-(3-1-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole)-1H-1 λ_3 —benzo [b]iodo-3(2H)-one (2c)



Following procedure **GP3**: starting from commercially available 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-indole (149 mg, 1.00 mmol), after 16 hours 1-(3-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-indole)-1*H*-1 λ_3 -benzo[*b*]iodo-3(2*H*)-one **2c** (276 mg, 0.549 mmol, 54% yield) was obtained as an orange 0.46 (DCM:MeOH 9:1). ¹**H NMR** (400 MHz, CD₂Cl₂) δ 8.32 (dd, *J* = 7.93 (s, 1H, N*CH*Cl), 7.81 (dd, *J* = 8.4, 1.1 Hz, 1H, Ar*H*), 7.74 (s, 1H,

amorphous solid. **Rf**: 0.46 (DCM:MeOH 9:1). ¹**H NMR** (400 MHz, CD₂Cl₂) δ 8.32 (dd, J = 7.5, 1.7 Hz, 1H, ArH), 7.93 (s, 1H, NCHCI), 7.81 (dd, J = 8.4, 1.1 Hz, 1H, ArH), 7.74 (s, 1H, CCHCBPin), 7.59 – 7.48 (m, 2H, ArH), 7.31 (ddd, J = 8.6, 7.1, 1.7 Hz, 1H, ArH), 6.85 (dd, J = 8.3, 0.9 Hz, 1H, ArH), 3.99 (s, 3H, NCH3), 1.30 (s, 12H, CBPin). ¹³C **NMR** (101 MHz, CD₂Cl₂) δ 167.0, 140.1, 139.6, 134.1, 133.8, 132.6, 131.0, 130.5, 129.5, 127.6, 126.0, 117.1, 110.7, 84.5, 80.3, 34.4, 25.2. NB: the Carbon-Boron bond is not observed as reported in literature. ^[18] **IR** ν 3095 (w), 2979 (w), 1611 (s), 1558 (w), 1507 (w), 1436 (w), 1360 (s), 1303


(w), 1263 (w), 1142 (s), 1114 (w), 1074 (w), 970 (w), 861 (w). **HR-ESI-MS** calcd for $C_{22}H_{24}BINO_4^+[M+H]^+504.0838$; found 504.0835.

$1-(3-1,2-Dimethyl-1H-indole)-1H-1\lambda_3-benzo[b]iodo-3(2H)-one (2d)$

Following procedure **GP3**: starting from 2-methyl-1-methyl-1*H*-indole **34a** (145 mg, 1.00 mmol), after 16 hours 1-(3-1,2-dimethyl-1*H*-indole)-1H- $1\lambda_3$ -benzo[b]iodo-3(2H)-one **2d** (364 mg, 0.930 mmol, 93% yield) was obtained as a dark violet foam. **Rf**: 0.43 (DCM:MeOH 9:1).). 1 **H NMR** (400 MHz, CDCl₃) δ 8.42 (dd, J = 7.3, 1.7 Hz, 1H, ArH), 7.52 (td,

J = 7.3, 0.9 Hz, 1H, Ar*H*), 7.44 (d, J = 8.2 Hz, 1H, Ar*H*), 7.35 (m, 2H, Ar*H*), 7.28 (m, 1H, Ar*H*), 7.23 (ddd, J = 8.2, 6.9, 1.0 Hz, 1H, Ar*H*), 6.77 (m, 1H, Ar*H*), 3.91 (s, 3H, CH_3N), 2.65 (s, 3H, ICH=CH CH_3). ¹³C NMR (101 MHz, CDCl₃) δ 166.8, 145.3, 137.9, 133.7, 133.2, 132.7, 130.5, 128.9, 124.7, 123.6, 122.4, 119.2, 115.5, 110.4, 80.1, 31.1, 13.2. IR v 3055 (w), 2987 (w), 2948 (w), 1717 (w), 1605 (s), 1584 (m), 1553 (m), 1516 (w), 1472 (w), 1437 (w), 1395 (m), 1378 (m), 1268 (m), 1154 (w), 1032 (w), 1011 (w), 829 (w). HR-ESI-MS calcd for $C_{17}H_{15}INO_2^+$ [M+H]⁺ 392.0142; found 392.0146.

1-(2-1-Methyl-1*H*-pyrrole)-1*H*-1 λ_3 -benzo[*b*]iodo-3(2*H*)-one (2e) and 1-(3-1-methyl-1*H*-pyrrole)-1*H*-1 λ_3 -benzo[*b*]iodo-3(2*H*)-one (2e').



Following procedure **GP3:** starting from commercially available 1-methyl-1*H*-pyrrole (0.890 ml, 1.00 mmol), after 12 hours 1-(2-1-methyl-1*H*-pyrrole)-1*H*-1 λ_3 -benzo[*b*]iodo-3(2*H*)-one **2e** and 1-(3-1-methyl-1*H*-pyrrole)-

 $1H-1\lambda_3$ -benzo[b]iodo-3(2H)-one **2e'** were obtained as a 1:1 mixture (310 mg, 0.948 mmol, overall yield 95%) as an off-white, sticky amorphous solid. Rf: 0.5 (DCM:MeOH 9:1). The two compounds were separated by slow flash column chromatography (EtOAc:MeOH 9:1).

1-(2-1-methyl-1*H*-pyrrole)-1*H*-1 λ_3 -benzo[*b*]iodo-3(2*H*)-one **2e** (152 mg, 0.465 mmol, 47% yield; off-white, sticky amorphous solid) **Rf:** 0.3 (EtOAc:MeOH 9:1). ¹**H NMR** (400 MHz, CD₃OD) δ 8.24 (dd, J = 7.5, 1.6 Hz, 1H, Ar*H*), 7.65 (td, J = 7.4, 1.0 Hz, 1H, Ar*H*), 7.55 (m, 1H, Ar*H*), 7.27 (t, J = 2.1 Hz, 1H, Ar*H*), 7.01 (dd, J = 3.9, 1.6 Hz, 1H, Ar*H*), 6.72 (dd, J =

8.3, 1.0 Hz, 1H, Ar*H*), 6.43 (dd, J = 3.9, 2.1 Hz, 1H, Ar*H*), 3.78 (s, 1H, N*CH*₃). ¹³**C NMR** (101 MHz, CD₃OD) δ 170.1, 135.5, 134.2, 133.2, 131.9, 131.4, 127.7, 126.6, 119.4, 112.9, 96.0,

37.4. **IR** v 3415 (w), 3105 (w), 3049 (w), 2950 (w), 1604 (s), 1584 (m), 1558 (w), 1508 (w), 1437 (w), 1346 (m), 1288 (m), 1223 (w), 1149 (w), 1091 (w), 1047 (w), 1005 (w), 829 (m). **HR-ESI-MS** calcd for $C_{12}H_{11}INO_{2}^{+}$ [M+H]⁺ 327.9829; found 327.9842.

Me 1-(3-1-methyl-1*H*-pyrrole)-1*H*-1 λ_3 -benzo[*b*]iodo-3(2*H*)-one **2e'** (158 mg, 0.483 mmol, 48% yield; off-white, sticky amorphous solid). **Rf:** 0.25 (EtOAc:MeOH 9:1). ¹**H NMR** (400 MHz, CD₃OD) δ 8.15 (dd, *J* = 7.5, 1.7 Hz, 1H, Ar*H*), 7.53 (td, *J* = 7.3, 1.1 Hz, 1H, Ar*H*), 7.49 – 7.40 (m, 2H, Ar*H*), 7.04 – 6.98 (m, 2H, Ar*H*), 6.58 (d, *J* = 1.2 Hz, 1H, Ar*H*),

3.85 (s, 3H, NMe). ¹³C NMR (101 MHz, CD₃OD) δ 170.0, 134.9, 134.2, 133.4, 132.8, 131.5, 127.9, 127.7, 117.4, 116.6, 82.8, 37.1. IR ν 3447 (w), 3106 (w), 2947 (w), 2863 (w), 1603 (s), 1591 (m), 1558 (m), 1512 (m), 1437 (w), 1354 (m), 1294 (w), 1110 (m), 1083 (w), 1007 (w), 829 (m). HR-ESI-MS calcd for C₁₂H₁₁INO₂⁺ [M+H]⁺ 327.9829; found 327.9842.

1-(2-1-benzyl-1*H*-pyrrole)-1*H*-1 λ_3 -benzo[*b*]iodo-3(2*H*)-one (2f) and 1-(3-1-benzyl-1*H*-pyrrole)-1*H*-1 λ_3 -benzo[*b*]iodo-3(2*H*)-one (2f')

Following procedure **GP3**: starting from commercially available 1-benzyl-1*H*-pyrrole (0.890 ml, 1.00 mmol), after 12 hours 1-(2-1-benzyl-1*H*-pyrrole)-1*H*-1 λ_3 -benzo[*b*]iodo-3(2*H*)-one **2f** and 1-(3-1-benzyl-1*H*-pyrrole)-1*H*-1 λ_3 -benzo[*b*]iodo-3(2*H*)-one **2f** were

obtained in 3:1 mixture (345 mg, 0.856 mmol, overall yield 86%), as a colorless amorphous solid. **Rf**: 0.7 (DCM:MeOH 9:1). The two compounds were separated by slow flash column chromatography (EtOAc:MeOH 9:1).

2f'

1-(2-1-benzyl-1*H*-pyrrole)-1*H*-1 λ_3 -benzo[*b*]iodo-3(2*H*)-one **2f** (85.0 mg, 0.211 mmol, 21% yield); colorless foam. **Rf**: 0.5 (EtOAc:MeOH 9:1). ¹**H NMR** (400 MHz, 2:1 mixture CD₃OD:C₆D₆, referered to CD₃OD) δ 8.18 (dd, J = 7.5, 1.6 Hz, 1H, Ar*H*), 7.28 (t, J = 7.4 Hz, 1H, Ar*H*), 7.10 (t, J = 2.2 Hz, 1H, Ar*H*), 6.92 (m, J = 7.6, 2.9 Hz, 6H, Ar*H* + C₆D₆), 6.71 (dd, J = 3.9, 1.7 Hz, 1H, Ar*H*), 6.35 (t, J = 3.4 Hz, 1H, Ar*H*), 6.23 (d, J = 8.3 Hz, 1H,


Ar*H*), 4.90 (s, 2H, N*CH*₂Ph). ¹³**C NMR** (101 MHz, 2:1 mixture *CD*₃*OD*: C_6D_6 , referered to *CD*₃*OD*) δ 169.8, 136.9, 134.6, 132.7, 131.2, 131.1, 129.5, 129.0, 128.5, 127.2, 119.2, 112.9,

94.8, 54.7 (two Carbon signals under the deuterated benzene). **IR** v 3109 (w), 3064 (w), 2968 (w), 2875 (w), 1609 (s), 1585 (m), 1558 (w), 1503 (w), 1456 (w), 1440 (w), 1357 (m), 1277 (w), 1103 (m), 1079 (w), 1032 (w), 1031 (w), 830 (w). **HR-ESI-MS** calcd for C₁₈H₁₅INO₂⁺ [M+H]⁺ 404.0142; found 404.0140.

1-(3-1-benzyl-1*H*-pyrrole)-1*H*-1 λ_3 -benzo[*b*]iodo-3(2*H*)-one **2f**' (260 mg, 0.645 mmol, 65% yield); colorless foam. **Rf:** 0.46 (EtOAc:MeOH 9:1). **¹H NMR** (400 MHz, 2:1 mixture $CD_3OD:C_6D_6$, refered to CD_3OD) δ 8.29 (dd, J = 7.5, 1.7 Hz, 1H,

Ar*H*), 7.36 (t, J = 7.3 Hz, 1H, Ar*H*), 7.30 – 7.20 (m, 3H Ar*H* + C₆D₆), 7.18 – 7.08 (m, 3H, Ar*H*), 6.97 (d, J = 2.0 Hz, 1H, Ar*H*), 6.83 – 6.78 (m, 2H, Ar*H*), 6.30 (dd, J = 3.0, 1.7 Hz, 1H, Ar*H*), 4.93 (s, 2H, N*CH*₂Ph). ¹³C **NMR** (101 MHz, 2:1 mixture *CD*₃*OD*: *C*₆D₆, refered to *CD*₃*OD*) δ 168.7, 136.8, 133.5, 133.0, 131.8, 130.9, 130.3, 128.8, 128.1, 127.4, 126.2, 125.5, 116.3, 115.3, 82.4, 53.5. **IR** v 3409 (w), 3114 (w), 2971 (w), 1609 (s), 1585 (m), 1558 (w), 1456 (w), 1438 (w), 1365 (m), 1277 (s), 1160 (w), 1079 (w), 1032 (m), 835 (w). **HR-ESI-MS** calcd for C₁₈H₁₅INO₂⁺ [M+H]⁺ 404.0142; found 404.0140.

1-(3-1-Methyl-1*H*-indole)-3,3-dimethyl-1,3-dihydro- $1\lambda^3$ -benzo[d][1,2]iodoxole (3a)



3a

Following procedure **GP3** (on 0.100 mmol scale): starting from commercially available 1-methyl-1-H-indole **5** (26.2 mg, 0.100 mmol) and 3,3-dimethyl-1 λ_3 -benzo[d][1,2]iodoxol-1(3H)-yl acetate **12e** (70.4 mg, 0.220 mmol, 1.10 equiv.), after 16 hours 1-(3-1-methyl-1H-indole)-3,3-dimethyl-1,3-dihydro-1 λ^3 -benzo[d][1,2]iodoxole **3a** (40.1

mg, 0.102 mmol, 51% yield) was obtained as a brown foam. **Rf:** 0.7 (DCM:MeOH 9:1). **IR** v 3115 (w), 3050 (w), 2986 (w), 1509 (w), 1455 (w), 1372 (w), 1284 (s), 1247 (s), 1225 (m), 1166 (m), 1110 (w), 1031 (s), 992 (w). **H NMR** (400 MHz, CDCl₃) δ 7.92 (s, 1H, N*CHCI*), 7.54 (m, 1H, Ar*H*), 7.47 (m, 1H, Ar*H*), 7.45 – 7.40 (m, 3H, Ar*H*), 7.34 (ddd, J = 8.0, 6.9, 1.0 Hz, 1H, Ar*H*), 7.08 (ddd, J = 8.7, 5.8, 2.9 Hz, 1H, Ar*H*), 6.87 (m, 1H, Ar*H*), 4.02 (s, 3H, N*CH*₃), 1.75 (s, 6H, C(*CH*₃)₂). ¹³**C NMR** (101 MHz, CDCl₃) δ 146.3, 140.2, 137.7, 130.9, 130.4, 128.9, 128.7, 127.0, 124.8, 123.3, 119.6, 111.0, 108.9, 74.6, 72.9, 34.2, 30.5. **HR-ESI-MS** calcd for C₁₈H₁₉INO⁺ [M+H]⁺ 392.0506; found 392.0510.

1-(3-1-Methyl-1H-indole)-3,3-bis(trifluoromethyl)-1,3-dihydro-1 λ 3-benzo[d][1,2]iodaoxole (4a)

Following procedure **GP3** (on 0.100 mmol scale): starting from commercially available 1-methyl-1-H-indole **5** (26.2 mg, 0.100 mmol), 1-acetoxy-1,3-dihydro-3,3-bis(trifluoromethyl)-1,2-benziodoxole **12f** (94.0 mg, 0.220 mmol, 1.10 equiv.) and in Et₂O **4a** 0.05 m, after 16 hours 1 (3-1-methyl-1*H*-indole)-3,3-bis(trifluoromethyl)-1,3-dihydro-
$$1\lambda^3$$
-benzo[d][1,2]iodaoxole **4a** (56.1 mg, 0.112 mmol, 56% yield) was obtained as a brown foam. **Rf**: 0.7 (DCM:MeOH 9:1). **IR** v 3069 (w), 2922 (w), 2852 (w), 1732 (w), 1504 (m), 1457 (w), 1263 (s), 1212 (m), 1178 (s), 1157 (s), 1130 (m), 1047 (w), 948 (s). **1H NMR** (400 MHz, CDCl₃) δ 7.86 (m, 1H, Ar*H*), 7.53 (s, 1H, N*CH*Cl), 7.52 – 7.46 (m, 3H, Ar*H*), 7.41 (ddd, J = 8.3, 7.0, 1.1 Hz, 1H, Ar*H*), 7.28 (m, 1H, Ar*H*), 7.23 (m, 1H, Ar*H*), 6.95 (d, J = 8.3 Hz, 1H, Ar*H*), 3.96 (s, 3H, N*CH*₃). **13C NMR** (101 MHz, CDCl₃) δ 137.5, 137.4, 131.7, 131.4, 130.1, 129.9, 126.9, 123.9, 123.2 (m), 122.1, 120.4, 112.2, 110.3, 84.2, 81.55 (dt, J = 57.1, 28.5 Hz), 33.6 (one aromatic Carbon signal not resolved). **HR-ESI-MS** calcd for C₁₈H₁₃F₆INO⁺ [M+H]⁺ 499.9941; found 499.9946.

General Procedure GP4 for the Synthesis of C2-IndoleBX Reagents 13a-13b.

Note: prior to the reaction, the glassware requires to be carefully cleaned with aqua regia to remove all metal traces; the commercially available heterocyclic starting material were purified through a short plug of silica prior to being used.

Following a reported procedure,^[21] commercially available spray-dried KF (581 mg, 10.0 mmol) was dried in a schlenk flask at 150 °C under vacuum over 5 min. After cooling down to r.t., 1-chloro-1,2-benziodoxol-(*1H*)-one **12d** (1.00 equiv.) was added to the vial, followed by anhydrous MeCN (5 mL). The yellow slurry of **12a** was stirred for 2 h at 80 °C. After cooling down to r.t., the suspension was filtered over a sintered glass filter in a dry schlenk flask under inert conditions (*NB*: oxygen has to be completely avoided). A solution of the correspondent

potassium trifluoroborate substrate **11a** or **11f** (2.00 mmol, in 15 mL MeCN, 1.00 equiv.) was added and the resulting solution stirred at r.t. The reaction was monitored in TLC (DCM:MeOH 9:1). After 2 hours the solution slightly changed its color. The reaction was left running overnight, and stopped after 30 h. Then 5% aqueous NaBF₄ (60 mL) was added and the reaction mixture was vigorously stirred for 1 additional hour. (The reaction was stopped upon completion checked by TLC). The quenched reaction mixture was extracted using DCM (2x40 mL), the combined organic layers washed with saturated NaHCO₃ solution (40 mL) and then the organic layer dried over Na₂SO₄. The solvent was then removed under reduced pressure and the crude product purified via column chromatography (DCM:MeOH 10:1) to afford pure reagents **13a-13b**.

1-(Tert-butyl 1H-indole-1-carboxylate)-1H- $1\lambda_3$ -benzo[b]iodo-3(2H)-one (13a)

Following general procedure **GP4**, starting from potassium trifluoro(1-*tert*-butoxycarbonyl-1*H*-indol-2-yl)borate **11a** (646 mg, 2.00 mmol, in 15 mL MeCN, 1.00 equiv.) and 1-chloro-1,2-benziodoxol-(*1H*)-one **11a** (565 mg, 2.00 mmol, 1.00 equiv.), 1-(*tert*-butyl 1*H*-indole-1-carboxylate)-1*H*-1 λ_3 -benzo[*b*]iodo-3(2*H*)-one **13a** (250 mg, 0.540

mmol, 27%), was obtained as a brown solid. **M.p.** 150 °C, decomposition. **R**f: 0.5 (DCM: MeOH 9:1). ¹**H NMR** (400 MHz, CDCl₃) δ 8.41 (dd, J = 7.6, 1.7 Hz, 1H, ArH), 8.31 (d, J = 8.5 Hz, 1H, ArH), 7.74 – 7.59 (m, 2H, ArH), 7.55 – 7.42 (m, 3H, ArH), 7.37 (t, J = 7.6 Hz, 1H, ArH), 7.00 (d, J = 8.4 Hz, 1H, ArH), 1.44 (s, 9H, C(CH_3)₃). ¹³C **NMR** (101 MHz, CDCl₃) δ 166.7, 148.5, 138.0, 134.0, 132.4, 130.9, 129.5, 127.5, 126.1, 126.0, 124.0, 121.7, 119.6, 116.1, 105.9, 86.8, 27.8. (*One aromatic carbon not resolved*). **IR** v 1728 (m), 1636 (s), 1567 (s), 1451 (m), 1349 (m), 1227 (m), 1156 (w), 968 (w). **HR-ESI-MS**: calcd for C₂₀H₁₉INO₄⁺ 464.0353 [M + H]⁺; found 464.0353.

$1-(2-1-(Tosyl)-1H-indol-2-yl)-1H-1\lambda_3$ -benzo[b]iodo-3(2H)-one (13b)

Following general procedure **GP4**, starting from potassium trifluoro(1-(tosyl)-IH-indol-2-yl)borate **11f** (943 mg, 2.50 mmol, 1.00 equiv.) and 1-chloro-1,2-benziodoxol-(IH)-one **xx** (706 mg, 2.50 mmol, 1.00 equiv.), **1**-(2-1-(tosyl)-IH-indol-2-yl)-IH- $I\lambda_3$ -benzo[b]iodo-3(2H)-one **13b** (205 mg, 0.400 mmol, 16% yield) was obtained as colorless

solid. **M.p.:** 185 °C. **R_f:** 0.5 (DCM: MeOH 9:1). ¹**H NMR** (400 MHz, Acetone- d_6) δ 8.22 (d, J = 8.5 Hz, 1H, ArH), 8.08 (d, J = 7.4 Hz, 1H, ArH), 7.92 – 7.84 (m, 2H, ArH), 7.73 (s, 1H, ArH),

7.67 (d, J = 7.9 Hz, 1H, ArH), 7.54 (t, J = 7.3 Hz, 1H, ArH), 7.47 (ddd, J = 8.5, 7.2, 1.3 Hz, 1H, ArH), 7.43 – 7.35 (m, 1H, ArH), 7.35 – 7.27 (m, 1H, ArH), 7.21 (d, J = 8.1 Hz, 2H, ArH), 6.82 (d, J = 8.4 Hz, 1H, ArH), 2.20 (s, 3H, CH_3). ¹³C NMR (101 MHz, Acetone- d_6) δ 166.9, 147.1, 138.6, 135.4, 134.9, 133.9, 132.2, 131.3, 131.2, 131.1, 128.2, 128.1, 127.9, 127.8, 125.1, 123.1, 120.0, 115.6, 110.1, 21.4. IR v 1646 (w), 1603 (s), 1558 (w), 1370 (m), 1173 (s), 1089 (s), 1007 (w), 827 (w). HR-ESI-MS: calcd for $C_{22}H_{16}INNaO_4S^+$ 539.9737 [M + Na]⁺; found 539.9736.

General Procedure GP5 for the Synthesis of C2-IndoleDBX Reagents 13c-13i.

$$R^{1}$$
 R^{2}
 R^{2}
 R^{3}
 R^{3}

Note: prior to the reaction, the glassware requires to be carefully cleaned with aqua regia to remove all metal traces; the commercially available heterocyclic starting material were purified through a short plug of silica prior to being used.

In a dry round bottom flask, commercially available 1-fluoro-3,3-dimethyl-1,2-benziodoxole **12b** (1.00 equiv.) was dissolved in anhydrous MeCN (0.050 M). Potassium trifluoro indole borate salt **11** (1.00 equiv.) was added, and the mixture was stirred at r.t under inert atmosphere. After 2 hour 5% aqueous NaBF₄ (30 mL/mmol, 13.6 equiv.) was added and the reaction mixture was additionally stirred for 1 hour. (The reaction was stopped upon completion, checked by TLC (DCM: MeOH 9:1). The quenched reaction mixture was extracted using DCM (2x20 mL), the combined organic layers were washed with saturated NaHCO₃ solution (20 mL), then the organic layer was dried over Na₂SO₄. Then the solvent was removed under reduced pressure. Column chromatrography purification with EtOAc: MeOH (10:1) afforded the desired C2-IndoleDBXs **13c-13i**.

1-(2-*Tert*-butyl 1*H*-indole-1-carboxylate)-3,3-dimethyl-1,3-dihydro- $1\lambda^3$ -benzo[d][1,2]iodoxol (13c)

Following general procedure **GP5**, starting from potassium trifluoro(1-(*tert*-butoxycarbonyl-1*H*-indol-2-yl)borate **11a** (168 mg, 0.520 mmol, 1.00 equiv.) and commercially available 1-fluoro-3,3-dimethyl-1,2-benziodoxole **12b** (146 mg, 0.520 mmol, 1.00 equiv.), 1-(2-*tert*-butyl 1*H*-indole-1-carboxylate)-3,3-dimethyl-1,3-dihydro-

1λ³-benzo[d][1,2] iodoxol **13c** was obtained (215 mg, 0.450 mmol, 86%) as an off-white foam (**M.p.**: 128-133 °C). [Using same procedure this reaction was scaled up upto 5.00 mmol scale (1.40 g of Indole salt 11a) and desired product 13c was obtained (2.02 g, 4.23 mmol, 85% yield) in same efficiency]. **R**_f: 0.6 (DCM: MeOH 9:1). ¹**H NMR** (400 MHz, CDCl₃) δ 8.34 (dd, J = 8.5, 1.0 Hz, 1H, ArH), 7.59 (dt, J = 7.8, 1.1 Hz, 1H, ArH), 7.46 (td, J = 7.3, 1.0 Hz, 1H, ArH), 7.43 – 7.36 (m, 2H, ArH), 7.32 – 7.26 (m, 1H, ArH), 7.20 – 7.16 (m, 1H, ArH), 7.15 (d, J = 0.8 Hz, 1H, ArH), 6.84 (dd, J = 8.3, 1.0 Hz, 1H, ArH), 1.54 (s, 6H, C(CH_3)₂), 1.46 (s, 9H, C(CH_3)₃). ¹³C **NMR** (101 MHz, CDCl₃) δ 149.3, 148.3, 137.7, 130.1, 129.9, 128.7, 127.0, 126.8, 125.7, 123.1, 122.3, 120.9, 119.3, 115.8, 113.9, 85.0, 74.8, 32.3, 27.8. **IR** v 2968 (w), 1729 (s), 1435 (m), 1354 (s), 1325 (s), 1159 (s), 1136 (m), 1032 (m), 970 (m), 801 (m), 746 (s). **HR**-**ESI-MS**: calcd for C₂₂H₂₅INO₃⁺ 478.0874 [M + H]⁺; found 478.0886.

$1-(2-1-Tosyl-1H-indole)-3,3-dimethyl-1,3-dihydro-1\lambda^3-benzo[d][1,2] iodoxole (13d)$

Following general procedure **GP5**, starting from potassium trifluoro(1-(tosyl)-1H-indol-2-yl)borate **11f** (566 mg, 1.50 mmol, 1.00 equiv.) and commercially available 1-fluoro-3,3-dimethyl-1,2-benziodoxole **12b** (420 mg, 1.5 mmol, 1.00 equiv.), 1-(2-1-tosyl-1H-indole)-3,3-dimethyl-1,3-dihydro- $1\lambda^3$ -benzo[d][1,2] iodoxole **13d**

(425 mg, 0.800 mmol, 53% yield) was obtained as colorless solid. **M.p.** 135-138 °C. **Rf:** 0.4 (DCM: MeOH 9:1). ¹**H NMR** (400 MHz, CDCl₃) δ 8.31 (dd, J = 8.5, 1.0 Hz, 1H, ArH), 7.81 – 7.74 (m, 2H, ArH), 7.56 (dt, J = 7.8, 1.1 Hz, 1H, ArH), 7.47 – 7.32 (m, 3H, ArH), 7.30 (td, J = 7.6, 1.0 Hz, 1H, ArH), 7.18 – 7.11 (m, 3H, ArH), 7.07 (ddd, J = 8.4, 6.8, 1.7 Hz, 1H), 6.69 (dd, J = 8.3, 0.9 Hz, 1H, ArH), 2.31 (s, 3H, CH_3), 1.58 (s, 6H, $C(CH_3)_2$). ¹³C **NMR** (101 MHz, CDCl₃) δ 148.3, 145.2, 137.6, 135.5, 130.6, 129.9, 129.8, 128.9, 127.1, 126.7, 126.4, 126.1, 123.7, 123.6, 121.4, 120.2, 114.7, 114.4, 75.2, 31.5, 21.5. **IR** v 2963 (w), 1597 (w), 1562 (w), 1430 (m), 1366 (s), 1155 (s), 1090 (s), 951 (m). **HR-ESI-MS**: calcd for $C_{24}H_{23}INO_3S^+$ 532.0438 [M + H]⁺; found 532.0436.

1-(2-5-Methoxy-1-*tert*-butyl-1*H*-indole-1-carboxylate)-3,3-dimethyl-1,3-dihydro- $1\lambda^3$ -benzo [*d*][1,2]iodoxole (13e)

Following general procedure **GP5**, starting from potassium trifluoro(1-(*tert*-butoxycarbonyl)-5-methoxy-1*H*-indol-2-yl)borate **11b** (706 mg, 2.00 mmol, 1.00 equiv.) and commercially available 1-fluoro-3,3-dimethyl-1,2-benziodoxole **12b** (560 mg, 2.00 mmol, 1.00 equiv.), 1-(2-5-

methoxy-1-*tert*-butyl-1*H*-indole-1-carboxylate)-3,3-dimethyl-1,3-dihydro-1 λ^3 -benzo [*d*][1,2]iodoxole **13e** (775 mg, 1.53 mmol, 76% yield) was obtained as brown solid foam. **M.p.** 72-75 °C. **R**_f: 0.5 (DCM: MeOH 9:1). ¹**H NMR** (400 MHz, CDCl₃) δ 8.18 – 8.06 (m, 1H, Ar*H*), 7.40 – 7.36 (m, 1H, Ar*H*), 7.30 (dd, *J* = 7.6, 1.6 Hz, 1H, Ar*H*), 7.10 (ddd, *J* = 8.4, 7.0, 1.6 Hz, 1H, Ar*H*), 7.01 (s, 1H, Ar*H*), 6.95 (dq, *J* = 5.9, 2.6 Hz, 2H, Ar*H*), 6.76 (dd, *J* = 8.3, 1.0 Hz, 1H, Ar*H*), 3.79 (s, 3H, O*CH*₃), 1.46 (s, 6H, C(*CH*₃)₂), 1.36 (s, 9H, C(*CH*₃)₃). ¹³**C NMR** (101 MHz, CDCl₃) δ 156.1, 149.3, 148.4, 132.5, 130.9, 130.0, 128.9, 127.2, 126.9, 122.3, 119.1, 116.6, 115.1, 114.0, 102.7, 85.0, 74.8, 55.6, 32.4, 27.9. **IR** v 2965 (w), 1727 (s), 1612 (w), 1434 (w), 1357 (m), 1325 (s), 1253 (m), 1159 (s), 1117 (s), 1026 (s), 844 (m), 756 (s). **HR-ESI-MS**: calcd for C₂₃H₂₇INO₄⁺ 508.0979 [M + H]⁺; found 508.0981.

1-(2-6-Methoxy-1-*tert*-butyl-1*H*-indole-1-carboxylate)-3,3-dimethyl-1,3-dihydro- $1\lambda^3$ -benzo [d][1,2]iodoxole (13f)

Following general procedure **GP5**, starting from potassium trifluoro(1-(*tert*-butoxycarbonyl)-6-methoxy-1*H*-indol-2-yl)borate **11c** (706 mg, 2.00 mmol, 1.00 equiv.) and commercially available 1-fluoro-3,3-dimethyl-1,2-benziodoxole **12b** (560 mg, 2.00 mmol, 1.00 equiv.), the

corresponding indole reagent **13f** (812 mg, 1.60 mmol, 80% yield) was obtained as brown solid foam, (**M.P**.: 70-75 °C). **R**_f: 0.6 (DCM: MeOH 9:1). ¹**H NMR** (400 MHz, CDCl₃) δ 7.89 (d, J = 2.3 Hz, 1H, ArH), 7.41 (d, J = 8.2 Hz, 2H, ArH), 7.34 (dd, J = 7.6, 1.6 Hz, 1H, ArH), 7.14 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H, ArH), 7.05 (s, 1H, ArH), 6.90 (dd, J = 8.6, 2.3 Hz, 1H, ArH), 6.85 – 6.80 (m, 1H, ArH), 3.88 (s, 3H, O CH_3), 1.50 (s, 6H, C(CH_3)₂), 1.41 (s, 9H, C(CH_3)₃). ¹³**C NMR** (101 MHz, CDCl₃) δ 158.8, 149.4, 148.3, 138.8, 129.8, 128.7, 126.9, 126.8, 123.8, 122.6, 121.3, 117.1, 114.1, 113.0, 99.4, 84.9, 74.7, 55.5, 32.4, 27.8. **IR** v 2963 (w), 1727 (m), 1613

(w), 1487 (w), 1362 (m), 1326 (s), 1155 (s), 1045 (m), 945 (m), 824 (m), 756 (m). **HR-ESI-MS**: calcd for $C_{23}H_{27}INO_4^+$ 508.0979 [M + H]⁺; found 508.0983.

1-(2-5-Bromo-1-*tert*-butyl-1*H*-indole-1-carboxylate)-3,3-dimethyl-1,3-dihydro- $1\lambda^3$ -benzo [*d*][1,2]iodoxole (13g)

Following general procedure **GP5**, starting from potassium trifluoro(1-(*tert*-butoxycarbonyl)-6-bromo-1*H*-indol-2-yl)borate **11d** (402 mg, 1.00 mmol, 1.00 equiv.) and commercially available 1-fluoro-3,3-dimethyl-1,2-benziodoxole **12b** (280 mg, 1.00 mmol, 1.00 equiv.), 1-(2-5-bromo-1-*tert*-butyl-1*H*-indole-1-

carboxylate)-3,3-dimethyl-1,3-dihydro- $1\lambda^3$ -benzo [d][1,2]iodoxole **13g** (377 mg, 0.680 mmol, 68% yield) was obtained as off-white solid foam. **M.p.** 73-78 °C **R** $_{\mathbf{f}}$: 0.5 (DCM: MeOH 9:1). $^{\mathbf{1}}$ **H NMR** (400 MHz, CDCl₃) δ 8.54 (dt, J = 1.5, 0.7 Hz, 1H, Ar $_{\mathbf{f}}$ H), 7.50 – 7.35 (m, 4H, Ar $_{\mathbf{f}}$ H), 7.18 (ddd, J = 8.4, 7.0, 1.6 Hz, 1H, Ar $_{\mathbf{f}}$ H), 7.13 (d, J = 0.8 Hz, 1H, Ar $_{\mathbf{f}}$ H), 6.80 (dd, J = 8.3, 1.0 Hz, 1H, Ar $_{\mathbf{f}}$ H), 1.54 (s, 6H, C($_{\mathbf{f}}$ H), 1.45 (s, 9H, C($_{\mathbf{f}}$ H), 1.52 NMR (101 MHz, CDCl₃) δ 149.1, 148.3, 138.3, 130.1, 129.1, 129.0, 127.2, 127.1, 126.6, 122.3, 121.9, 120.0, 119.1, 114.0, 85.9, 75.1, 32.2, 27.8 (one C is not resolved). IR v 2969 (w), 1731 (s), 1352 (s), 1321 (s), 1235 (m), 1157 (s), 1137 (m), 1031 (m), 970 (m), 908 (m), 754 (s). HR-ESI-MS: calcd for C₂₂H₂₄⁷⁹BrINO₃+ 555.9979 [M + H]⁺; found 556.0001

1-(2-3-Methyl-1-tert-butyl-1H-indole-1-carboxylate)-3,3-dimethyl-1,3-dihydro- $1\lambda^3$ -benzo [d][1,2]iodoxole (13h)

Following general procedure **GP5**, starting from potassium trifluoro(1-(*tert*-butoxycarbonyl)-3-methyl-1*H*-indol-2-yl)borate **11e** (1.69 g, 5.00 mmol, 1.00 equiv.) and commercially available 1-fluoro-3,3-dimethyl-1,2-benziodoxole **12b** (1.41 mg, 5.00 mmol, 1.00 equiv.), 1-(2-3-methyl-1-*tert*-butyl-1*H*-indole-1-carboxylate)-3,3-dimethyl-1,3-dihydro- $1\lambda^3$ -benzo [*d*][1,2]iodoxole **13h** (2.40 g,

4.88 mmol, 97% yield) was obtained as off-white foam. **M.p.** 128-130 °C. **Rf**: 0.6 (DCM: MeOH 9:1). ¹**H NMR** (400 MHz, CDCl₃) δ 8.27 (d, J = 8.4 Hz, 1H, ArH), 7.53 (d, J = 7.8 Hz, 1H, ArH), 7.46 – 7.32 (m, 3H, ArH), 7.28 (t, J = 7.5 Hz, 1H, ArH), 7.12 (t, J = 7.6 Hz, 1H, ArH), 6.80 (d, J = 8.3 Hz, 1H, ArH), 2.42 (s, 3H, CH_3), 1.54 (s, 6H, $C(CH_3)_2$), 1.45 (s, 9H, $C(CH_3)_3$). ¹³**C NMR** (101 MHz, CDCl₃) δ 149.3, 148.4, 137.5, 129.7, 129.6, 128.6, 126.8, 126.4, 125.8, 122.7, 119.3, 117.6, 115.8, 113.3, 84.5, 74.3, 32.3, 27.7, 11.9 (*one aromatic*

carbon signal is not resolved) **IR** v 1727 (w), 1352 (w), 1325 (m), 1157 (s), 1089 (m), 971 (w), 857 (w), 750 (s). **HR-ESI-MS**: calcd for $C_{23}H_{27}INO_3^+$ 492.1030 [M + H]⁺; found 492.1038.

1-(2-(1*H*-Indol-3-yl)ethyl)isoindoline-1,3-dione)-3,3-dimethyl-1,3-dihydro- $1\lambda^3$ -benzo[*d*][1,2] iodoxole (13i)

Following general procedure **GP5**, starting from potassium trifluoro(2-(2-(1*H*-indol-3-yl)ethyl)isoindoline-1,3-dione) borate **11g** (396 mg, 1.00 mmol, 1.00 equiv.) and commercially available 1-fluoro-3,3-dimethyl-1,2-benziodoxole (280 mg, 1.00 mmol, 1.00 equiv.), 1-(2-(1*H*-indol-3-yl)ethyl)isoindoline-1,3-dione)-3,3-

dimethyl-1,3-dihydro- $1\lambda^3$ -benzo[d][1,2] iodoxole **13i** (347 mg, 0.630 mmol, 63% yield) was obtained as yellow solid. **M.p.** 132-135 °C. **R**f: 0.4 (DCM: MeOH 9:1). ¹**H NMR** (400 MHz, CDCl₃) δ 7.73 – 7.58 (m, 5H, ArH), 7.48 (d, J = 8.4 Hz, 1H, ArH), 7.22 (d, J = 7.5 Hz, 3H, ArH), 7.07 (t, J = 7.5 Hz, 1H, ArH), 6.96 – 6.84 (m, 1H, ArH), 6.66 (d, J = 8.3 Hz, 1H, ArH), 3.83 (t, J = 7.7 Hz, 2H, NCH₂), 3.12 (bs, 2H, C-CH₂), 1.57 (s, 6H, C(CH₃)₂). (NH was not resolved). ¹³C **NMR** (101 MHz, CDCl₃) δ 167.9, 148.1, 139.5, 133.7, 131.9, 130.0, 129.3, 127.4, 126.9, 126.5, 123.8, 123.0, 121.0, 119.9, 119.1, 112.6, 112.4, 73.8, 38.5, 29.7, 25.6 (one aromatic Carbon signal is not resolved). **IR** v 2965 (w), 1704 (m), 1434 (m), 1356 (w), 1155 (s), 954 (s), 871 (m), 748 (s). **HR-ESI-MS**: calcd for C₂₇H₂₄IN₂O₃+ 551.0826 [M + H]+; found 551.0834.

3. Metal Free (Hetero)-Arylation of Indoles.

All commercially available chemicals were purchased from the suppliers quoted in Paragraph 1.0 of Supplementary Informations: these chemicals were purified through a short plug of celite prior to their use in catalysis. The synthesis of non commercial available compounds is presented below.

The synthesis of the starting materials **34a-34f** had been already described before.^[1] The procedures here reported are taken from the cited publication to facilitate reproduction of the results by having all the data in the same file.

3.1 Synthesis of Methylated Indoles.

General Procedure GP6 for the N-Methylation of Indoles.

GP6: The corresponding indole (1.00 - 5.00 mmol, 1.00 equiv.) was dissolved in dry THF (0.3 M). Sodium hydride (60% suspension in mineral oil; 1.50 equiv.) was slowly added under N_2 flow at 0 °C. After being stirred at 0 °C for 15 min,the reaction mixture was allowed to warm to r.t for 1.5 h. It was then cooled back to 0 °C and methyl iodide (1.30 equiv.) was added. The mixture was warmed to r.t. and stirred overnight. After cooling again to 0 °C, the reaction was quenched with water (10 mL), extracted with Et_2O (3 x 10 mL), the combined organic layers were dried over MgSO₄, and the solvent removed under reduced pressure. The resulting crude product was purified via flash column chromatography (Pentane:EtOAc 9:1-4:1), to give the desired N-methylated indole.




Figure 3.1 Methylated Indole used for IndoleBX's synthesis and Nucleophilic partners

1,2-Dimethyl-1*H***-indole** (**34a**)

Me Followin

Me Me Methylin

4.70 mm

MHz CD

Following procedure **GP6**: starting from commercially available 2-methylindole (656 mg, 5.00 mmol), 1,2-dimethyl-1H-indole **34a** (683 mg, 4.70 mmol, 94% yield) was obtained as an off-white solid. 1 H **NMR** (400 MHz CDCl₃) δ 7.69 (d, J = 7.8 Hz, 1H, ArH), 7.41 (dd, J = 8.1, 1.0 Hz, ArH),

7.32 (m, 1H, Ar*H*), 7.24 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H, Ar*H*), 6.42 (s, 1H, NC(CH₃)C*H*), 3.79 (s, 3H, NC*H*₃), 2.57 (d, J = 1.0 Hz, 3H, NC*CH*₃). ¹³C **NMR** (125 MHz, CDCl₃) δ 138.1, 136.9, 128.1, 120.6, 119.8, 119.4, 108.8, 99.7, 29.5, 12.9. **IR** v (neat) 3050 (w), 3020 (w), 2970 (m), 1610 (w), 1400 (s), 1340 (m), 1240 (m), 930 (m), 910 (w), 780 (m), 750 (m), 730 (s). ¹H NMR values are in accordance with the data reported in literature. ^[22]

5-Methoxy-1-methyl-1*H*-indole (34b)

Me N OMe Following procedure **GP6**: starting from commercially available 5-methoxy-1*H*-indole (736 mg, 5.00 mmol), 5-methoxy-1-methyl-1*H*-indole **34b** (730 mg, 4.53 mmol, 91% yield) was obtained as a colorless crystalline solid. 1 H **NMR** (400 MHz, CDCl₃) δ 7.30 (d, 1H, J = 8.5 Hz, ArH) 7.13 (s,

1H, Ar*H*), 7.05 (s, 1 H, Ar*H*), 6.92 (d, 1H, J = 8.8 Hz, Ar*H*), 6.43 (d, 1H, J = 1.0 Hz, Ar*H*), 3.90 (s, 3H, N*Me*), 3.80 (s, 3H, O*Me*). ¹³C NMR (101 MHz, CDCl₃) δ 154.0, 132.2, 129.3, 128.8, 111.9, 109.9, 102.5, 100.4, 55.9, 33.0. IR v 2952 (w), 2918 (w), 2834 (w), 1622 (m), 1608 (w), 1577 (w), 1496 (s), 1459 (w), 1450 (m), 1449 (m), 1421 (s), 1347 (w), 1293 (w), 1243 (s), 1191 (m), 1152 (s), 1102 (w), 1026 (m), 942 (w), 855 (m), 845 (w), 805 (s).

5-Chloro-1-methyl-1*H*-indole (34c)

Me N 34c Following procedure **GP6**: starting from commercially available 5-chloro-1*H*-indole (758 mg, 5.00 mmol), 5-chloro-1-methyl-1*H*-indole **34c** (800 mg, 4.83 mmol, 97% yield) was obtained as a colorless solid. ¹**H NMR** (400 MHz, CDCl₃) δ 7.64 (d, J = 2.1 Hz, 1H, Ar*H*), 7.30 – 7.19 (m, 2H, Ar*H*), 7.10 (d, J

= 3.1 Hz, 1H, Ar*H*), 6.47 (dd, J = 3.1, 0.7 Hz, 1H, Ar*H*), 3.80 (s, 3H, N*CH*₃). ¹³**C NMR** (101 MHz, CDCl₃) δ 135.1, 130.1, 130.1, 125.1, 121.8, 120.2, 110.2, 100.6, 33.1. **IR** v 3102 (w), 2943 (w), 2913 (w), 2881 (w), 2817 (w), 1567 (w), 1513 (m), 1475 (s), 1441 (m), 1421 (s), 1379 (w), 1331 (m), 1278 (s), 1241 (s), 1199 (m), 1146 (m), 1106 (w), 1082 (m), 1063 (s), 1009 (m), 909 (m), 870 (m), 869 (m).

5-Iodo-1*H***-indole** (**34d**)



Following procedure **GP6**: starting from commercially available 5-iodo-1*H*-indole (257 mg, 1.00 mmol), 5-iodo-1-methyl-1*H*-indole **34d** (380 mg, 0.755 mmol, 76% yield) was obtained as a colorless solid. ¹**H NMR** (400 MHz, CDCl₃) δ 7.98 (s, 1 H, Ar*H*), 7.49 (d, J = 8.6 Hz, 1H, Ar*H*), 7.13 (d, J = 8.6

Hz, 1H, Ar*H*), 7.04 (s, 1H, Ar*H*), 6.43 (s, 1H, Ar*H*), 3.80 (s, 3H, N*CH*₃). ¹³**C NMR** (101 MHz, CDCl₃) δ 135.8, 131.0, 129.8, 129.7, 129.6, 111.3, 100.3, 82.9, 33.0. **IR** v 3093 (w), 3053 (w), 2940 (w), 2919 (w), 2886 (w), 2876 (w), 2856 (w), 1557 (m), 1510 (s), 1473 (s), 1432 (m), 1420 (s), 1379 (w), 1329 (m), 1277 (s), 1242 (s), 1193 (w), 1151 (w), 1103 (m), 1079 (m), 1045 (w), 1007 (m), 888 (s), 868 (m).

6-(Benzyloxy)-1-methyl-1*H*-indole (34e)

Me N OBn

Following procedure **GP6**: starting from commercially available 6-benzyloxyindole (223 mg, 1.00 mmol), 6-(benzyloxy)-1-methyl-1*H*-indole **34e** (237 mg, 1.00 mmol, 100% yield) was obtained as a orange solid. ¹**H NMR** (400 MHz, CDCl₃) δ 7.53 – 7.48 (m, 3H, Ar*H*), 7.43 – 7.38 (m, 2H,

Ar*H*), 7.34 (m, 1H, Ar*H*), 6.96 (d, J = 3.1 Hz, 1H, Ar*H*), 6.93 – 6.85 (m, 2H, Ar*H*), 6.43 (dd, J = 3.1, 0.8 Hz, 1H, Ar*H*), 5.15 (s, 2H, CH_2), 3.73 (s, 3H, NMe). ¹H-NMR values are in accordance with the data reported in literature. ^[23]

3.2 Optimization of the Metal Free (Hetero)-Arylation of Indoles with the C3 Reagent.

Table 3.1: equivalents of 1 and LA screening:

Entry	Equiv. of xx	Lewis Acid (equiv.)	Yield%a xx/xx
1	1.5	TMSBr (2)	41.4%/17%
2	1	-	_b
3	1	TMSBr (2)	40%/23%
4	1	TMSBr (1)	44%/12%
5	1	TMSCl (1)	68%/-
6	1	TMSI (1)	_c

a) Substrate **2a** (0.100 mmol), 1,3,5 trimethoxybenzene **1** (equiv. given in the table), TMSCI-TMSBr-TMSI (x equiv.) and HFIP (0.1 M) at 25 °C. Isolated yield after flash chromatography is given. b) no conversion, reagent **2a** and nucleophile **1** are recovered. c) complete decomposition and polymerization.

Table 3.2: Screening of the solvent:

Entry	Solvent	Yield%a xx/xx
1	DCM	_b
2	DCE	_b
3	MeCN	4%/-
4	THF	_b

5	Et ₂ O	traces/-
6	HFIP	68%/-
7	МеОН	traces/-
8	TFE	20%/-

a) Substrate **2a** (0.100 mmol), 1,3,5 trimethoxybenzene **1** (0.100 mmol), TMSCl (1.00 equiv.) and HFIP (0.1 M) at 25 °C. Isolated yield after flash chromatography is given. b) no conversion, reagent **xx** and nucleophile **xx** are recovered.

Table 3.3: screening of TMSCl equivalents:

Entry	TMSCl (equiv.)	Yield% a xx/xx
1	0.1	_b
2	0.2	_b
3	0.4	4%/-
4	0.5	10%/-
5	0.8	39%/-
6	1	68%/-
7	1.2	70%/-
8	2	40%/-°

a) Substrate **2a** (0.100 mmol), 1,3,5 trimethoxybenzene **1** (0.100 mmol), TMSCl (X equiv.) and HFIP (0.1 M) at 25 °C. Isolated yield after flash chromatography is given. b) no conversion, reagent **2a** and nucleophile **1** are recovered. c) decomposition and polymerization of both reagent **2a** and nucleophile **1** are detected.

Table 3.4: Screening of substrate's molarity in HFIP:

Entry	HFIP (M)	Yield%a xx/xx
1	0.012	44%/- ^b
2	0.025	47%/- ^b
3	0.1	68%/-
4	0.25	64%/- ^c
5	0.5 = 20 equiv.	70%/- ^c

a) Substrate **2a** (0.100 mmol), 1,3,5 trimethoxybenzene **1** (0.100 mmol), TMSCl (1.00 equiv.) and HFIP (X M) at 25 °C. Isolated yield after flash chromatography is given. b) reagent **2a** and nucleophile **1** are recovered. c) solubility problem of reagent **2a**, incomplete reaction.

Table 3.5: Screening of HFIP equivalents and concentration in DCM:

Entry	DCM (M)	HFIP (equiv.)	Yield%a xx/xx
1	0.1	20 equiv. = 0.5 M	75%/-
2	0.1	10	68%/-
3	0.1	5	64%/-
4	0.1	2	_b
5	0.1	1	_b
6	0.2	5	66%/-

7	0.2	10	75%/-
8	0.2	20	75%/-
9	0.25	10	68%/- ^c

a) Substrate **2a** (0.100 mmol), 1,3,5 trimethoxybenzene **1** (0.100 mmol), TMSCl (1.00 equiv.) and HFIP (X equiv.) in DCM (X M) at 25 °C. Isolated yield after flash chromatography is given. b) no conversion, reagent **2a** and nucleophile **1** are recovered. c) decomposition of the reagent **2a** is detected

Table 3.6: screening of HFIP equivalents and concentration in DCM at 50 °C:

Entry	T (°C)	HFIP (equiv.)	DCM (M)	Yield%a xx/xx
1	25	10	0.2	75%/-
2	50	10	0.1	74%/- ^b
3	50	5	0.1	70%/- ^b
4	50	2	0.1	68%/- ^b
5	50	1	0.1	23%/- ^b

a) Substrate **2a** (0.100 mmol), 1,3,5 trimethoxybenzene **1** (0.100 mmol), TMSCl (1.00 equiv.) and HFIP (X equiv.) in DCM (X M) at 25 °C. Isolated yield after flash chromatography is given. b) decomposition of the reagent **2a** is detected

Substrate **3a** (0.100 mmol), 1,3,5 trimethoxybenzene **1** (0.100 mmol), TMSCl (1.00 equiv.) in HFIP (0.1 M) at 25 °C. Isolated yield after flash chromatography is given.


Substrate **4a** (0.100 mmol), 1,3,5 trimethoxybenzene **1** (0.100 mmol), TMSCl (1.00 equiv.) in HFIP (0.1 M) at 25 °C. Isolated yield after flash chromatography is given.

Table 3.7: Optimization for Lewis acid and solvents for Arylation of IndoleDBX

Entry ^a	Lewis Acid (equiv.)	Solvent	Yield% ^a
1	TMSCl (2)	HFIP (0.1 M)	_b
2	TMSCl (2)	HFIP (10.0 equiv.)+DCM(0.2 M)	Traces
3	TMSBr (2)	HFIP	60%
4	TMSBr (1)	HFIP (10.0 equiv.)+DCM(0.2 M)	77%
5	TMSI (2)	HFIP (10.0 equiv.)+DCM(0.2 M)	_c
6	TMS-1 <i>H</i> -imidazole (2)	HFIP (10.0 equiv.)+DCM(0.2 M)	_c

a) Substrate **13c** (0.100 mmol), 1,3,5 trimethoxybenzene **1** (xx 0.110mmol, 1.10 equiv.), TMSCI-TMSBr-TMSI (2 equiv.) at 25 °C. Isolated yield after flash chromatography is given. b) no conversion, reagent **13c** and nucleophile **1** are recovered. c) complete decomposition and polymerization.

1-Methyl-2,3-bis(2,4,6-trimethoxyphenyl)-1*H*-indole (8).



White resin. **Rf:** 0.38 (Pentane:EtOAc 1:1) ¹**H NMR** (400 MHz, CDCl₃) δ 7.37 – 7.28 (m, 2H, Ar*H*), 7.13 (ddd, J = 8.3, 7.0, 1.1 Hz, 1H, Ar*H*), 6.99 (ddd, J = 7.9, 7.0, 0.9 Hz, 1H, Ar*H*), 6.12 (s, 2H, Ar*H*), 6.11 (s, 2H, Ar*H*), 3.82 (s, 3H, O*Me*), 3.82 (s, 3H, O*Me*), 3.60 (s, 3H, O*Me*), 3.57 (s, 6H, N*Me*), 3.53 (s, 6H, O*Me*). ¹³**C NMR** (101 MHz, CDCl₃) δ 161.3, 159.8, 159.5, 159.2, 137.1, 131.8, 127.8, 120.6, 120.3,

118.4, 109.3, 107.2, 106.7, 103.8, 90.5, 90.4, 55.5, 55.5, 55.2, 55.2, 30.7. **IR** v 3001 (w), 2935 (w), 2836 (w), 1587 (m), 1584 (s), 1464 (m), 1415 (m), 1336 (w), 1226 (s), 1128 (s), 1041 (w), 811 (m), 741 (m). **HR-ESI-MS** calcd for $C_{27}H_{29}NO_6^+$ [M+H]⁺ 464.1995; found 464.2093.

3.3 Control experiments

In an open air vial, commercially available 3-Iodoindole **6** (26.0 mg, 0.100 mmol, 1.00 equiv.), 1,3,5-trimethoxybenzene **1** (25.0 mg, 0.150 mmol, 1.50 equiv.) and TMSBr (26.0 μ L, 0.200 mmol, 2.00 equiv.) were dissolved in HFIP (1 mL, 0.1 M). The reaction was stirred for three hours and then quenched with sat. aqueous NaHCO₃ (4 mL); the organic layer was extracted with DCM (3x5 mL), then the solvent was removed under reduced pressure. No conversion in the desired product 1-methyl-3-(2,4,6-trimethoxyphenyl)-1H-indole **7a** was detected.

In an open air vial, IndoleBX reagent 2a (38.0 mg, 0.100 mmol, 1.00 equiv.), 1,3,5-trimethoxybenzene 1 (25.0 mg, 0.150 mmol, 1.50 equiv.) and HCl in EtOH (80.0 μ L, 0.200 mmol, 2.00 equiv., 1.25 M in EtOH) were dissolved in HFIP (1 mL, 0.1 M). The reaction was stirred for three hours and then quenched with sat. aqueous NaHCO₃ (20 mL); the organic layer was extracted with DCM (3x5 mL), then the solvent was removed under reduced pressure. No conversion in the desired product 1-methyl-3-(2,4,6-trimethoxyphenyl)-1H-indole 7a was detected.

In an open air vial, commercially available N-methylindole **5** (13 μ L, 0.10 mmol, 1.00 equiv.) and commercially available 4F-PIDA (34.0 mg, 1.00 mmol, 1.00 equiv) were left stirring in HFIP (1 mL, 0.1 M) for 30 minutes. Then 1,3,5-trimethoxybenzene **1** (25.0 mg, 0.150 mmol, 1.50 equiv.) and TMSCl (25.5 μ L, 0.200 mmol, 2.00 equiv.) were added to the mixture. The reaction mixture was stirred for three hours and then quenched with sat. aqueous NaHCO₃ (4 mL); the organic layer was extracted with DCM (3x5 mL), then the solvent was removed under reduced pressure. 1-methyl-3-(2,4,6-trimethoxyphenyl)-1H-indole **7a** was obtained as white resin (4.80 mg, 16.0 μ mol, 16% yield). *For full characterization see the scope section*.

3.4 Scope of the Metal Free (Hetero)-Arylation of Indoles.

General Procedures GP7-GP9 Metal Free (Hetero)-Arylation of Indoles.

GP7: In an open air vial, the corresponding IndoleBX **2a-2f**' (0.300 mmol, 1.00 equiv.), the 1,3,5-trimethoxybenzene **1** (0.300 mmol, 1.00 equiv.), HFIP (315 μ L, 3.00 mmol, 10.0 equiv.) and TMSCl (38.0 μ L, 0.300 mmol, 1.00 equiv.) were dissolved in DCM (1.50 mL, 0.2 M). The reaction was stirred for three hours and then quenched with sat. aqueous NaHCO₃ (4 mL); the organic layer was extracted with DCM (3x5 mL), then the solvent was removed under reduced pressure. Flash column chromatography (Pentane:EtOAc 9:1) afforded the desired products **7a-7f**.

GP8: In an open air vial, IndoleBX **2a-2f**' (0.300 mmol, 1.00 equiv.), the corresponding heterocycle (0.300 mmol, 1.00 equiv.), HFIP (315 μ L, 3.00 mmol, 10.0 equiv.) and TMSCl (38.0 μ L, 0.300 mmol, 1.00 equiv.) were dissolved in DCM (1.50 mL, 0.2 M). The reaction was stirred for three hours and then quenched with sat. aqueous NaHCO₃ (4 mL); the organic layer was extracted with DCM (3x5 mL), then the solvent was removed under reduced pressure. Flash column chromatography (Pentane:DCM 1:1) afforded the desired products **8a-10b**.

GP9: In an open air vial, the corresponding C2-IndoleDBXs or C2-IndoleBXs **13a-13i** (0.20 mmol, 1.0 equiv.), the 1,3,5-trimethoxybenzene (**1**) or the heterocycle (0.22 mmol, 1.1 equiv.), HFIP (210 μ L, 2.00 mmol, 10.0 equiv.) and TMSBr (52.8 μ L, 0.400 mmol, 2.00 equiv.) were dissolved in DCM (1.0 mL, 0.20 M). The reaction was stirred for three hours and then quenched with saturated aqueous NaHCO₃ (4 mL); the organic layer was extracted with DCM (3x5 mL), then the solvent was removed under reduced pressure. Purification on Preparative TLC (with mixture of EtOAc and Pentane as eluent) afforded the desired products **14a-16**.


3.4.1: Scope of trimethoxyphenylated-N-protected-Indoles and -Pyrroles

1-Methyl-2-(2,4,6-trimethoxyphenyl)-1*H*-indole (7a)

Following procedure **GP7**: using IndoleBX reagent **2a** (113 mg, 0.300 mmol), after 3 hours 1-methyl-2-(2,4,6-trimethoxyphenyl)-1*H*-indole **7a** (64.0 mg, 0.216 mmol, 75% yield) was obtained as a white resin. **Rf:** 0.42 (Pentane:EtOAc 9:1). ¹**H NMR** (400 MHz, CDCl₃) δ 7.62 (d, J = 7.8 Hz, 1H, Ar*H*), 7.33 (d, J = 8.2 Hz, 1H, Ar*H*), 7.18 (ddd, J

= 8.1, 7.0, 1.2 Hz, 1H, Ar*H*), 7.08 (m, 1H, Ar*H*), 6.45 (s, 1H, Ar*H*), 6.24 (s, 2H, Ar*H*), 3.89 (s, 3H, O*Me*), 3.73 (s, 6H, O*Me*), 3.51 (s, 3H, N*Me*). ¹³**C NMR** (101 MHz, CDCl₃) δ 161.9, 160.0, 137.1, 133.2, 128.0, 120.5, 120.4, 118.9, 109.2, 103.0, 102.4, 90.7, 55.8, 55.4, 30.1. **IR** v 2379 (w), 2321 (w), 1627 (s), 1523 (m), 1438 (s), 1362 (m), 1287 (m), 1178 (w), 1106 (s), 1073 (s), 979 (w), 906 (m), 850 (m), 720 (s). **HR-ESI-MS** calcd for C₁₈H₂₀NO₃⁺ [M+H]⁺ 298.1438; found 298.1451.

5-Iodo-1-methyl-2-(2,4,6-trimethoxyphenyl)-1*H*-indole (7b) and and 5-iodo-1-methyl-2,3-bis(2,4,6-trimethoxyphenyl)-1*H*-indole (7b')



Following procedure **GP7**: using IndoleBX reagent **2c** (151 mg, 0.300 mmol), after 3 hours an unseparable mixture of mono-di products 5-Iodo-1-methyl-2-(2,4,6-trimethoxyphenyl)-1*H*-indole **7b** and and 5-iodo-1-methyl-2,3-bis(2,4,6-trimethoxyphenyl)-1*H*-indole **7b**'


(88.0 mg, 0.207 mmol, 69% yield, 9:1 *major-mono:minor-di*) were obtained as yellow oil. **Rf**: 0.38 (Pentane:EtOAc 9:1). ¹**H NMR** (400 MHz, CDCl₃) δ 7.94 (d, J = 1.7 Hz, 1H, ArH *major*), 7.81 (d, J = 1.7 Hz, 1H, ArH *minor*), 7.48 (dd, J = 8.6, 1.7 Hz, 1H, ArH *minor*), 7.42 (dd, J = 8.5, 1.7 Hz, 1H, ArH *major*), 7.11 (d, J = 8.6 Hz, 1H, ArH *major*), 7.07 (d, J = 8.8 Hz, 1H, ArH *minor*), 6.38 (s, 1H, ArH *major*), 6.24 (s, 2H, ArH *major*), 6.20 (s, 2H, ArH *minor*), 3.90 (s, 4.3H, OMe major + OMe minor), 3.82 (s, 3H, OMe minor), 3.73 (s, 6.8H, OMe major + 2xOMe minor), 3.54 (s, 3H, NMe minor), 3.48 (s, 3H, NMe major). ¹³C NMR (101 MHz, CDCl₃) *major* 162.1, 159.9 (2 aromatic carbon signals overlapped), 136.2, 134.2, 130.5, 128.9, 128.7, 111.3, 101.7, 90.6, 82.4, 55.8, 55.4, 30.2. *minor* 162.8, 160.0, 159.4, 156.5, 137.4, 136.4, 132.7, 130.1, 129.6, 111.6, 102.3, 91.5, 90.7, 83.2, 59.7, 56.3, 55.8, 55.5, 31.2 (two aromatic carbon not resolved). **IR** v 3006 (w), 2937 (w), 2838 (w), 1613 (s), 1587 (m), 1467 (s), 1415 (m), 1229 (m), 1128 (s), 1065 (w), 950 (w), 817 (w), 791 (m). **HR-ESI-MS** *mono*: $C_{18}H_{19}INO_3^+$ [M+H] $^+$ 424.0404; found 424.0412, di not detected.

1-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(2,4,6-trimethoxyphenyl)-1*H*-indole (7c)

Following procedure **GP7**: using IndoleBX reagent **2d** (151 mg, 0.300 mmol), after 3 hours 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(2,4,6-trimethoxyphenyl)-1*H*-indole **7c** (68.3 mg, 0.161 mmol, 54% yield) was obtained as a yellow oil. **Rf**: 0.40 (Pentane:EtOAc 9:1). ¹**H NMR** (400 MHz, CDCl₃) δ 8.15 (s, 1H,

Ar*H*), 7.63 (dd, J = 8.3, 1.2 Hz, 1H, Ar*H*), 7.32 (d, J = 8.3 Hz, 1H, Ar*H*), 6.47 (s, 1H, Ar*H*), 6.23 (s, 2H, Ar*H*), 3.89 (s, 3H, O*Me*), 3.71 (s, 6H, O*Me*), 3.50 (s, 3H, N*Me*), 1.37 (s, 12H, BPin-*Me*). ¹³C NMR (101 MHz, CDCl₃) δ 161.9, 160.0 (two aromatic carbon signals overlap), 139.1, 133.3, 128.3, 127.8, 126.8, 108.6, 103.2, 102.9, 90.7, 83.2, 55.8 (two methoxy carbon signals overlap), 55.4, 30.1, 24.9. IR v 2976 (w), 2935 (w), 2840 (w), 1610 (m), 1584 (m), 1354 (s), 1327 (s), 1204 (m), 1125 (s), 1064 (m), 966 (w), 860 (m). HR-ESI-MS calcd for $C_{24}H_{31}BNO_5^+$ [M+H] $^+$ 424.2290; found 424.2289.


1,2-Dimethyl-3-(2,4,6-trimethoxyphenyl)-1*H*-indole (7d)



Following procedure **GP7**: using IndoleBX reagent **2b** (117 mg, 0.300 mmol), after 3 hours 1,2-dimethyl-3-(2,4,6-trimethoxyphenyl)-1*H*-indole **7d** (37.1 mg, 0.120 mmol, 40% yield) was obtained as a yellow oil. **Rf**: 0.52 (Pentane:EtOAc 9:1). ¹**H NMR** (400 MHz, CDCl₃) δ 7.27 (m, 1H, Ar*H*), 7.21 (dt, J = 7.8, 1.0 Hz, 1H, Ar*H*), 7.11 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H, Ar*H*), 7.00 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H, Ar*H*), 6.28 (s, 2H, Ar*H*),

3.90 (s, 3H, OMe), 3.71 (s, 9H, OMe + NMe) 2.25 (s, 3H, NCCH₃). ¹³C NMR (101 MHz, CDCl₃) δ 160.3, 159.3, 136.7, 135.2, 127.7, 120.1, 119.7, 118.7, 108.7, 105.2, 104.6, 90.8, 55.7, 55.4, 29.7, 11.6. **IR** v 3002 (w), 2942 (w), 2837 (w), 1606 (m), 1585 (m), 1469 (m), 1414 (w), 1205 (s), 1126 (s), 1062 (w), 956 (w), 739 (m). **HR-ESI-MS** calcd for $C_{19}H_{22}NO_3^+$ [M+H]⁺ 312.1594; found 312.1596.

1-Methyl-2-(2,4,6-trimethoxyphenyl)-1*H*-pyrrole (7e)



Following procedure **GP7**: using PyrroleBX reagent **2e** or **2e'** (98.0 mg, 0.300 mmol), after 3 hours 1-methyl-2-(2,4,6-trimethoxyphenyl)-1*H*-pyrrole **7e** (52.4 mg, 0.212 mmol, 71% yield) was obtained as a white solid. **Rf:** 0.60 (Pentane:EtOAc 9:1). ¹**H NMR** (400 MHz, CDCl₃) δ 6.72

(dd, J = 2.7, 1.8 Hz, 1H, ArH), 6.23 (dd, J = 3.5, 2.6 Hz, 1H, ArH), 6.19 (s, 2H, ArH), 6.07 (dd, J = 3.5, 1.7 Hz, 1H, ArH), 3.86 (s, 3H, CH_3), 3.74 (s, 6H, CH_3), 3.39 (s, 3H, CH_3). ¹H-NMR values are in accordance with the data reported in literature. ^[24]

1-Benzyl-2-(2,4,6-trimethoxyphenyl)-1*H*-pyrrole (7f)

Following procedure **GP7**: using PyrroleBX reagent **2f** or **2f**' (121 mg, 0.300 mmol), after 3 hours 1-benzyl-2-(2,4,6-trimethoxyphenyl)-1*H*-pyrrole **7f** (57.1 mg, 0.177 mmol, 59% yield) was obtained as a white solid. **Rf**: 0.58 (Pentane:EtOAc 9:1). ¹**H NMR** (400 MHz, CDCl₃) δ 7.23 – 7.15 (m, 3H, *ArH*),

7.04 - 6.98 (m, 2H, ArH), 6.73 (dd, J = 2.8, 1.8 Hz, 1H, ArH), 6.30 (t, J = 3.1 Hz, 1H, ArH), 6.12 (s, 2H, ArH), 6.09 (m, 1H, ArH), 6.11 – 6.06 (m, 2H, $ArCH_2$), 3.83 (s, 3H, OMe), 3.62 (s, 6H, OMe). ^{1}H -NMR values are in accordance with the data reported in literature. $^{[24]}$

3.4.2: Scope of mixed 3'-2 biindoles.


1,1'-Dimethyl-1*H*,1'*H*-2,3'-biindole (8a)

Following procedure **GP8**: using commercially available N-Methyl-Indole **5** (113 mg, 0.300 mmol), after 3 hours 1,1'-dimethyl-1*H*,1'*H*-2,3'-biindole **8a** (61.2 mg, 0.230 mmol, 77% yield) was obtained as a white solid. **Rf**: 0.40 (Pentane:EtOAc 9:1). ¹**H NMR**

 $(400 \text{ MHz}, \text{CDCl}_3) \delta 7.82 \text{ (d, } J = 8.0 \text{ Hz}, 1\text{H}, ArH), 7.76 \text{ (d, } J = 7.7 \text{ Hz}, 1\text{H}, ArH), 7.50 - 7.46$

(m, 2H, ArH), 7.42 (t, J = 7.6 Hz, 1H, ArH), 7.37 – 7.22 (m, 4H, ArH), 6.74 (s, 1H, ArH), 3.93 (s, 3H, NMe), 3.84 (s, 3H, NMe). ¹H-NMR values are in accordance with the data reported in literature. ^[25]


1,1',5'-Trimethyl-1*H*,1'*H*-2,3'-biindole (8b)



Following procedure **GP8**: using commercially available 1,5-dimethyl-1H-indole (43.6 mg, 0.300 mmol), after 3 hours ,1',5'-trimethyl-1H,1'H-2,3'-biindole **8b** (52.6 mg, 0.192 mmol, 64% yield) was obtained as a yellow oil. **Rf**: 0.44 (Pentane:EtOAc 9:1). ¹H **NMR** (400 MHz, CDCl₃) δ 7.67 (dt, J = 7.8, 1.0 Hz, 1H, ArH), 7.51 (dt, J =

1.8, 0.9 Hz, 1H, Ar*H*), 7.40 (m, 1H, Ar*H*), 7.31 (d, J = 8.5 Hz, 1H, Ar*H*), 7.25 (m, 1H, Ar*H*), 7.22 – 7.12 (m, 3H, Ar*H*), 6.63 (s, 1H, Ar*H*), 3.86 (s, 3H, N*Me*), 3.77 (s, 3H, N*Me*), 2.49 (s, 3H, *CH*₃). ¹³**C NMR** (101 MHz, CDCl₃) δ 137.9, 135.3, 129.6, 128.5, 128.3, 127.9, 123.9, 120.9, 120.0, 119.9, 119.5, 109.3, 109.2, 106.6, 101.2, 33.0, 31.0, 21.5. **IR** v 3050 (w), 2916 (w), 1592 (w), 1467 (s), 1336 (m), 1249 (m), 1151 (w), 1015 (w), 788 (m), 749 (s). **HR-ESI-MS** calcd for C₁₉H₁₉N₂⁺ [M+H]⁺ 275.1543; found 275.1539.

5'-Methoxy-1,1'-dimethyl-1H,1'H-2,3'-biindole (8c) and 5'-methoxy-1,1'-dimethyl-1H,1'H-2,7'-biindole (8c')




Following procedure **GP8**: using 5-methoxy-1-methyl-1*H*-indole **34b** (48.4 mg, 0.300 mmol), after 3 hours, 5'-methoxy-1,1'-dimethyl-1*H*,1'*H*-2,3'-biindole **8c** and 5'-methoxy-1,1'-dimethyl-1*H*,1'*H*-2,7'-biindole

8c' (57.1 mg, 0.197 mmol, 65% yield, *ratio major* **8c**: *minor* **8c'** 12:1) were obtained as an unseparable mixture of yellow oil. **Rf:** 0.60 (Pentane:DCM 1:1). ¹**H NMR** (400 MHz, CDCl₃) δ 7.69 – 7.68 (m, 1H, Ar*H minor*), 7.65 (dd, J = 7.8, 1.0 Hz, 1H, Ar*H major*), 7.52 (s, 1H, Ar*H minor*), 7.39 (d, J = 8.3 Hz, 1H Ar*H major* + 1H Ar*H minor*), 7.29 (d, J = 8.8 Hz, 1H Ar*H major* + 2H Ar*H minor*), 7.25 – 7.22 (m, 1H Ar*H major* + 1H Ar*H minor*), 7.18 (br s, 1H, Ar*H major*), 7.15 (td, J = 7.5, 7.1, 1.0 Hz, 1H, Ar*H major*), 7.12 (d, J = 2.4 Hz, 1H, Ar*H major*), 6.97 (dd, J = 8.9, 2.5 Hz, 1H, Ar*H major*), 6.92 (d, J = 2.4 Hz, 1H, Ar*H minor*), 6.60 (br s, 1H, Ar*H major* – *fast exchange with CDCl*₃), 3.89 (s, 3H, *CH*₃ *minor*), 3.87 (s, 3H, *CH*₃ *major*), 3.82 (s, 3H, *CH*₃ *major*), 3.80 (s, 3H, *CH*₃ *minor*), 3.76 (s, 3H, *CH*₃ *major*), 3.69 (s, 3H, *CH*₃ *minor*). 13C NMR (101 MHz, CDCl₃) δ *major*: 154.8, 137.9, 132.2, 129.0, 129.0, 128.3, 128.1,

121.0, 120.0, 119.6, 112.9, 110.4, 109.3, 106.8, 101.6, 55.9, 33.2, 31.0 (one aromatic carbon signal not resolved - minor not resolved). **IR** v 3004 (w), 2950 (w), 2828 (w), 1668 (w), 1623 (m), 1542 (m), 1489 (s), 1421 (w), 1288 (m), 1220 (m), 1140 (m), 1025 (w), 901 (m), 798 (s). **HR-ESI-MS** calcd for $C_{19}H_{19}N_2O^+$ [M+H]⁺ 291.1492; found 291.1486.


5'-Chloro-1,1'-dimethyl-1*H*,1'*H*-2,3'-biindole (8d)



Following procedure **GP8**: using 5-chloro-1-methyl-1*H*-indole **34d** (49.7 mg, 0.300 mmol), after 3 hours 5'-chloro-1,1'-dimethyl-1*H*,1'*H*-2,3'-biindole **8d** (63.4 mg, 0.215 mmol, 72% yield) was obtained as a yellow oil. **Rf**: 0.38 (Pentane:EtOAc 9:1). ¹**H NMR** (400 MHz, CDCl₃) δ 7.66 (dd, J = 2.0, 0.7 Hz, 1H, Ar*H*), 7.64 (dt, J = 7.9, 1.1 Hz,

1H, Ar*H*), 7.35 (dd, J = 8.2, 0.9 Hz, 1H, Ar*H*), 7.27 (dd, J = 8.8, 0.7 Hz, 1H, Ar*H*), 7.26 – 7.21 (m, 2H, Ar*H*), 7.17 – 7.12 (m, 2H, Ar*H*), 6.60 (s, 1H, Ar*H*), 3.82 (s, 3H, N*Me*), 3.71 (s, 3H, N*Me*). ¹³C NMR (101 MHz, CDCl₃) 137.9, 135.3, 134.1, 129.4, 128.6, 128.2, 126.2, 122.6, 121.2, 120.1, 119.6, 119.6, 110.6, 109.3, 107.0, 101.6, 33.2, 30.9. δ . IR ν 3054 (w), 2942 (w), 2885 (w), 1590 (m), 1586 (m), 1466 (s), 1369 (m), 1271 (s), 1244 (m), 1145 (m), 1092 (m), 795 (s). HR-ESI-MS calcd for C₁₈H₁₆ClN₂⁺ [M+H]⁺ 295.0997; found 295.0995.

5'-Iodo-1,1'-dimethyl-1*H*,1'*H*-2,3'-biindole (8e).



Following procedure **GP8**: using 5-iodo-1*H*-indole **34e** (77.0 mg, 0.300 mmol), after 3 hours 5'-iodo-1,1'-dimethyl-1*H*,1'*H*-2,3'-biindole **8e** (82.5 mg, 0.214 mmol, 71% yield) was obtained as a yellow oil. **Rf:** 0.40 (Pentane:EtOAc 9:1). ¹**H NMR** (400 MHz, CDCl₃) δ 7.93 (dd, J = 1.7, 0.5 Hz, 1H, Ar*H*), 7.56 (dt, J = 7.8, 1.1 Hz, 1H, Ar*H*),

7.45 (dd, J = 8.6, 1.7 Hz, 1H, ArH), 7.28 (m, 1H, ArH), 7.16 (m, 1H, ArH), 7.09 – 7.04 (m, 2H, ArH), 7.03 (s, 1H, ArH), 6.51 (d, J = 0.8 Hz, 1H, ArH), 3.74 (s, 3H, NMe), 3.63 (s, 3H, NMe).

¹³C NMR (101 MHz, CDCl₃) δ 137.9, 136.0, 134.0, 130.6, 130.1, 129.0, 128.9, 128.2, 121.2, 120.1, 119.7, 111.5, 109.4, 106.7, 101.7, 83.8, 33.1, 30.9. IR ν 2931 (m), 2855 (m), 1828 (w), 1730 (s), 1655 (w), 1524 (w), 1436 (s), 1333 (m), 1278 (s), 1199 (s), 1058 (m), 992 (m), 897 (m), 762 (w). HR-ESI-MS calcd for C₁₈H₁₆IN₂⁺ [M+H]⁺ 387.0353; found 387.0355.

1,1'-Dimethyl-5'-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*,1'*H*-2,3'-biindole (8f)

Following procedure **GP8**: using commercially available 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-indole (77.0 mg, 0.300 mmol), after 3 hours 1,1'-dimethyl-5'-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*,1'*H*-2,3'-biindole **8f** (79.2 mg, 0.205 mmol, 68% yield) was obtained as a yellow oil. **Rf:** 0.38 (Pentane:EtOAc

9:1). ¹**H NMR** (400 MHz, CDCl₃) δ 8.19 (s, 1H, Ar*H*), 7.78 (dd, J = 8.3, 1.1 Hz, 1H, Ar*H*), 7.68 (dt, J = 7.8, 1.0 Hz, 1H, Ar*H*), 7.41 (dd, J = 4.8, 0.9 Hz, 1H, Ar*H*), 7.39 (dd, J = 4.7, 0.9 Hz, 1H, Ar*H*), 7.25 (m, 1H, Ar*H*), 7.18 (s, 1H, Ar*H*), 7.15 (m, 1H, Ar*H*), 6.66 (d, J = 0.8 Hz, 1H, Ar*H*), 3.88 (s, 3H, N*Me*), 3.75 (s, 3H, N*Me*), 1.36 (s, 12H, BPin-*Me*). ¹³C NMR (101 MHz, CDCl₃) δ 138.8, 137.9, 134.7, 128.5, 128.4, 128.3, 128.0, 127.5, 121.0, 120.0, 119.5, 109.3, 108.8, 108.0, 101.8, 83.5, 60.4, 33.0, 30.9, 24.8. *NB*: the Carbon-Boron bond is not observed as reported in literature. ^[18] IR v 3050 (w), 2978 (w), 2927 (w), 1614 (w), 1466 (m), 1352 (s), 1311 (m), 1143 (s), 1095 (m), 968 (w), 866 (m), 737 (s). HR-ESI-MS calcd for C₂₄H₂₈BN₂O₂⁺ [M+H]⁺ 387.2238; found 387.2244.

1,1'-Dimethyl-1*H*,1'*H*-[2,3'-biindol]-6'-ol (8g)

Following procedure **GP8**: using 6-(benzyloxy)-1-methyl-1*H*-indole **34e** (77.0 mg, 0.300 mmol), after 3 hours 1,1'-dimethyl-1*H*,1'*H*-[2,3'-biindol]-6'-ol **8g** (57.8 mg, 0.209 mmol, 70% yield) was obtained as a yellow oil. **Rf**: 0.28 (Pentane:EtOAc 9:1). ¹**H**


NMR (400 MHz, CDCl₃) δ 7.65 (d, J = 7.8 Hz, 1H, ArH), 7.54 (d, J = 8.5 Hz, 1H, ArH), 7.37 (m, 1H, ArH), 7.24 (m, 1H, ArH), 7.15 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H, ArH), 7.07 (s, 1H, ArH), 6.83 (d, J = 2.3 Hz, 1H, ArH), 6.74 (dd, J = 8.5, 2.3 Hz, 1H, ArH), 6.61 (s, 1H, ArH), 4.97 (br s, 1H, OH), 3.77 (s, 3H, NMe), 3.76 (s, 3H, NMe). ¹³**C NMR** (101 MHz, CDCl₃) δ 152.3, 137.9, 137.8, 135.1, 128.3, 127.3, 122.2, 121.1, 120.9, 119.9, 119.5, 110.2, 109.3, 107.4, 101.2, 95.3, 33.0, 30.9. **IR** v 3369 (w), 2941 (w), 2900 (w), 1627 (s), 1593 (s), 1463 (m), 1395 (m), 1320 (m), 1234 (m), 1183 (m), 1171 (m), 1081 (m), 966 (s), 780 (s). **HR-ESI-MS** calcd for calcd for $C_{18}H_{17}N_2O^+$ [M+H] $^+$ 277.1335; found 277.1344.

1-Methyl-1*H*,1'*H*-2,3'-biindole (8h)

Following procedure **GP8**: using commercially available 1*H*-indole (35.1 mg, 0.300 mmol), after 3 hours 1-methyl-1*H*,1'*H*-2,3'-biindole **8h** (48.3 mg, 0.196 mmol, 65% yield) was obtained as a yellow oil. **Rf**: 0.50 (Pentane:EtOAc 1:1). ¹**H NMR** (400 MHz, CDCl₃) δ 8.38 (br s, 1H,

N*H*), 7.72 (d, J = 8.0 Hz, 1H, Ar*H*), 7.66 (d, J = 7.8 Hz, 1H, Ar*H*), 7.48 (d, J = 8.2 Hz, 1H, Ar*H*), 7.43 – 7.33 (m, 2H, Ar*H*), 7.33 – 7.10 (m, 4H, Ar*H*), 6.66 (s, 1H, Ar*H*), 3.71 (s, 3H, N*Me*) (*NB*: the product is highly unstable under atmosphere – presence of grease in the proton *NMR*). ¹³C NMR (101 MHz, CDCl₃) δ 138.1, 136.1, 135.1, 128.4, 127.3, 124.0, 122.9, 121.2, 120.8, 120.3, 120.2, 119.7, 111.5, 109.5, 109.0, 101.7, 31.1. IR v 3402 (m), 3058 (w), 2926 (w), 2846 (w), 1593 (w), 1458 (m), 1329 (w), 1242 (m), 1097 (m), 1011 (w), 784 (m), 747 (s). HR-ESI-MS calcd for C₁₇H₁₅N₂⁺ [M+H]⁺ 247.1230; found 247.1226.


5'-Fluoro-1-methyl-1H,1'H-2,3'-biindole (8i)



Following procedure **GP8**: using commercially available 5-fluoro-1*H*-indole (40.5 mg, 0.300 mmol), after 3 hours 5'-fluoro-1-methyl-1H,1'H-2,3'-biindole **8i** (62.0 mg, 0.235 mmol, 78% yield) was obtained as a yellow resin. **Rf**: 0.42 (Pentane:EtOAc 1:1). ¹**H NMR** (400 MHz, CDCl₃) δ 8.35 (br s, 1H), 7.67 (d, J = 7.7 Hz, 1H, Ar*H*), 7.42 – 7.32 (m,

4H, Ar*H*), 7.26 (m, 1H, Ar*H*), 7.17 (t, J = 7.4 Hz, 1H, Ar*H*), 7.04 (td, J = 9.0, 2.5 Hz, 1H, Ar*H*), 6.64 (s, 1H, Ar*H*), 3.75 (s, 3H, N*Me*) (*NB*: the product is highly unstable under atmosphere – presence of grease in the proton *NMR*). ¹³**C NMR** (101 MHz, CDCl₃) δ 158.51 (d, J = 236.2 Hz), 137.9, 134.3, 132.5, 128.6, 128.2, 127.63 (d, J = 8.5 Hz), 127.0, 125.4, 121.2, 119.90 (d, J = 46.8 Hz), 112.05 (d, J = 7.3 Hz), 111.31 (d, J = 26.3 Hz), 105.10 (d, J = 24.2 Hz), 101.6, 30.9. **IR** v 3433 (w), 3400 (m), 3050 (w), 1583 (m), 1486 (s), 1467 (s), 1387 (w), 1281 (m), 1243 (m), 1163 (m), 930 (m), 744 (s). **HR-ESI-MS** calcd for C₁₇H₁₄FN₂⁺ [M+H]⁺ 265.1136; found 265.1137.

5'-Bromo-1-methyl-1H,1'H-2,3'-biindole (8j)



Following procedure **GP8**: using commercially available 5-bromo-1*H*-indole (58.8 mg, 0.300 mmol), after 3 hours 5'-bromo-1-methyl-1H,1'H-2,3'-biindole **8j** (60.8 mg, 0.187 mmol, 62% yield) was obtained as a yellow resin. **Rf**: 0.40 (Pentane:EtOAc 1:1). ¹**H NMR** (400 MHz, CDCl₃) δ 8.32 (br s, 1H, N*H*), 7.81 (d, J = 1.8 Hz, 1H, Ar*H*), 7.65 (d, J


= 7.8 Hz, 1H, Ar*H*), 7.35 (m, 2H, Ar*H*), 7.28 (s, 1H, Ar*H*), 7.28 – 7.22 (m, 2H, Ar*H*), 7.15 (td, J = 7.5, 1.1 Hz, 1H, Ar*H*), 6.62 (s, 1H, Ar*H*), 3.70 (s, 3H, N*Me*). ¹³C NMR (101 MHz, CDCl₃) δ 137.9, 134.6, 133.9, 128.9, 128.2, 125.7, 124.8, 122.7, 121.3, 120.2, 119.7, 114.0, 112.8, 109.4, 108.6, 101.9, 30.9. IR v 3399 (w), 3157 (w), 2987 (w), 2888 (w), 1621 (w), 1535 (w), 1477 (m), 1429 (m), 1267 (s), 1224 (s), 1090 (s), 1024 (s), 885 (m), 761 (m). HR-ESI-MS calcd for C₁₇H₁₄⁷⁹BrN₂⁺ [M+H]⁺ 325.0335; found 325.0329.

1,1',3-Trimethyl-1*H***,1'***H***-2,3'-biindole** (8k)

Following procedure **GP8**: using commercially available 1,3-dimethyl-1*H*-indole (43.6 mg, 0.300 mmol), after 3 hours 1,1',3-trimethyl-1*H*,1'*H*-2,3'-biindole **8k** (36.9 mg, 0.134 mmol, 45% yield) was obtained as a yellow oil. **Rf**: 0.44 (Pentane:EtOAc 9:1). ¹**H NMR** (400 MHz, CDCl₃) δ 7.62 (dt, J = 7.9, 1.0 Hz, 1H, Ar*H*), 7.46 (dt, J =

7.2, 0.7 Hz, 1H, Ar*H*), 7.44 (m, 1H, Ar*H*), 7.36 (dt, J = 8.0, 0.9 Hz, 1H, Ar*H*), 7.32 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H, Ar*H*), 7.17 (m, 2H, Ar*H*), 7.15 (m, 2H, Ar*H*), 3.92 (s, 3H, N*Me*), 3.63 (s, 3H, N*Me*), 2.29 (s, 3H, CH_3). ¹³C NMR (101 MHz, CDCl₃) δ 137.3, 136.9, 131.5, 129.4, 128.6, 128.2, 122.0, 121.1, 120.5, 119.9, 118.7, 118.5, 109.5, 109.1, 109.0, 106.1, 33.0, 30.8, 9.7. IR v 3422 (s), 1592 (m), 1493 (w), 1442 (w), 1360 (w), 1287 (w), 1222 (w), 1144 (w), 1025 (m). HR-ESI-MS calcd for $C_{19}H_{19}N_2^+$ [M+H]⁺ 275.1543; found 275.1542.

2-(1'-Methyl-1*H*,1'*H*-[2,3'-biindol]-3-yl)ethanol (8l)



Following procedure **GP8**: using commercially available 2-(1*H*-indol-3-yl)ethanol (48.4 mg, 0.300 mmol), after 3 hours 2-(1'-methyl-1*H*,1'*H*-[2,3'-biindol]-3-yl)ethanol **8l** (49.8 mg, 0.172 mmol, 57% yield) was obtained as a yellow oil. **Rf**: 0.60 (Pentane:EtOAc 1:1). ¹**H NMR** (400 MHz, CDCl₃) δ 8.23 (br s, 1H, N*H*), 7.78 (dt, *J* = 7.9, 1.0

Hz, 1H, ArH), 7.68 - 7.59 (m, 1H, ArH), 7.46 (s, 1H, ArH), 7.41 (m, 2H, ArH), 7.32 (ddd, J =8.2, 6.9, 1.2 Hz, 1H, ArH), 7.21 (m, 2H, ArH), 7.16 (ddd, J = 8.2, 7.1, 1.2 Hz, 1H, ArH), 3.95 $(t, J = 6.4 \text{ Hz}, 2H, CH_2), 3.86 \text{ (s, 3H, NMe)}, 3.15 \text{ (t, } J = 6.4 \text{ Hz}, 2H, CH_2), 1.55 \text{ (s, 1H, } OH).$ ¹³C NMR (101 MHz, CDCl₃) δ 137.0, 135.9, 131.3, 128.9, 128.5, 126.8, 122.4, 121.6, 120.2, 119.6, 119.5, 118.4, 110.7, 109.7, 107.7, 106.8, 62.9, 33.0, 28.3. **IR** v 2926 (w), 2866 (w), 1550 (s), 1528 (s), 1507 (s), 1475 (s), 1325 (s), 1276 (s), 1263 (s), 1193 (s), 1159 (s), 1116 (m), 1068 1003 930 811 (m), (m), (s), 886 (m), (m). **HR-ESI-MS** calcd $C_{19}H_{18}N_2NaO^+$ [M+Na]⁺ 313.1311; found 313.1314.

5-Iodo-1,1'-dimethyl-1*H*,1'*H*-2,3'-biindole (8m)

Following procedure **GP8**: using commercially available methylindole **5** (39.4 mg, 0.300 mmol) and IndoleBX **2c** (151 mg, 0.300 mmol), after 3 hours 5-iodo-1,1'-dimethyl-1*H*,1'*H*-2,3'-biindole **8m** (58.9 mg, 0.152 mmol, 51% yield) was obtained as a

yellow oil. **Rf:** 0.35 (Pentane:EtOAc 9:1). ¹**H NMR** (400 MHz, CDCl₃) δ 7.97 (d, J = 1.6 Hz, 1H, ArH), 7.69 (d, J = 8.0 Hz, 1H, ArH), 7.48 (dd, J = 8.6, 1.7 Hz, 1H, ArH), 7.42 (d, J = 8.3 Hz, 1H, ArH), 7.34 (m, 1H, ArH), 7.23 (m, 1H, ArH), 7.20 (s, 1H, ArH), 7.15 (d, J = 8.5 Hz, 1H, ArH), 6.55 (s, 1H, ArH), 3.89 (s, 3H, NMe), 3.73 (s, 3H, NMe). ¹³**C NMR** (101 MHz, CDCl₃) δ 137.0, 136.9, 136.0, 130.9, 129.1, 128.6, 128.5, 127.5, 122.4, 120.4, 120.2, 111.3, 109.6, 106.7, 100.5, 83.0, 33.1, 31.1. **IR** v 048 (w), 2928 (w), 1734 (w), 1618 (m), 1589 (m), 1467 (m), 1392 (m), 1372 (m), 1265 (m), 1248 (m), 1133 (w), 1089 (w), 1044 (w), 951 (w), 897 (w), 871 (w), 787 (m), 741 (s). **HR-ESI-MS**) calcd for C₁₈H₁₆IN₂⁺ [M+H]⁺ 387.0353; found 387.0356.

5'-Methoxy-1,1'-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*,1'*H*-2,3'-biindole (8n).

Following procedure **GP8**: using 5-methoxy-1-methyl-1*H*-indole **34b** (48.4 mg, 0.300 mmol) and IndoleBX **2d** (151 mg, 0.300 mmol), after 3 hours 5'-methoxy-1,1'-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*,1'*H*-2,3'-biindole **8n** (69.0 mg, 0.166 mmol, 55% yield) was obtained as a yellow oil.


Rf: 0.15 (Pentane:DCM 1:1). ¹**H NMR** (400 MHz, CDCl₃) δ 8.18 (s, 1H, Ar*H*), 7.68 (dd, J = 8.2, 1.2 Hz, 1H, Ar*H*), 7.37 (d, J = 8.2 Hz, 1H, Ar*H*), 7.29 (d, J = 8.9 Hz, 1H, Ar*H*), 7.17 (s, 1H, Ar*H*), 7.09 (d, J = 2.5 Hz, 1H, Ar*H*), 6.96 (dd, J = 8.9, 2.5 Hz, 1H, Ar*H*), 6.62 (s, 1H, Ar*H*), 3.86 (s, 3H, N*Me*), 3.81 (s, 3H, N*Me*), 3.75 (s, 3H, N*Me*), 1.38 (s, 12H, *BPin*). ¹³**C NMR** (101 MHz, CDCl₃) δ 154.8, 139.8, 135.3, 132.2, 128.9, 128.1, 128.1, 127.9, 127.2, 112.9, 110.4, 108.7, 106.7, 101.8, 101.4, 83.4, 55.9, 33.2, 30.9, 24.9. *NB: the Carbon-Boron bond is not observed as reported in literature.* ^[18] **IR** v 2996 (m), 2867 (w), 2837 (w), 1521 (m), 1431 (m), 1361 (w), 1288 (m), 1148 (w), 991 (s), 862 (s). **HR-ESI-MS** calcd for C₂₅H₂₉BN₂O₃⁺ [M+] 416.2094; found 416.2286.

5'-Nitro-1,1'-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*,1'*H*-2,3'-biindole (80)

Following procedure **GP8**: using commercially available 1-methyl-5-nitro-1*H*-indole (53.0 mg, 0.300 mmol) and IndoleBX **2d** (151 mg, 0.300 mmol), after 3 hours 5'-nitro-1,1'-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*,1'*H*-2,3'-biindole **8o** (65.4 mg, 0.152 mmol, 51% yield) was obtained as

an orange oil. **Rf:** 0.20 (Pentane:EtOAc 4:1). ¹**H NMR** (400 MHz, CDCl₃) δ 8.62 (s, 1H, Ar*H*), 8.25 – 8.15 (m, 2H, Ar*H*), 7.72 (m, 1H, Ar*H*), 7.44 – 7.35 (m, 2H, Ar*H*), 7.34 (d, *J* = 1.3 Hz, 1H, Ar*H*), 6.66 (s, 1H, Ar*H*), 3.94 (s, 3H, N*Me*), 3.75 (s, 3H, N*Me*), 1.39 (s, 12H, BPin-*Me*). ¹³**C NMR** (101 MHz, CDCl₃) δ 142.3, 140.0, 139.5, 132.8, 131.1, 128.2, 127.8 (2 aromatic carbon signals overlapped), 127.0, 118.0, 117.6, 110.1, 109.6, 108.9, 103.0, 83.4, 33.5, 31.0, 24.9. *NB:* the Carbon-bound to Boron is not observed as reported in literature. ^[18] **IR** v 3482 (w), 3333 (w), 3090 (w), 1519 (s), 1330 (s), 1282 (m), 1149 (m), 995 (m), 931 (s), 856 (s), 833 (s). **HR-ESI-MS** calcd for C₂₄H₂₆BN₃NaO₄⁺ [M+Na]⁺ 454.1909; found 454.1914.

3.4.3: Scope of pyrrole- and thiophene-2-methylindoles.



$1\hbox{-}Methyl\hbox{-}2\hbox{-}(1\hbox{-}methyl\hbox{-}1H\hbox{-}pyrrol\hbox{-}2\hbox{-}yl)\hbox{-}1H\hbox{-}indole\ (9a)$

Following procedure **GP8**: using commercially available 1-methyl-1*H*-pyrrole (27.0 μ L, 0.300 mmol), after 3 hours 1-methyl-2-(1-methyl-1*H*-pyrrol-2-yl)-1*H*-indole **9a** (44.3 mg, 0.211 mmol, 70% yield) was obtained as a yellow oil. **Rf**: 0.70 (Pentane:EtOAc 9:1). ¹**H NMR** (400 MHz, CDCl₃) δ 7.64 (d, J = 7.9 Hz, 1H, Ar*H*), 7.36 (d, J = 8.2 Hz, 1H, Ar*H*), 7.26 (m, 1H, Ar*H*), 7.15 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H, Ar*H*), 6.81 (dd, J = 2.7, 1.8 Hz, 1H, Ar*H*), 6.53 (s, 1H, Ar*H*), 6.30 (dd, J = 3.6, 1.7 Hz, 1H, Ar*H*), 6.27 (dd, J = 3.6, 2.6 Hz, 1H, Ar*H*), 3.66 (s, 3H, N*Me*), 3.60 (s, 3H, N*Me*). ¹³**C NMR** (101 MHz, CDCl₃) δ 137.5, 132.2, 127.6, 124.5, 123.6, 121.7, 120.4, 119.7, 111.4, 109.5, 107.8, 103.2, 34.7, 30.6. **IR** v 3050 (w), 2984 (w), 2887 (w), 1614

(w), 1471 (w), 1384 (w), 1259 (m), 1047 (m), 959 (s), 785 (m). **HR-ESI-MS** calcd for $C_{14}H_{15}N_2^+$ [M+H]⁺ 211.1230; found 211.1227.

1-Methyl-2-(1-phenyl-1*H*-pyrrol-2-yl)-1*H*-indole 9b and 1-methyl-2-(1-phenyl-1*H*-pyrrol-3-yl)-1*H*-indole (9b')

Following procedure **GP8**: using commercially available 1-phenyl-1*H*-pyrrole (43.0 μL, 0.300 mmol), after 3 hours a separable mixture of 1-methyl-2-(1-phenyl-1*H*-pyrrol-2-yl)-1*H*-indole

9b (26.2 mg, 96.0 μ mol, 32% yield) and 1-methyl-2-(1-phenyl-1*H*-pyrrol-3-yl)-1*H*-indole **9b**' (24.1 mg, 88.0 μ mol, 30% yield) was obtained as a yellow oil.

9b Rf: 0.40 (Pentane:EtOAc 9:1) ¹**H NMR** (400 MHz, CDCl₃) δ 7.57 (d, J = 7.9 Hz, 1H, ArH), 7.29 – 7.13 (m, 7H, ArH), 7.13 – 7.06 (m, 2H, ArH), 6.50 (dd, J = 3.5, 1.8 Hz, 1H, ArH), 6.44 (t, J = 3.2 Hz, 1H, ArH), 6.42 (s, 1H, ArH), 3.34 (s, 3H, NMe). ¹³**C NMR** (101 MHz, CDCl₃) δ 140.2, 137.4, 132.6, 129.1, 127.8, 126.4, 124.3, 124.2, 123.7, 121.5, 120.4, 119.5, 114.0, 109.4 (2 aromatic carbon signals overlapped), 103.5, 30.5. **IR** v 3106 (w), 2978 (w), 2901 (w), 1558 (s), 1489 (s), 1371 (s), 1292 (s), 1218 (s), 1054 (m), 818 (s). **HR-ESI-MS** calcd for $C_{19}H_{17}N_2^+$ [M+H]⁺ 273.1386; found 273.1379.

9b' Rf: 0.38 (Pentane:EtOAc 9:1). ¹**H NMR** (400 MHz, CDCl₃) δ 7.61 (d, J = 8.0 Hz, 1H, ArH), 7.30 – 7.18 (m, 7H, ArH), 7.07 (ddd, J = 8.0, 6.9, 1.2 Hz, 1H, ArH), 6.96 (dd, J = 2.9, 1.8 Hz, 1H, ArH), 6.51 (m, 1H, ArH), 6.49 (s, 1H, ArH), 6.42 (dd, J = 3.5, 2.8 Hz, 1H, ArH), 3.66 (s, 3H, NMe). ¹³**C NMR** (101 MHz, CDCl₃) δ 140.8, 136.5, 128.7, 127.4, 127.3, 127.1, 126.4, 125.7, 122.6, 121.7, 120.4, 119.5, 109.9, 109.1, 109.0, 107.7, 32.7. **IR** v 3106 (w), 3045 (w), 1599 (m), 1499 (s), 1426 (w), 1366 (m), 1321 (m), 1254 (w), 1103 (w), 912 (w), 743 (s). **HR-ESI-MS** calcd for C₁₉H₁₇N₂+ [M+H]+ 273.1386; found 273.1386.

2-(3-Methoxythiophen-2-yl)-1-methyl-1*H*-indole (10a)

Following procedure **GP8**: using commercially available 3-methoxythiophen (30.0 mg, 0.300 mmol), after 3 hours 2-(3-methoxythiophen-2-yl)-1-methyl-1*H*-indole **10a** (46.8 mg, 0.192 mmol, 64% yield) was obtained as a yellow oil. **Rf**: 0.80 (Pentane:EtOAc 4:1). ¹**H NMR** (400 MHz, CDCl₃) δ 7.62 (d, J = 7.8 Hz, 1H, Ar*H*), 7.36 (m, 1H, Ar*H*), 7.31 (d, J = 5.5

Hz, 1H, ArH), 7.24 (m, 1H, ArH), 7.12 (ddd, J = 7.9, 7.0, 1.0 Hz, 1H, ArH), 6.96 (d, J = 5.5Hz, 1H, ArH), 6.62 (s, 1H, ArH), 3.85 (s, 3H, NMe), 3.73 (s, 3H, OMe). ¹³C NMR (101 MHz, CDCl₃) δ 154.8, 137.9, 131.5, 127.8, 124.7, 121.7, 120.4, 119.6, 116.7, 110.4, 109.4, 103.5, 58.7, 30.8. **IR** v 3108 (w), 2935 (w), 2851 (w), 1583 (w), 1465 (m), 1378 (s), 1337 (m), 1252 (s), 1103 (w), 1070 (s), 929 (w), 780 (m), 750 (s). HR-ESI-MS calcd for $C_{14}H_{14}NOS^{+}$ [M+H]⁺ 244.0791; found 244.0787.

2-(2,5-Dimethylthiophen-3-yl)-1-methyl-1*H*-indole (10b)


Ме Ме

10b

dimethylthiophene (34.0 mg, 0.300 mmol), after 3 hours 2-(2,5dimethylthiophen-3-yl)-1-methyl-1*H*-indole **10b** (35.2 mg, 0.146 mmol, 49% yield) was obtained as a yellow oil. Rf: 0.85 (Pentane:EtOAc 4:1). ¹**H NMR** (400 MHz, CDCl₃) δ 7.65 (d, J = 7.9 Hz, 1H, ArH), 7.35 (m, 1H, ArH), 7.29 - 7.24 (m, 1H, ArH), 7.14 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H, ArH), 7.03 (s, 1H, ArH), 6.85 (d, J = 1.3 Hz, 1H, ArH), 3.84 (s, 3H, NMe), 2.48 (s, 3H, CH₃), 2.43 (s, 3H, CH₃). ¹³C NMR (101 MHz, CDCl₃) δ 136.7, 135.2, 131.2, 130.9, 127.6, 127.3, 127.1, 121.7, 120.3, 119.3, 111.4, 109.2, 32.8, 15.3, 14.2. **IR** v 3499 (w), 2919 (s), 2854 (m), 1685 (w), 1484 (m), 1332 (w), 1218 (m), 1137 (s), 1015 (m), 815 (m). **HR-APPI-MS** calcd for C₁₅H₁₅NS [M+] 241.0920; found 241.0926.

Following procedure **GP8**: using commercially available 2,5-

3.4.4: Scope of trimethoxy(methyl)phenylated-NH-indoles.



2-(2,4,6-Trimethoxyphenyl)-1*H***-indole (14a)**

Following procedure **GP9**: starting from C2-IndoleDBX **13c** (95.5 MeO OMe after 3 hours 0.200 mmol, 1.00 equiv.), trimethoxyphenyl)-1*H*-indole **14a** (43.4 mg, 0.150 mmol, 77% yield) MeÓ was obtained as a grey solid. M.p. 132-137 °C. Rf: 0.55 14a (Pentane:EtOAc 8:2). ¹**H NMR** (400 MHz, CDCl₃) δ 9.47 (s, 1H, N*H*), 7.64 (dt, J = 7.8, 1.0 Hz, 1H, ArH), 7.39 (dd, J = 8.0, 1.2 Hz, 1H, ArH), 7.16 (ddd, J = 8.1, 7.0, 1.3 Hz, 1H, ArH), 7.11 - 7.07 (m, 2H, ArH), 6.29 (s, 2H, ArH), 3.93 (s, 6H, o-OCH₃), 3.88 (s, 3H, p-OCH₃). ¹³C **NMR** (101 MHz, CDCl₃) δ 160.1, 158.7, 135.0, 131.2, 128.2, 121.1, 120.0, 119.1, 110.3, 103.7, 103.6, 91.5, 56.0, 55.3. **IR** v 3434 (w), 2938 (w), 2837 (w), 1605 (m), 1583 (m), 1486 (w), 1455 (s), 1414 (m), 1330 (m), 1204 (m), 1122 (s) **HR-ESI-MS**: calcd for C₁₇H₁₈NO₃⁺ 284.1281 $[M + H]^+$; found 284.1284.

NB: when C2-IndoleBX 13a was used, the desired compound 14a was obtained in 67% yield.

Following procedure **GP9**: starting from C2-IndoleDBX **13e** (101 mg, 0.200 mmol), after 3

hours 5-methoxy-2-(2,4,6-trimethoxyphenyl)-1*H*-indole **14b** (41.7 mg, 0.130 mmol, 67% yield) was obtained as a green solid. **M.p.** 115-120 °C. **Rf:** 0.45 (Pentane:EtOAc 8:2). ¹**H NMR** (400 MHz, CDCl₃) δ 9.38 (s, 1H, N*H*), 7.27 (d, J = 8.6 Hz, 1H, Ar*H*), 7.11 (d, J = 2.4 Hz, 1H, Ar*H*), 7.00 (s, 1H, Ar*H*), 6.82 (dd, J = 8.7, 2.4 Hz,

1H, Ar*H*), 6.28 (s, 2H, Ar*H*), 3.92 (s, 6H, o-O*CH*₃), 3.87 (s, 6H, p-O*CH*₃, and 5-O*CH*₃). ¹³C **NMR** (101 MHz, CDCl₃) δ 160.1, 158.6, 153.8, 131.9, 130.3, 128.5, 128.4, 111.5, 111.0, 103.6, 101.7, 91.5, 56.0, 55.8, 55.3. **IR** v 3431 (w), 2937 (w), 2841 (w), 1604 (m), 1580 (m), 1459 (m), 1204 (s), 1120 (s), 1034 (m), 799 (s). **HR-ESI-MS**: calcd for C₁₈H₂₀NO₄⁺ 314.1387[M + H]⁺; found 314.1391.

6-Methoxy-2-(2,4,6-trimethoxyphenyl)-1*H*-indole (14c)

Following procedure **GP9**: starting from C2-IndoleDBX **13f** (101 mg, 0.200 mmol), after 3 hours 6-methoxy-2-(2,4,6-trimethoxyphenyl)-1*H*-indole **14c** (31.1 mg, 0.100 mmol, 50% yield) was obtained as a green solid. **M.p** 165-168 °C. **Rf**: 0.51 (Pentane:EtOAc 8:2). ¹**H NMR** (400 MHz, CDCl₃) δ 9.38 (s,

1H, N*H*), 7.49 (d, J = 8.6 Hz, 1H, Ar*H*), 6.99 (dd, J = 2.1, 0.9 Hz, 1H, Ar*H*), 6.90 (d, J = 2.3 Hz, 1H, Ar*H*), 6.76 (dd, J = 8.6, 2.3 Hz, 1H, Ar*H*), 6.28 (s, 2H, Ar*H*), 3.92 (s, 6H, o-O*CH*₃), 3.87 (s, 3H, O*CH*₃), 3.86 (s, 3H, O*CH*₃). ¹³**C NMR** (101 MHz, CDCl₃) δ 159.8, 158.4, 155.9, 135.6, 130.0, 122.6, 120.7, 109.2, 103.8, 103.6, 93.9, 91.5, 56.0, 55.6, 55.3. **IR** v 3442 (s), 1604 (s), 1479 (s), 1329 (s), 1303 (s), 1234 (s), 1116 (w). **HR-ESI-MS**: calcd for C₁₈H₂₀NO₄⁺ 314.1387[M + H]⁺; found 314.1389.

6-Bromo-2-(2,4,6-trimethoxyphenyl)-1*H*-indole (14d)

Following procedure **GP9**: starting from C2-IndoleDBX **13g** (111 mg, 0.200 mmol), after 3 hours 6-bromo-2-(2,4,6-trimethoxyphenyl)-1*H*-indole **14d** (68.0 mg, 0.190 mmol, 94% yield) was obtained as a colorless solid. **M.p.** 133-138 °C. **Rf:** 0.49 (Pentane:EtOAc 8:2). ¹**H NMR** (400 MHz, CDCl₃) δ 9.52 (s, 1H,

N*H*), 7.53 (d, J = 1.8 Hz, 1H, Ar*H*), 7.47 (d, J = 8.4 Hz, 1H, Ar*H*), 7.16 (dd, J = 8.4, 1.7 Hz, 1H, Ar*H*), 7.03 (s, 1H, Ar*H*), 6.28 (s, 2H, Ar*H*), 3.93 (s, 6H, o-O*CH*₃), 3.87 (s, 3H, p-O*CH*₃).


¹³C NMR (101 MHz, CDCl₃) δ 160.4, 158.7, 135.7, 132.2, 127.1, 122.4, 121.2, 114.4, 113.2, 103.7, 102.9, 91.5, 56.0, 55.3. IR ν 3444 (w), 1605 (w), 1581 (w), 1454 (w), 1329 (w), 1205 (w), 1115 (s), 1067 (m). HR-ESI-MS: calcd for C₁₇H₁₇Br⁷⁹NO₃⁺ 362.0386 [M + H]⁺; found 362.0388.

3-Methyl-2-(2,4,6-trimethoxyphenyl)-1*H***-indole (14e)**

Following procedure **GP9**: starting from C2-IndoleDBX **13h** (98.0 mg, 0.200 mmol), after 3 hours 3-methyl-2-(2,4,6-trimethoxyphenyl)-1*H*-indole **14e** (49.0 mg, 0.160 mmol, 82% yield) was obtained as a pale yellow solid. **M.p.** 128-131 °C. **R**f: 0.46 (Pentane:EtOAc 8:2). ¹**H NMR** (400 MHz, CDCl₃) δ 8.15 (s, 1H, N*H*), 7.68 (ddt, J = 7.5, 1.6,

0.8 Hz, 1H, Ar*H*), 7.41 (dt, J = 8.0, 1.0 Hz, 1H, Ar*H*), 7.21 (dddd, J = 21.2, 8.2, 7.1, 1.2 Hz, 2H, Ar*H*), 6.34 (s, 2H, Ar*H*), 3.98 (s, 3H, p-OC H_3), 3.85 (s, 6H, o-OC H_3), 2.28 (s, 3H, CH_3). ¹³C **NMR** (101 MHz, CDCl₃) δ 161.5, 159.4, 135.9, 128.9, 127.1, 121.1, 118.5, 118.5, 110.8, 110.4, 103.1, 90.7, 55.7, 55.3, 9.7. **IR** v 3395 (w), 2939 (w), 2840 (w), 1609 (m), 1581 (m), 1456 (m), 1412 (m), 1224 (m), 1126 (s), 1033 (m), 941 (m), 816 (w). **HR-ESI-MS**: calcd for $C_{18}H_{20}NO_3^+$ 298.1438 [M + H]⁺; found 298.1440.

2-(2-(2-(2,4,6-Trimethoxyphenyl)-1*H*-indol-3-yl)ethyl)isoindoline-1,3-dione (14f)



Following procedure **GP9**: starting from C2-IndoleDBX **13i** (110 mg, 0.200 mmol), after 3 hours 2-(2-(2-(2,4,6-trimethoxyphenyl)-1*H*-indol-3-yl)ethyl)isoindoline-1,3-dione **14f** (68.1 mg, 0.150 mmol, 75% yield) was obtained as an orange solid. **M.p.** 195-200 °C. **Rf**: 0.68 (Pentane:EtOAc 8:2). ¹**H NMR** (400 MHz, CDCl₃) δ 8.08 (s, 1H, N*H*),

7.90 (dd, J = 6.5, 2.3 Hz, 1H, ArH), 7.79 (dt, J = 7.0, 3.5 Hz, 2H, ArH), 7.68 (dd, J = 5.5, 3.0 Hz, 2H, ArH), 7.35 (dt, J = 7.3, 2.1 Hz, 1H, ArH), 7.20 – 7.09 (m, 2H, ArH), 6.18 (s, 2H, ArH), 4.01 – 3.99 (m, 2H, CH₂), 3.87 (s, 3H, p-OC H_3), 3.75 (s, 6H, o-OC H_3), 3.03 – 2.99 (m, 2H, CH₂). ¹³C NMR (101 MHz, CDCl₃) δ 168.2, 161.6, 159.4, 135.9, 133.5, 132.3, 128.1, 128.0, 122.9, 121.3, 119.0, 118.8, 111.1, 110.6, 102.4, 90.5, 55.7, 55.3, 37.7, 24.7. IR v 3392 (w), 1770 (w), 1704 (s), 1395 (s), 1359 (m), 1127 (m), 1042 (w). HR-ESI-MS: calcd for C₂₇H₂₅N₂O₅⁺ 457.1758 [M + H]⁺; found 457.1766.


2-(2,4,6-trimethoxy-3-methylphenyl)-1*H*-indole (14g)

Following procedure GP9: starting from C2-IndoleDBX 13c (95.5 mg, 0.200 mmol), after 3

hours 2-(2,4,6-trimethoxy-3-methylphenyl)-1*H*-indole **14g** (27.1 mg, 90.0 µmol, 46% yield) was obtained as a white solid. **M.p.** 135-138 °C. **Rf:** 0.62 (Pentane:EtOAc 9:1). ¹**H NMR** (400 MHz, CDCl₃) δ 9.46 (s, 1H, N*H*), 7.64 (dd, J = 7.8, 1.3 Hz, 1H, Ar*H*), 7.40 (d, J = 8.0 Hz, 1H, Ar*H*), 7.16 (ddd, J = 8.1, 7.0, 1.3 Hz, 1H, Ar*H*), 7.09 (ddd, J = 8.0,

7.0, 1.1 Hz, 2H, Ar*H*), 6.41 (s, 1H, Ar*H*), 3.92 (s, 3H, O*CH*₃), 3.90 (s, 3H, O*CH*₃), 3.53 (s, 3H, O*CH*₃), 2.17 (s, 3H, *CH*₃). ¹³C **NMR** (101 MHz, CDCl₃) δ 158.2, 157.4, 156.3, 135.3, 131.1, 128.4, 121.3, 120.2, 119.3, 112.8, 110.4, 107.6, 103.7, 92.3, 60.2, 56.2, 55.6, 8.4. **IR** v 3325 (w), 2960 (w), 1611 (m), 1452 (m), 1201 (m), 1110 (s), 797 (m). **HR-ESI-MS**: calcd for C₁₈H₂₀NO₃⁺ 298.1438[M + H]⁺; found 298.1443.

3-Methyl-2-(2,4,6-trimethoxy-3-methylphenyl)-1*H*-indole (14h)



Following procedure **GP9**: starting from C2-IndoleDBX **13h** (98.0 mg, 0.200 mmol), after 3 hours 3-methyl-2-(2,4,6-trimethoxy-3-methylphenyl)-1*H*-indole **14h** (40.6 mg, 0.130 mmol, 65% yield) was obtained as a brown solid. **M.p**. 164-166 °C. **Rf**: 0.58 (Pentane:EtOAc 8:2). ¹**H NMR** (400 MHz, CDCl₃) δ 8.18 (s, 1H, N*H*), 7.63 – 7.61 (m,

1H, Ar*H*), 7.35 (dt, J = 8.1, 1.0 Hz, 1H, Ar*H*), 7.15 (dddd, J = 21.4, 8.1, 7.1, 1.2 Hz, 2H, Ar*H*), 6.39 (s, 1H, Ar*H*), 3.92 (s, 3H, O*CH*₃), 3.79 (s, 3H, O*CH*₃), 3.30 (s, 3H, O*CH*₃), 2.24 (s, 3H, *CH*₃), 2.15 (s, 3H, *CH*₃). ¹³**C NMR** (101 MHz, CDCl₃) δ 159.1, 158.3, 156.9, 136.0, 128.9, 127.4, 121.3, 118.6, 118.5, 111.9, 110.8, 110.4, 107.4, 91.5, 60.0, 55.9, 55.6, 9.7, 8.4. **IR** v 3353 (w), 2935 (w), 1606 (w), 1449 (m), 1434 (m), 1326 (m), 1185 (m), 1111 (s), 1006 (w), 806 (m), 736 (s). **HR-ESI-MS**: calcd for C₁₉H₂₂NO₃⁺ 312.1594 [M + H]⁺; found 312.1593.

3.4.5: Scope of mixed 3'-2-NH-biindoles.

6'-Bromo-1*H*,1'*H*-2,3'-biindole (15a)

(Pentane:EtOAc 7:3). ¹**H NMR** (400 MHz, CD₃CN) δ 9.64 (s, 1H, N*H*), 9.54 (s, 1H, N*H*), 7.91 (dd, J = 8.5, 0.6 Hz, 1H, Ar*H*), 7.70 (dd, J = 1.8, 0.6 Hz, 1H, Ar*H*), 7.65 (d, J = 2.7 Hz, 1H, Ar*H*), 7.59 – 7.52 (m, 1H, Ar*H*), 7.41 (dd, J = 8.0, 1.0 Hz, 1H, Ar*H*), 7.31 (dd, J = 8.5, 1.8 Hz, 1H, Ar*H*), 7.11 (ddd, J = 8.1, 7.1, 1.3 Hz, 1H, Ar*H*), 7.04 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H, Ar*H*), 6.76 (dd, J = 2.2, 0.9 Hz, 1H, Ar*H*). ¹³C NMR (101 MHz, CD₃CN) δ 138.6, 137.3, 134.1, 130.4, 125.0, 124.4, 124.1, 122.2, 122.1, 120.5, 120.4, 116.2, 115.6, 111.5, 110.3, 99.1. **IR** v 3413 (w), 3395 (w), 1615 (m), 1595 (m), 1454 (s), 1308 (s), 1230 (m), 1103 (m), 894 (s). **HR-ESI-MS**: calcd for C₁₆H₁₂Br⁷⁹N₂+ 311.0178 [M + H]+; found 311.0173.

6'-Fluoro-1*H*,1'*H*-2,3'-biindole (15b)

Following procedure **GP9** and using TMSCl as promoter: starting from commercially available 6-fluoro-1H indole (30.0 mg, 0.200 mmol), after 3 hours 6'-fluoro-1
$$H$$
,1' H -2,3'-biindole **15b** (28.0 mg, 0.112 mmol, 56% yield) was obtained as a brown oil. **R**f: 0.42 (Pentane:EtOAc 7:3). ¹ H NMR (400 MHz, Acetone- d_6) δ 10.63 (s, 1 H , N H), 10.43 (s, 1 H , N H), 8.04 (dd, J = 8.8, 5.3 Hz, 1 H , Ar H), 7.85 (d, J = 2.5 Hz, 1 H , Ar H), 7.55 (dd, J = 7.5, 1.3 Hz, 1 H , Ar H), 7.37 (dd, J = 7.9, 1.3 Hz, 1 H , Ar H), 7.25 (dd, J = 9.8, 2.4 Hz, 1 H , Ar H), 7.13 – 6.93


(m, 3H, Ar*H*), 6.86 - 6.71 (m, 1H, Ar*H*) (^{13}C could not recorded due to unstable nature of this compound in solution). **HR-ESI-MS** calcd for $C_{16}H_{11}FN_2^+$ 250.0901 [M]⁺ found 250.0903.

6-Bromo-5',6'-dimethoxy-1*H*,1'*H*-2,3'-biindole (15c)

Following procedure **GP9**: using commercially available 5,6-dimethoxy-1*H*-indole (53.2 mg, 0.200 mmol), after 3 hours 6-bromo-5',6'-dimethoxy-1*H*,1'*H*-2,3'-biindole **15c** (38.1 mg, 0.103 mmol, 34% yield) was obtained as a yellow oil. **Rf**: 0.35 (Pentane:EtOAc 1:1). ¹**H NMR** (400 MHz, CDCl₃) δ 8.21 (br

s, 1H, N*H*), 8.16 (br s, 1H, N*H*), 7.53 (s, 1H, Ar*H*), 7.49 (d, J = 8.4 Hz, 1H, Ar*H*), 7.35 (s, 1H, Ar*H*), 7.32 (d, J = 2.6 Hz, 1H, Ar*H*), 7.22 (dd, J = 8.3, 1.7 Hz, 1H, Ar*H*), 6.94 (s, 1H, Ar*H*), 6.70 (dd, J = 2.0, 0.9 Hz, 1H, Ar*H*), 3.99 (s, 3H, O*Me*), 3.94 (s, 3H, O*Me*). ¹³C NMR (101 MHz, CDCl₃) δ 147.8, 146.0, 136.8, 134.2, 130.8, 128.5, 123.2, 121.0, 119.8, 118.1, 114.6, 113.3, 109.8, 101.4, 99.0, 94.6, 56.5, 56.2 (the compound spontaneously decompose in acidic deuterated solvents, it presents about 9% of decomposed products – grease signal not purified). IR v 2873 (m), 1691 (m), 1349 (m), 1277 (w), 1046 (s), 970 (m), 850 (s), 766 (w), 749 (w). HR-ESI-MS calcd for C₁₈H₁₅⁷⁹BrN₂NaO₂+ [M+Na]+ 393.0209; found 393.0201.

2-(3-Methoxythiophen-2-yl)-1*H*-indole (16)





Following procedure **GP9**: using commercially available 3-methoxythiophen (22.8 mg, 0.200 mmol), after 3 hours 2-(3-methoxythiophen-2-yl)-1H-indole **16** (13.0 mg, 60.0 μ mol, 28% yield)

was obtained as a green oil. **R**_f: 0.6 (Pentane:EtOAc 9:1). ¹**H NMR** (400 MHz, CDCl₃) δ 9.30 (s, 1H, N*H*), 7.56 (dq, J = 7.7, 1.0 Hz, 1H, Ar*H*), 7.38 (dt, J = 8.0, 1.0 Hz, 1H, Ar*H*), 7.19 – 7.04 (m, 3H, Ar*H*), 6.90 (d, J = 5.5 Hz, 1H, Ar*H*), 6.60 (dd, J = 2.1, 0.9 Hz, 1H, Ar*H*), 4.04 (s, 3H, O*CH*₃). ¹³**C NMR** (101 MHz, CDCl₃) δ 153.5, 135.8, 131.8, 128.3, 122.3, 121.6, 119.9, 119.9, 116.3, 112.8, 110.5, 97.9, 58.9. **IR** ν 3440 (w), 1706 (w), 1588 (w), 1516 (w), 1457 (w), 1380 (m), 1293 (m), 1069 (s), 776 (s), 747 (s). **HR-ESI-MS**: calcd for C₁₃H₁₂NOS⁺ 230.0634[M + H]⁺; found 230.0637.


4. Working model for the reaction mechanism.


In order to establish the role of both promoter and fluorinated solvent we performed several NMR experiments in deuterated CDCl₃ (solvent of characterization) and CD₂Cl₂ (solvent of reaction). We screened different equivalents of HFIP and TMSCl. As we've seen in the control experiment, the presence of TMSCl as promoter is essential. When we added 1.0 equiv. of TMSCl to reagent 2a in deuterated solvent, we immediately observed decomposition of the reagent in its constituents. The observed aromatic peaks corresponds to the ones of iodo-benzoic acid. ^[26] In the carbon it is possible to observe that the hypervalent character of C-I bond is lost, as it shift from 78 ppm to 94 ppm. HFIP alone doesn't promote immediate decomposition but shift of peaks; it is possible that it coordinates with the reagent via hydrogen bond-type interactions. However, HFIP plays an important role in stabilizing the intermediate form, as the sole Lewis Acid would immediately decompose the hypervalent iodine reagent. When we mixed both fluorinated solvent and TMSCl we observed decomposition in absence of a suitable nucleophile.






NMR analysis in CD₂Cl₂ showed the same reactivity pattern as in CDCl₃





We currently hypothetize three possible mechanisms for this transformation, a Path A would involve ligand exchange with the nucleophile and reductive elimination to afford the product. Path B envisages a SET pathway and Path C a S_NAr pathway, in which a iodonium carbene resonance structure may play a role (Scheme SI).



 $Scheme \ S1: Three \ mechanistical \ hypotheses \ for \ the \ hypervalent \ iodine-mediated \ oxidative \ coupling.$

As already reported, [27] heteroatom-ligands of the I^(III) can exchange with different nucleophiles. For Path A, two pathways could be considered: associative and dissociative (Scheme S2). In the associative pathway we speculate that the Cl⁻ derived from TMSCl rapidly add to the C-I σ^* orbital and form a trans tetracoordinated [12-I-4] iodate I with a square-planar arrangement. Rapid isomerization and elimination of the carboxylate form a $\lambda 3$ -iodane III. The addition-elimination sequence proceed at a low-energy barrier and is generally reversible. Conversely, the dissociative pathway would involve a high-energy dicoordinated [8-I-2] iodonium species, possibly stabilized by ionic or hydrogen interaction with the protic fluorinated solvent on apical sites to arrive at II. Addition of Cl⁻ would lead to intermediate III. For addition of (hetero) aryl-H the same mechanisms are considered, but a rearomatization of the nucleophile has also to be accounted to get intermediate IV.

Associative Pathway TMSCI TM

Scheme S2: Associative and Dissociative pathways for the formation of III and IV.

To explain the regio-distribution of the product, we hypothetize that **IV**, the C3 regiosisomer would exist in equilibrium with **V**, the C2 one (*Scheme S3*). When a C3-alkylated indole is used as nucleophile, the equilibrium should be shifted towards intermediate **IV** due to sterical hindrance.

Substrate control on the regiodistribution

Scheme S3: Equilibrium of two regioisomers IV and V.

Finally, the hypervalent λ3 -iodanes **IV** or **V** would undergo reductive elimination to afford the coupled product and iodo-benzoic acid as monovalent iodide. The process if facile because the hypervalent iodine is a hypernucleofuge (hypervalent leaving group better than a super-ion as OTf). The process is most probably concerted, (as shown in *Scheme S4*) and require therefore isomerization of the reagent to have the two desired aryl groups in cis relationship. In this step, elimination to form the more sterically hindered product may be more difficult, allowing also to rationalize the regioselectivity based on kinetics instead of thermodynamics. A stepwise, mechanism involving high energy carbo-cation and –anion intermediates is less probable. A weak point of pathway A is that it is difficult to rationalize the high selectivity observed for biheteroaryl formation: In fact, at least some reductive elimination to give undesired cross-products with iodobenzoic acid would have been expected.

Scheme S4: Reductive elimination

Another proposal involves, as theorized by Kita for the oxidative coupling of arenes and heterocycles, [28,29] a radical mechanism. This would be a viable alternative to the ligand

exchange proposed in *Path A*. The TMSCl should induce the formation of Charge-Transfer complex **VI** (CT-complex) between the (hetero)arene and the electrophilic hypervalent iodine (*Scheme S5*). A SET would form the oxidized cationic radical (hetero)arene and transfer one electron on the electrophilic iodane. The aromatic cation radical intermediate **VII** could be stabilized by the enamine bond of the indole, with the iodane shifting between the C2-C3 carbons. Intramolecular deprotonation by either the chlorine moiety or the carboxylate the would afford intermediates **VIII** and **IX**. Final SET recombination would afford the corresponding mixed bi-(hetero)arenes. Alternatively, recombination on iodine would lead back to intermediate **IV** and **V**, which could then undergo reductive elimination.

Scheme S5: SET pathway

Finally, $Path\ C$ takes into account the donating effect of the N-lone pair in stabilizing **III** via its resonance form **X**. S_N Ar attack of the nucleophile would form intermediate **XI**. Finally, 1,2-proton shift of the C2-proton on the C3-iodo-carbene would afford the desired product (*Scheme S6*).

TMSCI
$$^{\delta}$$

TMSCI $^{\delta}$

TMSC

Scheme S6: Vicarious nucleophilic aromatic substitution.

5. Further Modifications of the (Hetero)-Arylated Indoles.

All commercially available chemicals were purchased from the suppliers quoted in Paragraph 1.0 of Supplementary Informations: these chemicals were purified through a short plug of celite prior to their use in catalysis.

Synthesis of 2-bromo-12-methyl-5,12-dihydroindolo[3,2-a]carbazole (18)

Following a reported procedure, [30] in a flame dried vial under nitrogen atmosphere, 5'-bromo-1-methyl-1*H*,1'*H*-2,3'-biindole **8j** (32.5 mg, 1.00 mmol, 1.00 equiv.) was dissolved in AcOH (1 mL, 0.1 M); commercially available 2,2-diethoxy-N,N-dimethylethanamine (20.0 µL, 1.00 mmol, 1.00 equiv.) 17 was added under vigorous stirring. The reaction mixture was heated up to reflux (135 °C) and monitored via TLC (1:1 Pentane/EtOAc). Upon complete consumption of the starting material (1 hour), the reaction was cooled to room temperature and the solvent removed under reduced pressure. The crude product was purified via flash chromatography (gradient 5:1-1:2 Pentane:EtOAc) to afford 2-bromo-12-methyl-5,12-dihydroindolo[3,2alcarbazole 18 (28.3 mg, 81.0 µmol, 81% yield) as a yellow oil. Rf 0.4 (Pentane:EtOAc 1:1) ¹**H NMR** (400 MHz, CDCl₃) δ 8.64 (d, J = 1.7 Hz, 1H, ArH), 8.37 (s, 1H, NH), 8.13 (d, J = 8.4Hz, 1H, ArH), 8.09 (dt, J = 7.7, 0.9 Hz, 1H, ArH), 7.54 - 7.43 (m, 3H, ArH), 7.37 (d, J = 8.5Hz, 1H, ArH), 7.33 - 7.26 (m, 2H, ArH), 4.48 (s, 3H, NMe). ¹³C NMR (101 MHz, CDCl₃) δ 140.8, 140.4, 137.5, 137.2, 127.1, 125.2, 124.1, 124.1, 123.5, 119.7, 119.6, 118.9, 116.6, 112.3, 112.1, 108.9, 107.0, 103.5, 34.7. **IR** v 3053 (w), 2939 (w), 1619 (w), 1589 (w), 1466 (s), 1369 (m), 1339 (m), 1272 (m), 1244 (m), 1145 (m), 1092 (w), 830 (m), 790 (s), 748 (a). No high resolution mass spectrum could be obtained for this compound due to insufficient ionization.


Synthesis of 2-chloro-5,12-dimethyl-6,7-diphenyl-5,12-dihydroindolo[3,2-a]carbazole (20)

Following a reported procedure, [31] Pd(OAc)₂ (2.25 mg, 10.0 μmol, 10.0 mol%), K₂CO₃ (4.15 mg, 30.0 μmol, 30 mol%), TBAB (16.0 mg, 50.0 μmol, 0.5 equiv.), PivOH (10.2 mg, 0.100 mmol, 1.00 equiv.), 5'-chloro-1,1'-dimethyl-1*H*,1'*H*-2,3'-biindole **8d** (29.5 mg, 0.100 mmol) and commercially available diphenylacetylene 19 (35.6 mg, 0.200 mmol, 2.00 equiv.) were added to a flame dried vial under nitrogen atmosphere. The tube was purged with O₂ three times before DMF (1.0 mL, 0.1 M) was added. The reaction mixture was stirred at 100 °C under O₂ (1 atm) for 12 h and was monitored by TLC (Pentane:EtOAc 4:1). The solution was then cooled to RT, diluted with ethyl acetate (10 mL), washed with H₂O (3x10 mL), dried over MgSO₄, filtered, and dried under vaccum. The crude product was purified by column chromatography on silica gel (gradient 10:1 to 4:1 Pentane:EtOAc) to afford 2-chloro-5,12-dimethyl-6,7diphenyl-5,12-dihydroindolo[3,2-a]carbazole **20** (35.1 mg, 75.0 μmol, 75% yield). **Rf** 0.7 (Pentane:EtOAc 4:1) ¹**H NMR** (400 MHz, CDCl₃) δ 8.58 (d, J = 1.9 Hz, 1H, ArH), 7.49 (d, J= 8.1 Hz, 1H, ArH), 7.43 (dd, J = 8.7, 2.0 Hz, 1H, ArH), 7.37 (d, J = 7.5 Hz, 1H, ArH), 7.35 -7.17 (m, 11H, ArH), 6.92 (t, J = 7.5 Hz, 1H, ArH), 6.51 (d, J = 7.9 Hz, 1H, ArH), 4.50 (s, 3H, NMe), 3.26 (s, 3H, NMe). ¹³C NMR (101 MHz, CDCl₃) δ 142.2, 140.1, 139.8, 139.7, 138.4, 136.7, 136.5, 132.2, 130.2, 127.9, 127.3, 126.7, 124.5, 124.3, 124.3, 124.0, 122.1, 121.9, 121.1, 119.5, 118.3, 115.2, 110.0, 108.9, 106.5, 35.5, 33.1 (one aromatic Carbon not resolved). **IR** v 2975 (w), 2943 (w), 2903 (w), 1722 (w), 1613 (w), 1468 (s), 1422 (m), 1369 (m), 1338 (m), 1271 (m), 1247 (m), 1208 (w), 1087 (m), 1045 (m), 880 (w), 787 (m), 750 (s). **HR-ESI-MS** calcd for $C_{32}H_{24}ClN_2^+$ [M+H]⁺ 471.1623; found 471.1616.


Synthesis of 3-Chloro-2-(2,4,6-trimethoxyphenyl)quinolone (21)

With slight modification of a reported procedure [32,33] 50% aqueous KOH (72.0 µL, 0.635 mmol, 7.50 equiv.) was added to a vigorously stirred solution of 2-(2,4,6-trimethoxyphenyl)-1*H*-indole **14a** (24.0 mg, 85.0 μmol, 1.00 equiv.) and "Bu₄NHSO₄ (2.88 mg, 8.47 μmol, 0.100 equiv.) in chloroform (1.10 mL) under ice-cooling bath. The reaction mixture was stirred at 0 °C for 2 h and left overnight at room temperature. After 16 h The aqueous layer was separated and extracted with chloroform. The organic layers were dried over MgSO₄. After filtration and evaporation, the crude purified by PTLC, and 3-chloro-2-(2,4,6was trimethoxyphenyl)quinoline 21 (20.0 mg, 60.0 µmol, 72% yield) was obtained as brown crystalline solid. M.p. 158-162 °C Rf: 0.35 (25% EtOAc in Pentane). ¹H NMR (400 MHz, Acetone-d6) δ 8.44 (s, 1H, ArH), 8.09 – 8.02 (m, 1H, ArH), 7.97 (dd, J = 8.1, 1.5 Hz, 1H, ArH), 7.81 - 7.73 (m, 1H, ArH), 7.65 (ddd, J = 8.1, 6.9, 1.2 Hz, 1H, ArH), 6.37 (s, 2H, ArH), 3.90 (s, 3H, p-OCH₃), 3.70 (s, 6H, o-OCH₃). ¹³C NMR (101 MHz, Acetone-d6) δ 163.1, 159.8, 154.8, 147.1, 135.4, 131.2, 130.3, 129.8, 128.9, 128.1, 127.8, 110.5, 91.5, 56.1, 55.7. **IR** v 2256 (w), 1728 (m), 1704 (s), 1611 (w), 1340 (w), 1249 (s), 1158 (w), 1131 (w), 1035 (w), 971 (w). **HR-ESI-MS**: calcd for $C_{18}H_{17}ClNO_3^+$ 330.0891[M + H]⁺; found 330.0895.

6. Crystal Structures.



A single crystal was grown by slow diffusion of the solution of **13h** in CDCl₃. Supplementary crystallographic data for this compound have been deposited at Cambridge Crystallographic Data Centre (**1824408**) and can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif.




A single crystal was grown by removal of reaction solvent from **14a** by evaporation. Supplementary crystallographic data for this compound have been deposited at Cambridge Crystallographic Data Centre (**1824407**) and can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif.

7. Determination of the regio-distribution.


Given the all-aromatic nature of the mixed bi-indole frameworks, NMR studies were required to assign the correct regiodistribution of the products. NMR-analysis of bis-methylated bi-indoles **8a-8h** already shown a 3'-2/2'-3 connectivity between the two heterocyclic core. We then decide to procede in steps, focusing our attention on mixed bi-indole obtained when a NH-indole was used as nucleophile in the reaction.

In *Figure 7.1* all four possible regioisomers **I-IV** are reported: in order to determine the correct structure we performed bidimensional NMR analysis of product **8i-8j** and their derivatives **35**-



36. We concentrated our attention to the H-signal at about 6.6 ppm: given the shift we postulated its belonging to either C2-C3 carbons of one of the two indoles. HMBC analysis of products **8i-8j** didn't show correlation between the N*CH*₃-carbon and the H-signal at about 6.6 ppm. For this reason we were able to exclude

regioisomers of classes ${\bf I}$ and ${\bf II}$ and assign the singlet to a C3-carbon.



To distinguish between the remaining two regioisomers **III** and **IV**, it was not possible to use COSY correlation between the NH bond and the C2-H, as the signal was too weak, independently of the substitution pattern. We therefore methylated **8i-8j** to obtain **35-36**.

Following general procedure GP6: the corresponding biindoles $\bf 8i-8j$ (0.100 mmol, 1.00 equiv.) were dissolved in dry THF (1.00 mL, 0.1 M). Sodium hydride (4.00 mg, 1.00 mmol, 1.00 equiv. 60% suspension in mineral oil) was slowly added under N₂ flow at 0 °C. After being stirred at 0 °C for 15 min,the reaction mixture was allowed to warm to r.t for 1.5 h. It was then cooled back to 0 °C and methyl iodide (11.0 μ L, 1.00 mmol, 1.00 equiv.) was added. The mixture was warmed to r.t. and stirred overnight. After cooling again to 0 °C, the reaction was quenched with water (10 mL), extracted with Et₂O (3 x 10 mL), the combined organic layers were dried over MgSO₄, and the solvent removed under reduced pressure. The resulting crude product was purified via flash column chromatography (Pentane:EtOAc 4:1) to give methylated bi-indoles 35-36.

5'-Fluoro-1,1'-dimethyl-1*H*,1'*H*-2,3'-biindole (35).

Following general procedure GP6 *on a 0.1 mmol scale and using 1.0 equiv. of NaH and MeI*: starting from 5'-fluoro-1-methyl-1*H*,1'*H*-2,3'-biindole **8i** (26.4 mg, 0.100 mmol, 1.00 equiv.), 5'-fluoro-1,1'-dimethyl-1*H*,1'*H*-2,3'-biindole **xx** (21.3 mg, 77.0 μmol, 77% yield) as a yellow oil. **Rf** 0.4 (Pentane:EtOAc 4:1) ¹**H NMR** (400 MHz, CDCl₃)

δ 7.65 (d, J = 7.7 Hz, 1H, ArH), 7.36 (ddd, J = 11.9, 8.9, 1.7 Hz, 2H, ArH), 7.31 (dd, J = 8.9, 4.2 Hz, 1H, ArH), 7.26 – 7.22 (m, 2H, ArH), 7.15 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H, ArH), 7.06 (td, J = 9.0, 2.5 Hz, 1H, ArH), 6.60 (d, J = 0.9 Hz, 1H, ArH), 3.89 (s, 3H, NMe), 3.75 (s, 3H, NMe). ¹³C NMR (101 MHz, CDCl₃) δ 158.5 (d, J = 235.7 Hz), 137.9, 134.4, 133.6, 129.8, 128.3, 128.0 (d, J = 10.1 Hz), 121.1, 120.0, 119.6, 110.8 (d, J = 26.6 Hz), 110.2 (d, J = 9.8 Hz), 109.3, 107.3 (d, J = 4.6 Hz), 105.2 (d, J = 24.2 Hz), 101.4, 33.3, 30.9. IR ν 3054 (w), 2929 (w), 2854 (w), 1626 (w), 1592 (w), 1489 (m), 1467 (w), 1280 (m), 1241 (w), 1194 (w), 1119 (w), 1013 (w), 913 (m), 748 (s). HR-ESI-MS calcd for C₁₈H₁₆FN₂⁺ [M+H]⁺ 279.1292; found 279.1287.

5'-Bromo-1,1'-dimethyl-1*H*,1'*H*-2,3'-biindole (36).


Following general procedure GP6 *on a 0.1 mmol scale and using 1.0 equiv. of NaH and MeI*: starting from 5'-bromo-1-methyl-1*H*,1'*H*-2,3'-biindole **8j** (32.5 mg, 0.100 mmol, 1.00 equiv.) 5'-bromo-1,1'-dimethyl-1*H*,1'*H*-2,3'-biindole **36** (27.9 mg, 82.0 µmol, 82% yield)


was obtained as yellow oil. **Rf** 0.75 (Pentane:EtOAc 4:1) ¹**H NMR** (400 MHz, CDCl₃) δ 7.81 (dd, J = 1.9, 0.5 Hz, 1H, ArH), 7.64 (m, 1H, ArH), 7.38 (dd, J = 4.1, 1.4 Hz, 1H, ArH), 7.36 (dd, J = 3.6, 1.4 Hz, 1H, ArH), 7.25 – 7.21 (m, 2H, ArH), 7.17 (s, 1H, ArH), 7.14 (ddd, J = 8.0, 7.1, 1.1 Hz, 1H, ArH), 6.59 (s, 1H, ArH), 3.85 (s, 3H, NMe), 3.72 (s, 3H, NMe). ¹³**C NMR** (101 MHz, CDCl₃) δ 137.9, 135.6, 134.0, 129.3, 129.3, 128.2, 125.2, 122.8, 121.2, 120.1, 119.7, 113.7, 111.0, 109.4, 107.0, 101.7, 33.2, 30.9. **IR** v 2957 (w), 2932 (w), 2869 (w), 1718 (s), 1610 (w), 1537 (w), 1452 (w), 1436 (w), 1385 (m), 1255 (m), 1214 (m), 1162 (m), 1060 (w), 1035 (w), 880 (w), 803 (w), 721 (m). **HR-ESI-MS** calcd for C₁₈H₁₆⁷⁹BrN₂⁺ [M+H]⁺ 339.0491; found 339.0485.

The HMBC analysis showed interaction between the H-singlet at 7.25 (**35**) and 7.16 (**36**) and the newly installed NCH₃, thereby excluding the 2'-2 connection and allowing to assign the structure. As expected we obtained the 3'-2 connection. The structure of the other bi-indoles obtained in the scope was assigned by analogy, except for compounds **81-8m**.

The latter compounds were obtained with a C3-alkylated indole as nucleophile and the steric

hindrance played an important role in reversing the regio-distribution. An insight on the mechanism is given in SI-Par.4.






6. DSC studies.

$DSC\ analysis\ of\ C2\text{-}NBoc\text{-}IndoleDBX\ (13a)$

Measured by: Marylène Stempien

Weight after analysis: 4.205mg




7. Bibliography


- [1] P. Caramenti, S. Nicolai, J. Waser, *Chem. A Eur. J.* **2017**, *23*, 14702–14706.
- [2] A. T. Parsons, S. L. Buchwald, *Angew. Chem. Int. Ed.* **2011**, *50*, 9120–9123.
- [3] M. V. Vita, P. Caramenti, J. Waser, *Org. Lett.* **2015**, *17*, 5832–5835.
- [4] H. T. Yasuyuki Kita, Shuji Akai, Takayuki Okuno, Masahiro Egi, Takeshi Takada, *Heterocycles* **1996**, *42*, 47–51.
- [5] E. F. Perozzi, R. S. Michalak, G. D. Figuly, W. H. Stevenson, D. Dess, M. R. Ross, J. C. Martin, *J. Org. Chem.* **1981**, *46*, 1049–1053.
- [6] P. Eisenberger, S. Gischig, A. Togni, *Chem. A Eur. J.* **2006**, *12*, 2579–2586.
- [7] G. L. Tolnai, S. Ganss, J. P. Brand, J. Waser, *Org. Lett.* **2013**, *15*, 112–115.
- [8] Y. Li, J. Waser, Angew. Chem. Int. Ed. 2015, 54, 5438–5442.
- [9] J. A. Leitch, C. L. McMullin, M. F. Mahon, Y. Bhonoah, C. G. Frost, *ACS Catal.* **2017**, 7, 2616–2623.
- [10] J. B. McManus, D. A. Nicewicz, J. Am. Chem. Soc. 2017, 139, 2880–2883.
- [11] J.-L. Zhou, M.-C. Ye, X.-L. Sun, Y. Tang, Tetrahedron 2009, 65, 6877–6881.
- [12] M. Prieto, E. Zurita, E. Rosa, L. Muñoz, P. Lloyd-Williams, E. Giralt, *J. Org. Chem.* **2004**, *69*, 6812–6820.
- [13] G. Özüduru, T. Schubach, M. M. K. Boysen, *Org. Lett.* **2012**, *14*, 4990–4993.
- [14] D. J. Rivinoja, Y. S. Gee, M. G. Gardiner, J. H. Ryan, C. J. T. Hyland, *ACS Catal.* **2017**, *7*, 1053–1056.
- [15] D. Tu, X. Cheng, Y. Gao, P. Yang, Y. Ding, C. Jiang, *Org. Biomol. Chem.* **2016**, *14*, 7443–7446.
- [16] R. Singudas, S. R. Adusumalli, P. N. Joshi, V. Rai, *Chem. Commun.* **2015**, *51*, 473–476.
- [17] P. Kassis, V. Bénéteau, J.-Y. Mérour, S. Routier, *Synthesis (Stuttg)*. **2009**, *14*, 2447–2453.
- [18] N. Pagano, J. Maksimoska, H. Bregman, D. S. Williams, R. D. Webster, F. Xue, E. Meggers, *Org. Biomol. Chem.* **2007**, *5*, 1218–1227.
- [19] J. Amaudrut, B. Boubia, M. J. P. Van Dongen, F. Guillier, O. Poupardin-Olivier, *Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease US2012/232070*, **2012**, US2012/232070.
- [20] F. Kolundzic, M. N. Noshi, M. Tjandra, M. Movassaghi, S. J. Miller, *J. Am. Chem. Soc.* **2011**, *133*, 9104–9111.
- [21] V. Matoušek, E. Pietrasiak, R. Schwenk, A. Togni, J. Org. Chem. **2013**, 78, 6763–6768.

- [22] J. P. Brand, J. Charpentier, J. Waser, Angew. Chem. Int. Ed. 2009, 48, 9346–9349.
- [23] Y. Nagase, T. Sugiyama, S. Nomiyama, K. Yonekura, T. Tsuchimoto, *Adv. Synth. Catal.* **2014**, *356*, 347–352.
- [24] K. Morimoto, Y. Ohnishi, D. Koseki, A. Nakamura, T. Dohi, Y. Kita, *Org. Biomol. Chem.* **2016**, *14*, 8947–8951.
- [25] Z. Liang, J. Zhao, Y. Zhang, J. Org. Chem. **2010**, 75, 170–177.
- [26] H. Hanchu, Z. Guojin, C. Yiyun, *Angew. Chem. Int. Ed.* **2015**, *54*, 7872–7876.
- [27] T. Wirth, *Hypervalent Iodine Chemistry*, Springer International Publishing, **2016**.
- [28] T. Dohi, M. Ito, K. Morimoto, M. Iwata, Y. Kita, *Angew. Chem. Int. Ed.* **2008**, *47*, 1301–1304.
- [29] Y. Kita, T. Dohi, *Chem. Rec.* **2015**, *15*, 886–906.
- [30] J. Bergman, E. Desarbre, E. Koch, *Tetrahedron* **1999**, *55*, 2363–2370.
- [31] Z. Shi, S. Ding, Y. Cui, N. Jiao, Angew. Chem. Int. Ed. 2009, 48, 7895–7898.
- [32] G. L. Ciamician, M. Dennstedt, *Berichte der Dtsch. Chem. Gesellschaft* **1881**, *14*, 1153–1163.
- [33] K. Joshi, R. Jain, S. Arora, J. Indian Chem. Soc. 1993, 70, 567–568.


8. S	pectra	of	new	compour	ıds
------	--------	----	-----	---------	-----


Potassium trifluoro(1-(tert-butoxycarbonyl)-6-methoxy-1H-indol-2-yl)borate (11c)







$Potassium\ trifluoro (1-(\textit{tert}-butoxycarbonyl)-6-bromo-\textit{1}\textit{H}-indol-2-yl) borate\ (11d):$







Potassium trifluoro(1-(tert-butoxycarbonyl)-3-methyl-1H-indol-2-yl)borate (11e):






Potassium trifluoro(1-(tosyl)-1H-indol-2-yl)borate (11f):







Potassium trifluoro(2-(2-(1*H*-indol-3-yl)ethyl)isoindoline-1,3-dione)borate (11g):





1-(Tert-butyl 1H-indole-1-carboxylate)-1H- $1\lambda_3$ -benzo[b]iodo-3(2H)-one (13a):






$1\hbox{-}(2\hbox{-}1\hbox{-}(Tosyl)\hbox{-}1H\hbox{-}indol\hbox{-}2\hbox{-}yl)\hbox{-}1H\hbox{-}1\lambda_3\hbox{-}benzo[b]iodo\hbox{-}3(2H)\hbox{-}one\ (13b)\hbox{:}$







1-(2-Tert-butyl 1H-indole-1-carboxylate)-3,3-dimethyl-1,3-dihydro- $1\lambda^3$ -benzo[d][1,2]iodoxol (13c):




$1-(2-1-Tosyl-1H-indole)-3,3-dimethyl-1,3-dihydro-1\lambda^3-benzo[d][1,2]$ iodoxole (13d):







1-(2-5-Methoxy-1-*tert*-butyl-1*H*-indole-1-carboxylate)-3,3-dimethyl-1,3-dihydro- $1\lambda^3$ -benzo [d][1,2]iodoxole (13e):




1-(2-6-Methoxy-1-*tert*-butyl-1*H*-indole-1-carboxylate)-3,3-dimethyl-1,3-dihydro- $1\lambda^3$ -benzo [*d*][1,2]iodoxole (13f):




1-(2-5-Bromo-1-tert-butyl-1H-indole-1-carboxylate)-3,3-dimethyl-1,3-dihydro- $1\lambda^3$ -benzo [d][1,2]iodoxole (13g):




1-(2-3-Methyl-1-tert-butyl-1H-indole-1-carboxylate)-3,3-dimethyl-1,3-dihydro- $1\lambda^3$ -benzo [d][1,2]iodoxole (13h):




1-(2-(1*H*-Indol-3-yl)ethyl)isoindoline-1,3-dione)-3,3-dimethyl-1,3-dihydro- $1\lambda^3$ -benzo[d][1,2] iodoxole (13i):





1-Methyl-2-(2,4,6-trimethoxyphenyl)-1*H*-indole (7a)







1-Methyl-2,3-bis(2,4,6-trimethoxyphenyl)-1*H*-indole (8).










5-Iodo-1-methyl-2-(2,4,6-trimethoxyphenyl)-1*H*-indole (7b) and and 5-iodo-1-methyl-2,3-bis(2,4,6-trimethoxyphenyl)-1*H*-indole (7b')







$1-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(2,4,6-trimethoxyphenyl)-1 \\ H-indole~(7c)$






1,2-Dimethyl-3-(2,4,6-trimethoxyphenyl)-1*H*-indole (7d)







1,1'-Dimethyl-1*H*,1'*H*-2,3'-biindole (8b)




5'-Methoxy-1,1'-dimethyl-1H,1'H-2,3'-biindole (8c) and 5'-methoxy-1,1'-dimethyl-1H,1'H-2,7'-biindole (8c')




5'-Chloro-1,1'-dimethyl-1*H*,1'*H*-2,3'-biindole (8d)




5'-Iodo-1,1'-dimethyl-1*H*,1'*H*-2,3'-biindole (8e)




$1,1'-Dimethyl-5'-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1\\ H,1'H-2,3'-biindole~(8f)$




1,1'-Dimethyl-1*H*,1'*H*-[2,3'-biindol]-6'-ol (8g)




1-Methyl-1*H*,1'*H*-2,3'-biindole (8h)




5'-Fluoro-1-methyl-1H,1'H-2,3'-biindole (8i)




$5'\text{-}Bromo\text{-}1\text{-}methyl\text{-}1H,}1'H\text{-}2,}3'\text{-}biindole} \ (8j)$




1,1',3-Trimethyl-1H,1'H-2,3'-biindole (8k)




2-(1'-Methyl-1*H*,1'*H*-[2,3'-biindol]-3-yl)ethanol (8l)




5-Iodo-1,1'-dimethyl-1H,1'H-2,3'-biindole (8m)




5'-Methoxy-1,1'-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H,1'H-2,3'-biindole (8n).




5'-Nitro-1,1'-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H,1'H-2,3'-biindole (80)




1-Methyl-2-(1-methyl-1H-pyrrol-2-yl)-1H-indole (9a)




${\bf 1\text{-}Methyl\text{-}2\text{-}(1\text{-}phenyl\text{-}1} \\ H\text{-}pyrrol\text{-}2\text{-}yl)\text{-}1} \\ H\text{-}indole~(9b)$




1-methyl-2-(1-phenyl-1*H*-pyrrol-3-yl)-1*H*-indole (9b')




 $\hbox{2-}(\hbox{3-Methoxythiophen-2-yl})\hbox{-1-methyl-1} H\hbox{-indole}\ (\hbox{10a})$




$\hbox{2-}(2, \hbox{5-Dimethylthiophen-3-yl}) \hbox{-1-methyl-1} H \hbox{-indole } (10b)$




2-(2,4,6-Trimethoxyphenyl)-1*H*-indole (14a)







5-Methoxy-2-(2,4,6-trimethoxyphenyl)-1*H*-indole (14b)





6-Methoxy-2-(2,4,6-trimethoxyphenyl)-1*H*-indole (14c)






6-Bromo-2-(2,4,6-trimethoxyphenyl)-1*H*-indole (14d)







3-Methyl-2-(2,4,6-trimethoxyphenyl)-1*H*-indole (14e)





2-(2-(2-(2-4,6-Trimethoxyphenyl)-1*H*-indol-3-yl)ethyl)isoindoline-1,3-dione (14f)







2-(2,4,6-Trimethoxy-3-methylphenyl)-1*H*-indole (14g)







3-Methyl-2-(2,4,6-trimethoxy-3-methylphenyl)-1*H*-indole (14h)






6'-Bromo-1*H*,1'*H*-2,3'-biindole (15a)







$6'\text{-Fluoro-}1H, 1'H\text{-}2, 3'\text{-biindole } (15\mathrm{b}) \\$





6-Bromo-5',6'-dimethoxy-1*H*,1'*H*-2,3'-biindole (15c)




$\hbox{2-}(\hbox{3-Methoxythiophen-2-yl})\hbox{-}1H\hbox{-indole}\ (\hbox{16})$







$2\text{-}Chloro-5, 12\text{-}dimethyl-6, 7\text{-}diphenyl-5, 12\text{-}dihydroindolo[3, 2\text{-}a] carbazole\ (20)$



3-Chloro-2-(2,4,6-trimethoxyphenyl)quinolone (21)

